<?xml version="1.0" ?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.3 20210610//EN"  "JATS-archivearticle1-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">elife</journal-id>
<journal-id journal-id-type="publisher-id">eLife</journal-id>
<journal-title-group>
<journal-title>eLife</journal-title>
</journal-title-group>
<issn publication-format="electronic" pub-type="epub">2050-084X</issn>
<publisher>
<publisher-name>eLife Sciences Publications, Ltd</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">88849</article-id>
<article-id pub-id-type="doi">10.7554/eLife.88849</article-id>
<article-id pub-id-type="doi" specific-use="version">10.7554/eLife.88849.2</article-id>
<article-version-alternatives>
<article-version article-version-type="publication-state">reviewed preprint</article-version>
<article-version article-version-type="preprint-version">1.4</article-version>
</article-version-alternatives>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Immunology and Inflammation</subject>
</subj-group>
<subj-group subj-group-type="heading">
<subject>Microbiology and Infectious Disease</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>SIV-specific neutralizing antibody induction following selection of a PI3K drive-attenuated <italic>nef</italic> variant</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-0708-9373</contrib-id>
<name>
<surname>Yamamoto</surname>
<given-names>Hiroyuki</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a2">2</xref>
<xref ref-type="aff" rid="a3">3</xref>
<email>h-yamato@niid.go.jp</email>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Matano</surname>
<given-names>Tetsuro</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a3">3</xref>
<xref ref-type="aff" rid="a4">4</xref>
<email>tmatano@niid.go.jp</email>
</contrib>
<aff id="a1"><label>1</label><institution>AIDS Research Center, National Institute of Infectious Diseases</institution>, <city>Tokyo</city>, <country>Japan</country></aff>
<aff id="a2"><label>2</label><institution>Department of Biomedicine, University Hospital Basel</institution>, <city>Basel</city>, <country>Switzerland</country></aff>
<aff id="a3"><label>3</label><institution>Joint Research Center for Human Retrovirus Infection, Kumamoto University</institution>, <city>Kumamoto</city>, <country>Japan</country></aff>
<aff id="a4"><label>4</label><institution>The Institute of Medical Science, The University of Tokyo</institution>, 4-6-1 <city>Minato-ku</city>, <country>Japan</country></aff>
</contrib-group>
<contrib-group content-type="section">
<contrib contrib-type="editor">
<name>
<surname>Kirchhoff</surname>
<given-names>Frank</given-names>
</name>
<role>Reviewing Editor</role>
<aff>
<institution-wrap>
<institution>Ulm University Medical Center</institution>
</institution-wrap>
<city>Ulm</city>
<country>Germany</country>
</aff>
</contrib>
<contrib contrib-type="senior_editor">
<name>
<surname>Diamond</surname>
<given-names>Betty</given-names>
</name>
<role>Senior Editor</role>
<aff>
<institution-wrap>
<institution>The Feinstein Institute for Medical Research</institution>
</institution-wrap>
<city>Manhasset</city>
<country>United States of America</country>
</aff>
</contrib>
</contrib-group>
<pub-date date-type="original-publication" iso-8601-date="2023-08-08">
<day>08</day>
<month>08</month>
<year>2023</year>
</pub-date>
<pub-date date-type="update" iso-8601-date="2024-10-25">
<day>25</day>
<month>10</month>
<year>2024</year>
</pub-date>
<volume>12</volume>
<elocation-id>RP88849</elocation-id>
<history>
<date date-type="sent-for-review" iso-8601-date="2023-06-03">
<day>03</day>
<month>06</month>
<year>2023</year>
</date>
</history>
<pub-history>
<event>
<event-desc>Preprint posted</event-desc>
<date date-type="preprint" iso-8601-date="2023-04-24">
<day>24</day>
<month>04</month>
<year>2023</year>
</date>
<self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2023.04.19.537602"/>
</event>
<event>
<event-desc>Reviewed preprint v1</event-desc>
<date date-type="reviewed-preprint" iso-8601-date="2023-08-08">
<day>08</day>
<month>08</month>
<year>2023</year>
</date>
<self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.88849.1"/>
<self-uri content-type="editor-report" xlink:href="https://doi.org/10.7554/eLife.88849.1.sa2">eLife assessment</self-uri>
<self-uri content-type="referee-report" xlink:href="https://doi.org/10.7554/eLife.88849.1.sa1">Reviewer #1 (Public Review):</self-uri>
<self-uri content-type="referee-report" xlink:href="https://doi.org/10.7554/eLife.88849.1.sa0">Reviewer #2 (Public Review):</self-uri>
</event>
</pub-history>
<permissions>
<copyright-statement>© 2023, Yamamoto &amp; Matano</copyright-statement>
<copyright-year>2023</copyright-year>
<copyright-holder>Yamamoto &amp; Matano</copyright-holder>
<ali:free_to_read/>
<license xlink:href="https://creativecommons.org/licenses/by/4.0/">
<ali:license_ref>https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
<license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="elife-preprint-88849-v2.pdf"/>
<abstract>
<title>Abstract</title><p>HIV and simian immunodeficiency virus (SIV) infections are known for impaired neutralizing antibody (NAb) responses. While sequential virus-host B cell interaction appears to be basally required for NAb induction, driver molecular signatures predisposing to NAb induction still remain largely unknown. Here we describe SIV-specific NAb induction following a virus-host interplay decreasing aberrant viral drive of phosphoinositide 3-kinase (PI3K). Screening of seventy difficult-to-neutralize SIV<sub>mac239</sub>-infected macaques found nine NAb-inducing animals, with seven selecting for a specific CD8<sup>+</sup> T-cell escape mutation in viral <italic>nef</italic> before NAb induction. This Nef-G63E mutation reduced excess Nef interaction-mediated drive of B-cell maturation-limiting PI3K/mammalian target of rapamycin complex 2 (mTORC2). <italic>In vivo</italic> imaging cytometry depicted preferential Nef perturbation of cognate Envelope-specific B cells, suggestive of polarized contact-dependent Nef transfer and corroborating cognate B-cell maturation post-mutant selection up to NAb induction. Results collectively exemplify a NAb induction pattern extrinsically reciprocal to human PI3K gain-of-function antibody-dysregulating disease, and indicate that harnessing the PI3K/mTORC2 axis may facilitate NAb induction against difficult-to-neutralize viruses including HIV/SIV.</p>
</abstract>
<kwd-group kwd-group-type="author">
<title>Keywords</title>
<kwd>neutralizing antibody</kwd>
<kwd>B cells</kwd>
<kwd>CD8+ T cells</kwd>
<kwd>PI3 kinase</kwd>
<kwd>inborn errors of immunity</kwd>
<kwd>HIV/SIV</kwd>
</kwd-group>
<custom-meta-group>
<custom-meta specific-use="meta-only">
<meta-name>publishing-route</meta-name>
<meta-value>prc</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
<notes>
<notes notes-type="competing-interest-statement">
<title>Competing Interest Statement</title><p>The authors have declared no competing interest.</p></notes>
<fn-group content-type="summary-of-updates">
<title>Summary of Updates:</title>
<fn fn-type="update"><p>Figure 4-Supplemental File 2 and Figure 5-Supplemental File 1 were placed back to the correct order</p></fn>
</fn-group>
</notes>
</front>
<body>
<sec id="s1">
<title>Introduction</title>
<p>Virus-specific neutralizing antibody (NAb) responses by B cells are induced by a tight cooperation of adaptive immune cells (<xref ref-type="bibr" rid="c53">Kumar et al., 2010</xref>; <xref ref-type="bibr" rid="c102">Shulman et al., 2014</xref>; <xref ref-type="bibr" rid="c25">Giltin et al., 2014</xref>; <xref ref-type="bibr" rid="c113">Wang et al., 2014</xref>) and often play a central role in clearance of acute viral infections (<xref ref-type="bibr" rid="c45">Junt et al., 2007</xref>). In contrast, persistence-prone viruses such as human immunodeficiency virus type 1 (HIV-1), simian immunodeficiency virus (SIV) and lymphocytic choriomeningitis virus (LCMV) variously equip themselves with B cell/antibody-inhibitory countermeasures (<xref ref-type="bibr" rid="c70">Moir et al., 2001</xref>; <xref ref-type="bibr" rid="c67">Mattapallil et al., 2005</xref>; <xref ref-type="bibr" rid="c104">Sommerstein et al., 2015</xref>; <xref ref-type="bibr" rid="c94">Sammicheli et al., 2016</xref>; <xref ref-type="bibr" rid="c19">Fallet et al., 2016</xref>; <xref ref-type="bibr" rid="c65">Mason et al., 2016</xref>) and NAb responses are impaired (<xref ref-type="bibr" rid="c57">Levesque et al., 2009</xref>; <xref ref-type="bibr" rid="c69">Mikell et al., 2011</xref>). These viruses successfully suppress elicitation of potent NAb responses particularly in acute infection (<xref ref-type="bibr" rid="c35">Hunziker et al., 2003</xref>; <xref ref-type="bibr" rid="c111">Tomaras et al., 2008</xref>) and establish viral persistence, posing considerable challenge for developing protective strategies. Particularly, HIV and SIV establish early a large <italic>in vivo</italic> body of infection with a distinct host genome-integrating retroviral life cycle (<xref ref-type="bibr" rid="c114">Whitney et al., 2014</xref>). In addition, lentiviruses HIV/SIV are unique in launching a matrix of host immune-perturbing interactions mainly by their six remarkably pleiotropic accessory viral proteins optimally fueling pathogenesis (<xref ref-type="bibr" rid="c51">Kirchhoff et al., 1995</xref>; <xref ref-type="bibr" rid="c100">Sheehy et al., 2002</xref>; <xref ref-type="bibr" rid="c29">Harris et al., 2003</xref>; <xref ref-type="bibr" rid="c98">Schindler et al., 2006</xref>; <xref ref-type="bibr" rid="c77">Neil et al., 2008</xref>; <xref ref-type="bibr" rid="c121">Zhang et al., 2009</xref>; <xref ref-type="bibr" rid="c54">Laguette et al., 2011</xref>; <xref ref-type="bibr" rid="c118">Yamada et al., 2018</xref>; <xref ref-type="bibr" rid="c41">Joas et al., 2018</xref>; <xref ref-type="bibr" rid="c55">Langer et al., 2019</xref>; <xref ref-type="bibr" rid="c120">Yan et al., 2019</xref>; <xref ref-type="bibr" rid="c42">Joas et al., 2020</xref>; <xref ref-type="bibr" rid="c49">Khan et al., 2020</xref>; <xref ref-type="bibr" rid="c112">Volcic et al., 2020</xref>; <xref ref-type="bibr" rid="c91">Reuschl et al., 2022</xref>). A body of evidence has depicted this over these 30 years, whereas its entity, including focal mechanisms of humoral immune perturbation in HIV/SIV infection, still remains elusive.</p>
<p>Contrasting this detrimental consequence of acute-phase endogenous NAb absence driven by adverse virus-host interactions in early HIV/SIV infection, we and others have previously described in <italic>in vivo</italic> experimental models that acute-phase passive NAb infusion can trigger an endogenous T-cell synergism resulting in robust SIV/SHIV (simian/human immunodeficiency virus) replication control (<xref ref-type="bibr" rid="c27">Haigwood et al., 1996</xref>; <xref ref-type="bibr" rid="c119">Yamamoto et al., 2007</xref>; <xref ref-type="bibr" rid="c78">Ng et al., 2010</xref>; <xref ref-type="bibr" rid="c36">Iseda et al., 2016</xref>; <xref ref-type="bibr" rid="c80">Nishimura et al., 2017</xref>). This shows that virus-specific Nabs not only confer sterile protection but also can evoke T-cell-mediated non-sterile viral control, suggesting the importance of inducing endogenous NAb responses during an optimal time frame as well as humoral-cellular response synergisms. Therefore, identifying mechanisms driving NAb induction against such viruses is an important step to eventually design NAb-based HIV control strategies.</p>
<p>As an approach, analysis of <italic>in vivo</italic> immunological events linked with NAb induction against difficult-to-neutralize SIVs in a non-human primate model can provide important insights into this goal. Various <italic>in vivo</italic> signatures of HIV-specific NAb induction, such as antibody-NAb coevolution (<xref ref-type="bibr" rid="c72">Moore et al., 2012</xref>), autoimmune-driven induction (<xref ref-type="bibr" rid="c71">Moody et al., 2016</xref>) and natural killer cell-related host polymorphisms (<xref ref-type="bibr" rid="c10">Bradley et al., 2018</xref>) have been reported to date. The variety collectively, and interestingly, indicates that pathways to NAb induction against difficult-to-neutralize viruses including HIV/SIV are redundant, conversely implicating as-yet-unknown mechanisms driving NAb induction. For example, the neutralization resistance of certain SIV strains apparently is not explanatory by any of the aforementioned, posing such models as attractive analytic targets of NAb induction mechanisms.</p>
<p>In the present study, we examined virus-specific antibody responses in rhesus macaques infected with a highly difficult-to-neutralize SIV strain, SIV<sub>mac239</sub>. This virus is pathogenic in rhesus macaques causing simian AIDS across a broad range of geographical origin of macaques (<xref ref-type="bibr" rid="c15">Cumont et al., 2008</xref>), shows persistent viremia and hosts lack NAb responses throughout infection (<xref ref-type="bibr" rid="c48">Kestler et al., 1991</xref>; <xref ref-type="bibr" rid="c81">Nomura et al., 2012</xref>). Yet, upon performing a large-scale screening of SIV<sub>mac239</sub>-infected Burmese rhesus macaques for up to 100 weeks, we noticed a subgroup inducing NAbs in the chronic phase. Interestingly, these animals commonly selected for a specific CD8<sup>+</sup> cytotoxic T lymphocyte (CTL) escape mutation in the viral Nef-coding gene before NAb induction. The mutant Nef, compared with wild-type (WT) Nef, manifested a decrease in aberrant interaction with phosphoinositide 3-kinase (PI3K)/mammalian target of rapamycin complex 2 (mTORC2), resulting in decreased downstream hyperactivation of the canonical B-cell negative regulator Akt (<xref ref-type="bibr" rid="c83">Omori et al., 2006</xref>; <xref ref-type="bibr" rid="c59">Limon et al., 2014</xref>). Nef was graphically identified via machine learning-assisted imaging cytometry to preferentially target Env-specific B cells <italic>in vivo</italic>, and in those macaques inducing NAbs, the NAb induction was linked with sustained Env-specific B-cell responses after or during the mutant Nef selection. Results describe a B-cell functional boosting phenotypically reciprocal to a recently found human PI3K gain-of-function and antibody-dysregulating inborn error of immunity (IEI), activated PI3 kinase delta syndrome (APDS) (<xref ref-type="bibr" rid="c4">Angulo et al., 2013</xref>; <xref ref-type="bibr" rid="c62">Lucas et al., 2014</xref>), and suggest that intervening PI3K/mTORC2 signaling can potentially result in harnessing NAb induction against difficult-to-neutralize viruses.</p>
</sec>
<sec id="s2">
<title>Results</title>
<sec id="s2a">
<title>Identification of macaques inducing SIV<sub>mac239</sub>-neutralizing antibodies</title>
<p>We performed a retrospective antibody profile screening in rhesus macaques infected with NAb-resistant SIV<sub>mac239</sub> (<italic>n</italic> = 70) (<xref rid="fig1" ref-type="fig">Figure 1A</xref>) and identified a group of animals inducing anti-SIV<sub>mac239</sub> NAb responses (<italic>n</italic> = 9), which were subjected to characterization. These NAb inducers showed persistent viremia with no significant difference in viral loads compared with a profile-clarified naïve, major histocompatibility complex class I (MHC-I) haplotype-balanced subgroup of NAb non-inducers (<italic>n</italic> = 19) representatively utilized for comparison hereafter (<xref rid="fig1" ref-type="fig">Figure 1B</xref> and <xref rid="figs1a" ref-type="fig">Figure 1-figure supplement 1</xref>). Plasma SIV<sub>mac239</sub>-NAb titers measured by 10 TCID<sub>50</sub> SIV<sub>mac239</sub> virus-killing assay showed an average maximum titer of 1:16, being induced at an average of 48 weeks post-infection (p.i.) (<xref rid="fig1" ref-type="fig">Figure 1C</xref>). Two of the nine NAb inducers showed detectable NAb responses before six months p.i., while the remaining seven induced NAbs after six months. Anti-SIV<sub>mac239</sub> neutralizing activity was confirmed in immunoglobulin G (IgG) purified from plasma of these NAb inducers (<xref rid="figs1b" ref-type="fig">Figure 1-figure supplement 2</xref>). SIV Env-binding IgGs developed from early infection in NAb inducers as well as non-rapid-progressing NAb non-inducers, the latter differing from rapid progressors known to manifest serological failure (<xref ref-type="bibr" rid="c33">Hirsch et al., 2004</xref>; <xref ref-type="bibr" rid="c75">Nakane et al., 2013</xref>) (<xref rid="figs1c" ref-type="fig">Figure 1-figure supplement 3A</xref>); titers were not higher but rather lower at year 1 p.i. in the NAb inducers (<xref rid="figs1c" ref-type="fig">Figure 1-figure supplement 3B and 3C</xref>). This was consistent with other reports (<xref ref-type="bibr" rid="c32">Havenar-Daughton et al., 2016</xref>) and differing with gross B-cell enhancement in Nef-deleted SIV infection with enhanced anti-SIV binding antibody titers accompanying marginal neutralization (<xref ref-type="bibr" rid="c1">Adnan et al., 2016</xref>). NAb inducers and non-inducers showed similar patterns of variations in viral <italic>env</italic> sequences (<xref ref-type="bibr" rid="c11">Burns et al., 1993</xref>), mainly in variable regions 1, 2 and 4 (V1, V2 and V4) (<xref rid="figs1c" ref-type="fig">Figure 1-figure supplement 4</xref>).</p>
<fig id="fig1" position="float" orientation="portrait" fig-type="figure">
<label>Figure 1.</label>
<caption><title>NAb induction against NAb-resistant SIV<sub>mac239</sub></title>
<p>(A) Study design.</p><p>(B) Plasma viral loads (SIV <italic>gag</italic> RNA copies/ml plasma) in NAb non-inducers (left) and inducers (right).</p><p>(C) Plasma SIV<sub>mac239</sub> 100% neutralizing end point titers by 10 TCID<sub>50</sub> killing assay on MT4-R5 cells. Points on the dotted line show marginally NAb-positive results (&lt; 1:2). In some animals, titers were comparable with our reported results using MT4 cells.</p></caption>
<graphic xlink:href="537602v4_fig1.tif" mime-subtype="tiff" mimetype="image"/>
</fig>
</sec>
<sec id="s2b">
<title>Selection of a viral <italic>nef</italic> mutation (Nef-G63E) precedes chronic-phase SIV<sub>mac239</sub>-specific NAb induction</title>
<p>Viral nonsynonymous polymorphisms outside <italic>env</italic> were next assessed. Strikingly, we found selection of a viral genome mutation resulting in G (glycine)-to-E (glutamic acid) substitution at residue 63 of Nef (Nef-G63E) in seven of the nine NAb inducers (<xref rid="fig2" ref-type="fig">Figure 2A</xref>). This 63rd residue lies in the unstructured N-terminus of Nef, flanked by two α-helices conserved in SIVmac/SIVsmm (<xref rid="fig2" ref-type="fig">Figure 2B</xref>). This region is generally polymorphic among HIV-1/HIV-2/SIV, occasionally being deleted in laboratory and primary isolate HIV-1 strains (<xref ref-type="bibr" rid="c24">Geyer et al., 2001</xref>). AlphaFold2-based structure prediction did not derive palpable change except for low-probability disruption of the alpha helices (data not shown). The Nef G63E mutation was not observed in two early NAb inducers (with detectable NAbs before 6 months p.i.) but selected in all of the remaining seven inducing detectable NAb responses after 6 months. In contrast, this mutation was found only in two of the nineteen NAb non-inducers, including one rapid progressor (<xref rid="figs1a" ref-type="fig">Figure 1-figure supplement 1</xref>) and selection was significantly enriched in the NAb inducers as compared to the nineteen non-inducers (<xref rid="fig2" ref-type="fig">Figure 2C</xref>). Analysis of Nef-G63E mutation frequencies in plasma viruses showed that Nef-G63E selection preceded or at least paralleled NAb induction (<xref rid="fig2" ref-type="fig">Figure 2D</xref>).</p>
<fig id="fig2" position="float" orientation="portrait" fig-type="figure">
<label>Figure 2.</label>
<caption><title>Selection of a viral <italic>nef</italic> mutation (Nef-G63E) before NAb induction.</title>
<p>(A) Viral <italic>nef</italic> mutations in NAb inducers. A linear schema indicating Nef functional domains is aligned above. Mutations at timepoints with NAb<sup>-</sup> (indicated by white wedge; mostly before 6 months p.i.), NAb<sup>+/-</sup> (green wedge) and NAb<sup>+</sup>) (purple wedge; mostly after 1 year) are shown in individual animals. Black and dark gray represent dominant and subdominant mutations (or deletion in R-360) by direct sequencing, respectively. Red and pink indicate dominant and subdominant G63E detection, respectively.</p><p>(B) Schema of SIV<sub>mac239</sub> Nef structure and Nef-G63E mutation orientation.</p><p>(C) Comparison of frequencies of macaques having Nef-G63E in plasma viruses between NAb non-inducers and inducers. Compared by Fisher’s exact test.</p><p>(D) Temporal relationship of Nef G63E frequencies in plasma virus and NAb induction. Black boxes (left Y axis) show log<sub>2</sub> NAb titers; red triangles and blue diamonds (right Y axis) show percentage of G63E and G63R mutations detected by subcloning (15 clones/point on average), respectively.</p></caption>
<graphic xlink:href="537602v4_fig2.tif" mime-subtype="tiff" mimetype="image"/>
</fig>
</sec>
<sec id="s2c">
<title>Nef-G63E is a CD8<sup>+</sup> T-cell escape mutation</title>
<p>These seven NAb inducers selecting this mutation elicited CD8<sup>+</sup> T-cell responses specific for a 9-mer peptide Nef<sub>62–70</sub> QW9 (QGQYMNTPW) (<xref rid="fig3" ref-type="fig">Figure 3A</xref>). This Nef<sub>62–70</sub> QW9 epitope is restricted by MHC-I molecules Mamu-B*004:01 and Mamu-B*039:01 (<xref ref-type="bibr" rid="c18">Evans et al., 1999</xref>; <xref ref-type="bibr" rid="c99">Sette et al., 2012</xref>). Possession of these accounted for six cases of Nef-G63E selection (<xref rid="fig3" ref-type="fig">Figure 3A</xref>), and the remaining one animal possessed Mamu-A1*032:02 predicted to bind to Nef<sub>63–70</sub> GW8 (NetMHCpan). Ten of nineteen NAb non-inducers also had either of these alleles (<xref rid="figs1a" ref-type="fig">Figure 1-figure supplement 1</xref>). This did not significantly differ with the NAb inducer group (<italic>P</italic> = 0.25 by Fisher’s exact test, data not shown), indicating that NAb induction was not simply linked with possession of these MHC-I genotypes but instead required furthermore specific selection of the Nef-G63E mutation (<xref rid="fig2" ref-type="fig">Figure 2C</xref>). Nef-G63E was confirmed to be an escape mutation from Nef<sub>62-70</sub>-specific CD8<sup>+</sup> T-cell responses (<xref rid="fig3" ref-type="fig">Figure 3B</xref>). NAb non-inducers possessing these alleles elicited little or no Nef<sub>62-70</sub>-specific CD8<sup>+</sup> T-cell responses (<xref rid="figs3a" ref-type="fig">Figure 3-figure supplement 1A</xref>), suggesting that <italic>in vivo</italic> selection and fixation of this Nef-G63E SIV was indeed Nef<sub>62-70</sub>-specific CD8<sup>+</sup> T cell-dependent. Replication kinetics of SIV carrying the Nef-G63E mutation was comparable with wild-type (WT) on a cynomolgus macaque HSC-F CD4<sup>+</sup> T-cell line (<xref ref-type="bibr" rid="c2">Akari et al., 1996</xref>), excluding the possibility that the mutation critically impairs viral replication (<xref rid="figs3a" ref-type="fig">Figure 3-figure supplement 1B</xref>), and plasma viral loads were comparable between Nef-G63E mutant-selecting NAb inducers versus non-inducers (<xref rid="figs3a" ref-type="fig">Figure 3-figure supplement 1C</xref>). These results indicate NAb induction following <italic>in vivo</italic> selection and fixation of the CD8<sup>+</sup> T-cell escape <italic>nef</italic> mutation, Nef-G63E under viral persistence.</p>
<fig id="fig3" position="float" orientation="portrait" fig-type="figure">
<label>Figure 3.</label>
<caption><title>Nef-G63E is a CD8<sup>+</sup> T-cell escape mutation.</title>
<p><bold>(A)</bold> Nef<sub>62–70</sub> QW9-specific CD8<sup>+</sup> T-cell frequencies and related MHC-I alleles in seven NAb inducers selecting Nef-G63E. Mamu-B*039:01 and Mamu-B*004:01 are known to restrict Nef<sub>62–70</sub> QW9 epitope and binding of Nef<sub>63–70</sub> peptide to Mamu-A1*032:02 was predicted.</p><p><bold>(B)</bold> CD8<sup>+</sup> T-cell responses specific to wild-type Nef<sub>62–70</sub> or mutant Nef<sub>62–70</sub>.G63E or Nef<sub>62– 70</sub>.G63R peptides.</p></caption>
<graphic xlink:href="537602v4_fig3.tif" mime-subtype="tiff" mimetype="image"/>
</fig>
</sec>
<sec id="s2d">
<title>G63E mutation reduces aberrant Nef interaction-mediated drive of PI3K/mTORC2</title>
<p>We next focused on the functional phenotype of this highlighted Nef-G63E mutant SIV in infected cells. An essence of host perturbation by Nef is its wide-spectrum molecular downregulation, ultimately increasing viral replication (<xref ref-type="bibr" rid="c97">Schindler et al., 2004</xref>; <xref ref-type="bibr" rid="c121">Zhang et al., 2009</xref>). To address possible amelioration, we compared downregulation of major targets CD3, CD4, MHC-I, CXCR4 and BST-2 (<xref ref-type="bibr" rid="c40">Jia et al., 2009</xref>) in infected HSC-F cells. Nef-G63E mutation did not confer notable change compared with wild-type (WT) [<italic>P</italic> = not significant (<italic>n.s</italic>.) for all molecules, data not shown], implicating other non-canonical changes (<xref rid="fig4" ref-type="fig">Figure 4A</xref>). Literature suggested ferritin to exert negative influence on B cells proportionate to HIV-infected macrophage-derived production (<xref ref-type="bibr" rid="c108">Swingler et al., 2008</xref>). Here, plasma ferritin levels showed no differences (<xref rid="figs4a" ref-type="fig">Figure 4-figure supplement 1A</xref>) and viral loads were comparable between Nef-G63E-selecting NAb inducers and non-inducers (<xref rid="figs4a" ref-type="fig">Figure 4-figure supplement 1B and 1C</xref>), arguing against gross involvement of ferritin as well as other viral replication-changing Nef phenotypes at least in this model.</p>
<fig id="fig4" position="float" orientation="portrait" fig-type="figure">
<label>Figure 4.</label>
<caption><title>Nef-G63E mutation reduces PI3K/mTORC2 binding and pAkt drive.</title>
<p><bold>(A)</bold> Representative surface expression level histograms of CD3, CD4, MHC class I, CXCR4 and BST-2 in CD4<sup>lo</sup>Nef<sup>+</sup> subpopulations after wild-type (WT) or Nef-G63E mutant SIV infection at multiplicity of infection (MOI) 0.1 on HSC-F cells.</p><p><bold>(B)</bold> Left: representative histograms of relative pAkt serine (Ser) 473 levels in p27<sup>+</sup> subpopulations after WT or Nef-G63E mutant SIV infection at MOI 0.1 on HSC-F cells. Numbers show pAkt Ser473 mean fluorescence intensities (MFIs) for each. Right: Deviation of pAkt Ser473 MFIs in p27<sup>+</sup> HSC-F cells compared with mean MFI of uninfected cells. Compared by unpaired t test.</p><p><bold>(C)</bold> Left: Relative pAkt Ser473 levels (normalized to mean MFI of uninfected controls) in Nef<sup>+</sup> HSC-F cells assessed for serum starvation (MOI 0.2, 1 day p.i.). Adjusted <italic>P</italic> values show results of comparison via Sidak’s post-hoc test of 2-way ANOVA (C, left). Right: Deviation of pAkt Ser473 MFIs in Nef<sup>+</sup> HSC-F cells assessed for high-MOI infection (MOI 5, 1-day p.i.). Compared by unpaired t test.</p><p><bold>(D)</bold> Proximity ligation assay (PLA) of Nef binding with mTOR, GβL/mLST8, PI3Kp85 and PI3Kp110α. MFI-based binding index was calculated as (anti-Nef/anti-partner) - (isotype/anti-partner) - (anti-Nef/isotype) + (isotype/isotype). Histograms for samples and isotype/isotype are representatively shown. Differences in MFI binding indexes can be enhanced compared with comparison of raw MFIs. Compared by paired t tests.</p><p><bold>(E)</bold> Sin1 co-immunoprecipitation analysis of WT versus Nef-G63E mutant SIV-infected HSC-F cells (infected at MOI 0.05, day 3). Immunoblotting of Nef (37 kDa) in whole cell lysates (lanes 4-6) and anti-Sin1 antibody immunoprecipitates (lanes 1-3) are shown.</p><p><bold>(F)</bold> Cell death frequencies of SIV-infected cells measured by Annexin V positivity (% of CD4<sup>lo</sup>) (infected at MOI 0.1, day 3). Compared by unpaired t test.</p><p>Data represent one of two [(A); (B); (C, right)] independent experiments in quadruplicate, four independent experiments performed in triplicate [(C, left)], four independent single-well comparison experiments pooled for statistical analysis (D), two experiments (E) or two experiments performed with six wells/control (F). Bars: mean ± SD (B, C right), mean ± SEM (C left, F).</p></caption>
<graphic xlink:href="537602v4_fig4.tif" mime-subtype="tiff" mimetype="image"/>
</fig>
<p>Thus, we took interest in immunosignaling-modulating properties of Nef-G63E SIV. Analysis of Akt, the predominant immune-intrinsic negative brake of B-cell maturation and AFC/antibody responses <italic>in vivo</italic> (<xref ref-type="bibr" rid="c83">Omori et al., 2006</xref>; <xref ref-type="bibr" rid="c59">Limon et al., 2014</xref>; <xref ref-type="bibr" rid="c21">Fruman et al., 1999</xref>; <xref ref-type="bibr" rid="c88">Ray et al., 2015</xref>; <xref ref-type="bibr" rid="c95">Sander et al., 2015</xref>), revealed that its serine 473 phosphorylation, non-canonically known for Nef-mediated upregulation (<xref ref-type="bibr" rid="c52">Kumar et al., 2016</xref>), was significantly lower on day 3 after Nef-G63E SIV infection at low multiplicity of infection (MOI) compared with WT (<xref rid="fig4" ref-type="fig">Figure 4B</xref>), stronger than histogram deviation levels in PI3K gain-of-function mice with full recapitulation of B-cell/antibody-dysregulating human APDS disease phenotype (<xref ref-type="bibr" rid="c6">Avery et al., 2018</xref>). The threonine 308-phosphorylated Akt (pAkt Thr308) level remained unaffected (<xref rid="figs4a" ref-type="fig">Figure 4-figure supplement 1B</xref>).</p>
<p>We further assessed properties of serine 473-phoyphorylated Akt (pAkt Ser473) inhibition by Nef-G63E SIV, and found that external PI3K stimuli (serum starvation) (<xref ref-type="bibr" rid="c47">Kennedy et al., 1997</xref>) accelerated phenotype appearance from day 3 to day 1 post-infection (<xref rid="fig4" ref-type="fig">Figure 4C</xref>, left). A similar trend was obtained by short-term PI3K stimulation with interferon-γ (<xref ref-type="bibr" rid="c79">Nguyen et al., 2001</xref>), interleukin-2 (<xref ref-type="bibr" rid="c64">Marzec et al., 2008</xref>) and SIV Env (<xref ref-type="bibr" rid="c20">François &amp; Klotman, 2003</xref>) (<xref rid="figs4a" ref-type="fig">Figure 4-figure supplement 1C</xref>). A high-MOI SIV infection, comprising higher initial concentration of extracellular Env stimuli, also accelerated phenotype appearance from day 3 to day 1 post-infection, with stronger pAkt reduction (<xref rid="fig4" ref-type="fig">Figure 4C</xref>, right). These showed that the Akt-inhibitory G63E mutant Nef phenotype is PI3K stimuli-dependent. Transcriptome analysis signatured decrease in PI3K-pAkt-FoxO1-related genes in mutant SIV infection (<xref rid="figs4a" ref-type="fig">Figure 4-figure supplement 1D</xref>). As Akt is also a survival mediator this implicated that Nef-G63E mutation may be Th-cytopathic, decreasing Th dysfunctional expansion (<xref ref-type="bibr" rid="c9">Baumjohann et al., 2013</xref>) as had been observed in LCMV strain WE (<xref ref-type="bibr" rid="c89">Recher et al., 2004</xref>) and chronic HIV/SIV (<xref ref-type="bibr" rid="c26">Gray et al., 2011</xref>; <xref ref-type="bibr" rid="c60">Lindqvist et al., 2012</xref>; <xref ref-type="bibr" rid="c85">Petrovas et al., 2012</xref>) infections. Here, reduced chronic-phase peripheral CXCR3<sup>-</sup>CXCR5<sup>+</sup>PD-1<sup>+</sup> memory follicular Th (Tfh), linked with antibody cross-reactivity in one cohort (<xref ref-type="bibr" rid="c61">Locci et al., 2013</xref>), was somewhat in line with this notion (<xref rid="figs4a" ref-type="fig">Figure 4-figure supplement 1E and 1F</xref>). We additionally examined another CTL escape mutant Nef-G63R, selected with marginal statistical significance primarily in early stage (<xref rid="figs4b" ref-type="fig">Figure 4-figure supplement 2A</xref>). This mutant did not associate with NAb induction in one control animal (R06-034) even upon preferential selection (<xref rid="figs4b" ref-type="fig">Figure 4-figure supplement 2B</xref>) and Nef-G63R mutant was not similarly decreased in pAkt drive (<xref rid="figs4b" ref-type="fig">Figure 4-figure supplement 2C</xref>), implicating that the Nef-G63E mutation was more tightly linked with Nab induction in terms of an immunosignaling phenotype.</p>
<p>We further explored molecular traits of this decreased Akt hyperactivation. We reasoned that comparing endogenous Nef binding patterns would be adequate and analyzed SIV-infected HSC-F cells with a flow cytometry-based proximity ligation assay (PLA) (<xref ref-type="bibr" rid="c56">Leuchowius et al., 2009</xref>; <xref ref-type="bibr" rid="c7">Avin et al., 2017</xref>), by calculating a mean fluorescence intensity (MFI) deviation-based binding index for each. We found that this Nef-G63E mutation causes significant decrease in Nef binding to PI3K p85/p110α and downstream mTORC2 components mTOR (<xref ref-type="bibr" rid="c96">Sarbassov et al., 2005</xref>) and GβL/mLST8 (<xref ref-type="bibr" rid="c50">Kim et al., 2003</xref>) in the CD4<sup>lo</sup>-SIV Gag p27<sup>+</sup> infected population (<xref rid="fig4" ref-type="fig">Figure 4D</xref>). Results were biochemically confirmed by a decrease in G63E-mutated Nef binding to the mTORC2-intrinsic cofactor Sin1 in coimmunoprecipitation analysis of infected HSC-F cells (<xref rid="fig4" ref-type="fig">Figure 4E</xref>). Collectively, the Nef-G63E mutation results in decreased aberrant Nef bridging and signal transduction of PI3K/mTORC2, explaining decreased substrate Akt Ser473 phosphorylation by mTORC2. These properties were in keeping with an acceleration in CD4-downregulated/infected HSC-F cell apoptosis upon Nef-G63E SIV infection (<xref rid="fig4" ref-type="fig">Figure 4F</xref>). Thus, Nef-G63E SIV is a mutant virus decreased in aberrant interaction/drive of B-cell-inhibitory PI3K/mTORC2 signaling, manifesting a molecular signature reciprocal to human APDS (<xref ref-type="bibr" rid="c4">Angulo et al., 2013</xref>; <xref ref-type="bibr" rid="c62">Lucas et al., 2014</xref>; <xref ref-type="bibr" rid="c6">Avery et al., 2018</xref>).</p>
</sec>
<sec id="s2e">
<title>Targeting of lymph node Env-specific B cells by Nef <italic>in vivo</italic></title>
<p>Next, we analyzed <italic>in vivo</italic> targeting of virus-specific B cells by Nef in lymph nodes to explore the potential B-cell-intrinsic influence of the G63E-Nef phenotype. Previously suggested influence of soluble Nef itself (<xref ref-type="bibr" rid="c86">Qiao et al., 2006</xref>) and/or related host factors (<xref ref-type="bibr" rid="c108">Swingler et al., 2008</xref>) may derive generalized influence on B cells; however, SIV antigen-specific binding antibody responses were rather decreased in NAb inducers (<xref rid="figs1a" ref-type="fig">Figure 1-figure supplement 1</xref>), viremia was comparable (<xref rid="figs3a" ref-type="fig">Figure 3-figure supplement 1C</xref>) and ferritin levels were not altered (<xref rid="figs4a" ref-type="fig">Figure 4-figure supplement 1A</xref>), differing from the aforementioned literature stating positive correlation between the three. Therefore, we surmised that some targeted Nef intrusion against Env-specific B cells may be occurring and that the decreased aberrant Nef-PI3K/mTORC2 drive may result in their enhanced lymph node maturation.</p>
<p>While reports (<xref ref-type="bibr" rid="c117">Xu et al., 2009</xref>) histologically proposed Nef B-cell transfer, quantitative traits, e.g., invasion frequency and influence on virus-specific B cells, have remained unvisited. Intracellular Nef staining is dim (particularly for B cell-acquired Nef), difficult to examine by conventional flow cytometry. Defining staining cutline requires single-cell images, overcoming confounding of high Nef false-staining via pre-permeation rupture and post-permeation confounding as judged by biologically discontinuous staining and/or batch-inflated signals. Collectively, at the expense of spatial information, we judged that sophisticating imaging cytometry would best visualize Nef-mediated B-cell perturbation <italic>in vivo</italic>. We analyzed lymph node B cells with Image Stream X MKII, with high-power (&gt; 10-fold) antigen detection [e.g., molecules of equivalent soluble fluorochrome (MESF) 5 <italic>vs.</italic> MESF 80 in an average flow cytometer for FITC detection] ideal for detection/single-cell verification.</p>
<p>We designed a triple noise cancellation strategy to overcome the above. Firstly, amine reactive dye staining (<xref ref-type="bibr" rid="c84">Perfetto et al., 2006</xref>) gated out B cells being Nef-positive due to pre-experimental membrane damage (<xref rid="figs5a" ref-type="fig">Figure 5-figure supplement 1A</xref>, left). Next, we deployed secondary quantitative parameters of Nef signals deriving from each pixel of the images. Definition of a gray-level cooccurrence matrix (GLCM) (<xref ref-type="bibr" rid="c28">Haralick et al., 1973</xref>) numerating adjacent signal deviation as their frequencies on a transpose matrix enables calculation of a variety of feature values summarizing traits of the whole image. A biological assumption of Nef signal continuity in a true staining suggested that the sum of weighted square variance of GLCM, i.e., the {sum of [square of (value – average signal strength) × frequency of each value occurrence]} would separate natural versus artificial Nef signals. This value, Haralick variance, was computed for multiple directions and averaged, deriving Haralick variance mean (<xref rid="figs5a" ref-type="fig">Figure 5-figure supplement 1A</xref>, X axis), proportionate with staining image unnaturalness. Finally, Nef signal intensity threshold (<xref rid="figs5a" ref-type="fig">Figure 5-figure supplement 1A</xref>, Y axis) gated out overtly-stained cells void for true-false verification. These excluded B cells showing non-specific, strong-signal binary-clustered staining pixels for Nef deriving a large summated variance (X axis), and/or cells batch-stained for Nef (Y axis), likely originating from post-experimental membrane damage.</p>
<p>With this approach we acquired images of a Live/Dead<sup>-</sup>-Nef signal Haralick variance mean<sup>lo</sup>-Nef signal intensity threshold<sup>lo</sup>-Nef<sup>+</sup>CD19<sup>+</sup> B-cells, with fine-textured gradation of Nef<sup>int-</sup> <sup>lo</sup> staining with continuity from membrane-proximal regions without sporadic staining speckles (<xref rid="fig5" ref-type="fig">Figure 5A</xref> and <xref rid="figs5a" ref-type="fig">Figure 5-figure supplement 1</xref>). A linear discriminant analysis-based machine learning module, scoring segregation of typical void/valid images, showed this gating to provide the highest two-dimensional separation (<xref rid="figs5a" ref-type="fig">Figure 5-figure supplement 1</xref>). Combined with biotinylated Env/streptavidin staining, this reproducibly obtained images of Env-specific (Ch 12) CD19<sup>+</sup> (Ch 11) B cells without membrane ruptures (Ch 08) and showing fine-textured transferred Nef (Ch 02) (<xref rid="fig5" ref-type="fig">Figure 5B</xref>). Nef invasion upregulated pAkt Ser473 (Ch 03) to a range resembling <italic>in vitro</italic> analysis (<xref rid="fig5" ref-type="fig">Figure 5C</xref>), stating that Nef-driven aberrant PI3K/mTORC2 signaling does occur in Nef-invaded B cells <italic>in vivo</italic> and the current phenotypic change likely affects B-cell dynamics. Strikingly, lymph node Env-specific B cells showed significantly higher Nef-positive frequencies as compared with batch non-Env-specific B cells (<xref rid="fig5" ref-type="fig">Figure 5D</xref>). This indicated that infected cell-generated Nef preferentially targets adjacent Env-specific B cells, putatively through infected CD4<sup>+</sup> cell-to-B-cell contact/transfer (<xref ref-type="bibr" rid="c117">Xu et al., 2009</xref>; <xref ref-type="bibr" rid="c30">Hashimoto et al., 2016</xref>) and that a Nef phenotypic change likely dictates Env-specific B-cell maturation.</p>
<fig id="fig5" position="float" orientation="portrait" fig-type="figure">
<label>Figure 5.</label>
<caption><title>Preferential targeting of lymph node Env-specific B cells by Nef <italic>in vivo</italic>.</title>
<p><bold>(A)</bold> Representative gating of triple noise-cancellation <italic>in vivo</italic> Nef staining in B cells analyzed by ImageStreamX MKII. Pre-experimental damaged cells are first excluded with Live/Dead from focused/centroid/singlet image-acquired CD19<sup>+</sup> B cells (first lane right/R4 gated on “Focused”). Following Nef<sup>+</sup> gating (second lane left/R5 gated on R4), a second step of Nef noise cancellation (second lane middle/R7 on R5) comprises double-negative removal of post-experimental stochastic irregular staining building a disparate intracellular staining gradient (X axis, Nef signal pixel Haralick variance mean) and post-experimental batch overt cellular staining (Y axis, Nef signal pixel intensity threshold). This outputs a B-cell population with a fine-textured pericellular Nef<sup>int-lo</sup> staining, biologically concordant with Nef membrane-anchoring. Probing of anti-Env BCR (αEnv) by recombinant SIV Env (second lane, right) is combined, resulting in a 2-D panel of intracellular Nef versus αEnv for noise-cancelled Nef<sup>+</sup> B cells (R7) plus Nef<sup>-</sup> B cells (R8) (third lane left/“R7+R8”). pAkt Ser473 expression (third lane right) and cellular morphology (B) was further analyzed. DN, double-negative.</p><p><bold>(B)</bold> Typical images of Nef-transferred Env-specific B cells defined αEnv<sup>+</sup>-intracellular Nef<sup>+</sup>-Nef Haralick variance mean<sup>lo</sup>-Nef Intensity threshold<sup>lo</sup>-Live/Dead<sup>-</sup>-CD19<sup>+</sup> cells [“Nef<sup>+</sup>aEnv<sup>+</sup>” population of lower left panel in (A), gated on “R7, R8”]. Note the pericellular pAkt Ser473 upregulation in these cells (Ch 03/yellow). Data on inguinal lymph node lymphocytes of macaque R10-007 at week 62 post-SIV<sub>mac239</sub> infection are shown in (A) and (B).</p><p><bold>(C)</bold> Comparison of pAkt Ser473 median fluorescence (medFI) intensity levels in Nef<sup>-</sup> B cells (R8) versus noise-cancelled Nef<sup>+</sup> B cells (R7). Analyzed by paired t test.</p><p><bold>(D)</bold> Comparison of Nef-positive cell frequencies in non-Env-specific (left) versus Env-specific (right) B cells in lymph nodes of persistently SIV-infected macaques (<italic>n</italic> = 6). Analyzed by paired t test.</p></caption>
<graphic xlink:href="537602v4_fig5.tif" mime-subtype="tiff" mimetype="image"/>
</fig>
</sec>
<sec id="s2f">
<title>Cell contact-dependent B-cell invasion from infected cells <italic>in vitro</italic></title>
<p>To understand cell-intrinsic properties enhancing B-cell Nef acquisition <italic>in vivo</italic>, we addressed in an <italic>in vitro</italic> coculture reconstitution how infected cell-to-B-cell Nef invasion may take place or be modulated. We performed imaging cytometry on a twelve-hour coculture of SIV-disseminating HSC-F cells (reaching around 30% Nef-positivity at moment of coculture) with Ramos B cells (<xref rid="fig6" ref-type="fig">Figure 6A</xref>, top left), independent of MHC-related interactions known to enhance T-cell/B-cell contact (<xref ref-type="bibr" rid="c115">Wülfing et al., 1998</xref>). Machine learning-verified noise cancellation of fragmented signal acquisition (<xref rid="fig6" ref-type="fig">Figure 6A</xref>, middle left) filtered reproducible images of Nef-positive HSC-F cells directly adhering to Ramos B cells within the doublet population (<xref rid="fig6" ref-type="fig">Figure 6A</xref>, top to middle right). Importantly, addition of a soluble macaque CD3 stimulation-competent antibody resulted in enhanced Nef<sup>+</sup> T-cell adhesion to B cells (<xref rid="fig6" ref-type="fig">Figure 6A</xref>, bottom center), accompanying images of polarized Nef protrusion/injection from T cells to B cells (second column, filled wedges) as well as trogocytosed B-cell membranes (third column, open wedge), in keeping with dynamic B-cell Nef acquisition. Centrifugation strengths upon cell collection and staining (190 x <italic>g</italic> versus 1,200 x <italic>g</italic> and 600 x <italic>g</italic> versus 1,200 x <italic>g</italic>, respectively) shifted the tendency between enriched Nef<sup>+</sup> HSC-F-B-cell doublet versus Nef<sup>+</sup> B-cell singlet detection via CD3 stimulation, respectively (<xref rid="fig6" ref-type="fig">Figure 6A</xref>, lower right).</p>
<fig id="fig6" position="float" orientation="portrait" fig-type="figure">
<label>Figure 6.</label>
<caption><title>Contact-dependent enhancement of B-cell Nef acquisition in reconstitution.</title><p><bold>(A)</bold> Imaging flow cytometric analyses of stimuli-dependent enhancement of infected HSC-F cell adhesion to non-permissive CD19<sup>+</sup> Ramos B cells with the indicated gating (left). Cocultured doublet cells subjected to machine learning-verified filtration of fragmented signal acquisition (via gating Nef pixel signal contrast<sup>lo</sup>-Nef mean pixel per object<sup>hi</sup> cells) deriving typical images of infected HSC-F cell (Nef stain shown in pale blue pseudocolor) adhesion to Ramos cells (CD19 stain shown in purple pseudocolor) are shown. Analyzed by unpaired t test for doublet formation in the unstimulated versus anti-CD3 monoclonal antibody (clone FN-18)-stimulated group.</p><p><bold>(B)</bold> Flow cytometric analyses of Nef-acquiring live CD19<sup>+</sup> Ramos B cells upon coculture with SIV-infected HSC-F cells with or without the indicated stimuli. Analyzed by one-way ANOVA with Tukey’s post-hoc multiple comparison tests.</p><p><bold>(C)</bold> Representative flow cytometric plot (left), histogram (middle) and pAkt Ser473 signal deviation in wild type versus G63E Nef-acquiring CD20<sup>+</sup> primary B cells (six wells/control). Analyzed by unpaired t test. Data represent pooled data of two (A) or three [(B) and (C)] independent experiments with indicated number of replicates showing similar results.</p></caption>
<graphic xlink:href="537602v4_fig6.tif" mime-subtype="tiff" mimetype="image"/>
</fig>
<p>Substantiated by the acquired images, an enhancement of live singlet Ramos B-cell Nef acquisition (Nef<sup>+</sup> frequencies/total) was also observed by CD3 stimulation in conventional flow cytometry (<xref rid="fig6" ref-type="fig">Figure 6B</xref>). We observed a similar enhancement by phytohemagglutinin (PHA) stimulation whereas phorbol-12-myristate-13-acetate (PMA)/ionomycin did not enhance B-cell Nef acquisition. In a similar 72-hour static infected cell coculture with primary CD20<sup>+</sup> B cells, we detected recapitulation of the decreased B-cell pAkt Ser473 phosphorylation upon G63E Nef transfer compared to that of WT Nef (<xref rid="fig6" ref-type="fig">Figure 6C</xref>), implicating that the Nef-G63E mutation can directly alleviate maturation inhibition in preferentially Nef-targeted Env-specific B cells.</p>
</sec>
<sec id="s2g">
<title>Enhanced Env-specific B-cell responses after PI3K-diminuting mutant selection</title>
<p>Finally, peripheral SIV Env-specific IgG<sup>+</sup> B-cell responses comprising plasmablasts (PBs) and memory B cells (B<sub>mem</sub>) were analyzed to assess <italic>in vivo</italic> B-cell quality in NAb inducers with Nef-G63E mutant selection. After excluding lineage-specific cells [T/NK/pro-B cells/monocytes/myeloid dendritic cells (DCs)/plasmacytoid DCs], we defined IgG<sup>+</sup> PBs as showing: high replication (Ki-67<sup>+</sup>), post-activation (HLA-DR<sup>+</sup>), transcriptional switching for terminal differentiation (IRF4<sup>hi</sup>) and downregulated antigen surface binding (surface [s]Env<sup>lo</sup>-cytoplasmic [Cy]Env<sup>+</sup>) (<xref ref-type="bibr" rid="c82">Nutt et al., 2015</xref>; <xref ref-type="bibr" rid="c103">Silveira et al, 2015</xref>). Env-specific PBs were defined as CD3<sup>-</sup>CD8<sup>-</sup>CD10<sup>-</sup>CD14<sup>-</sup>CD16<sup>-</sup>CD11c<sup>-</sup>CD123<sup>-</sup>CD19<sup>-</sup>CyIgG<sup>+</sup>Ki-67<sup>+</sup>IRF4<sup>hi</sup>HLA-DR<sup>+</sup> (total PB) sEnv<sup>lo</sup>CyEnv<sup>+</sup> (Env-specific) (<xref rid="fig7" ref-type="fig">Figure 7A</xref> and <xref rid="figs7a" ref-type="fig">Figure 7-figure supplement 1</xref>). NAb inducers showed significantly higher Env-specific IgG<sup>+</sup> PB responses around week 30 p.i., after Nef-G63E selection, compared to those in NAb non-inducers (<xref rid="fig7" ref-type="fig">Figures 7B</xref> and <xref rid="fig7" ref-type="fig">7C</xref>). At 1 year, this difference became enhanced; Env-specific PB frequencies were reduced in non-inducers, while this reduction was ameliorated in the NAb inducers with Nef-G63E.</p>
<fig id="fig7" position="float" orientation="portrait" fig-type="figure">
<label>Figure 7.</label>
<caption><title>Enhanced SIV Env-specific B-cell output up to NAb induction following Nef-G63E selection.</title><p>(A) Representative gating (R02-004, week 32 p.i.) of SIV Env gp140-specific memory B cells (B<sub>mem</sub>) and plasmablasts (PBs). Two panels for PB gating are shown in lower resolution for visibility. B<sub>mem</sub> staining was performed separately and gating are merged with PB panels (second row, panels 2–4). For lineage-specific exclusion (first row, panel 4), CD10 was stained independently for B<sub>mem</sub> (see parenthesis).</p><p>(B) Changes in SIV Env gp140-specific plasmablast (PB) frequencies in viremic NAb non-inducers (left, <italic>n</italic> = 12) and Nef-G63E-selecting NAb inducers (right, <italic>n</italic> = 6). Available samples of twelve viremic NAb non-inducers (including ten with ≥ 1-year survival) and six NAb inducers were tracked. In the right panel, the frequencies in NAb non-inducers are shown in background (gray) for comparison.</p><p>(C) Comparison of Env gp140-specific PB frequencies between NAb non-inducers and inducers by Mann Whitney U tests. In the right, the frequencies at NAb induction were compared with those at year 1 in NAb non-inducers with ≥ 1-year survival (<italic>n</italic> = 10). Bars: mean ± SD.</p><p>(D) Left: vector chart of Env gp140-specific memory B cell (B<sub>mem</sub>) and PB levels. Legends for each animal correspond to the ones in (B). Right: NAb non-inducer vectors empirically define a polygonal GC output attractor area <italic>D<sub>n</sub></italic> (gray area surrounded with dotted lines) on which they converge by and beyond year 1 p.i. The NAb inducer vectors (shown up to the time of NAb induction) remained outside of <italic>D<sub>n</sub></italic>. At the moment of NAb induction they converged on a second GC output attractor area <italic>D<sub>i</sub></italic> (red area surrounded with dotted lines), mutually exclusive with <italic>D<sub>n</sub></italic> (<italic>P</italic> &lt; 0.0001 by Fisher’s exact test on NAb inducer vector convergence frequency within <italic>D<sub>n</sub></italic>). Legends for year 1 p.i. in the NAb non-inducers and moment of NAb induction in the NAb inducers are specified.</p></caption>
<graphic xlink:href="537602v4_fig7.tif" mime-subtype="tiff" mimetype="image"/>
</fig>
<p>Concomitant determination of Env-specific IgD<sup>-</sup>CD27<sup>+</sup>IgG<sup>+</sup> B<sub>mem</sub> responses allowed pair-wise analysis of Env-specific IgG<sup>+</sup> B<sub>mem</sub>/PB as a projection of germinal center (GC) output as an indicator of overall B-cell response quality (<xref ref-type="bibr" rid="c122">Zotos et al., 2010</xref>) (<xref rid="fig7" ref-type="fig">Figure 7D</xref>, left). In this two-dimensional vector charting of Env-specific B<sub>mem</sub>/PB responses, vector protrusion towards upper right reasonably represents higher gross GC output of antibody-forming cells (AFCs) (B<sub>mem</sub>/PBs). In NAb non-inducers, all vectors converged on an empirically defined polygonal attractor area <italic>D<sub>n</sub></italic> (gray area surrounded with dotted lines in <xref rid="fig7" ref-type="fig">Figure 7D</xref>, right) at year 1 p.i. and beyond, describing that these NAb non-inducers failed to sustain Env-specific GC output. In contrast, the vectors were consistently tracked outside <italic>D<sub>n</sub></italic> in the NAb inducers with Nef G63E (<xref rid="fig7" ref-type="fig">Figure 7D</xref>). At the moment of NAb induction, they converged on another upper-right GC output attractor area <italic>D<sub>i</sub></italic> (red area surrounded with dotted lines in <xref rid="fig7" ref-type="fig">Figure 7D</xref>, right), mutually exclusive with <italic>D<sub>n</sub></italic> (<italic>P</italic> &lt; 0.0001 by Fisher’s exact test on NAb non-inducer/inducer vector distribution frequency within <italic>D<sub>n</sub></italic>). These suggest more robust virus-specific IgG<sup>+</sup> B-cell responses following Nef-G63E CD8<sup>+</sup> T-cell escape mutant selection, predisposing to NAb induction. This enhanced cognate B-cell signature was also an inverted pattern of impaired terminally-differentiated B-cell responses in APDS (<xref ref-type="bibr" rid="c3">Al Qureshah et al., 2021</xref>).</p>
<p>Taken together, in the current model, Nef<sub>62-70</sub>-specific CD8<sup>+</sup> T-cell responses in persistently SIV<sub>mac239</sub>-infected macaques selected for an escape mutant, Nef-G63E SIV, which decreased aberrant Nef binding and drive of B-cell-inhibitory PI3K/mTORC2. B-cell Nef invasion <italic>in vivo</italic> occurred more preferentially in Env-specific B cells, suggesting diminution in tonic Nef-mediated B-cell dysregulation after mutant selection. These predisposed to enhanced Env-specific B-cell responses and subsequent SIV<sub>mac239</sub>-specific NAb induction, altogether, in a manner reciprocal to human APDS-mediated immune dysregulation.</p>
</sec>
</sec>
<sec id="s3">
<title>Discussion</title>
<p>In the present study, we found NAb induction against an NAb-resistant SIV after selection of a CD8<sup>+</sup> T-cell escape <italic>nef</italic> mutant virus. The Nef-G63E mutation, positioned in cognate B cells, results in reduction of binding/drive of PI3K/mTORC2, being concordant with <italic>in vivo</italic> enhancement of Env-specific IgG<sup>+</sup> B cells up to NAb induction following mutant selection. Importantly, this manifested through a pAkt deviation level more vivid than wild-type versus germline <italic>PIK3CD</italic> gain-of-function mutation heterozygote mice recapitulating full human APDS phenotype (<xref ref-type="bibr" rid="c6">Avery et al., 2018</xref>). Thus, the current Nef-G63E-associated B-cell/NAb phenotype likely occurs in a “reciprocal APDS-like” manner. This proposition was enhanced based on extension of immune cell-intrinsic Nef influence on cognate B cells (<xref rid="fig5" ref-type="fig">Fig. 5</xref>), in addition to infected T cells. This work is, to our knowledge, the first to interlink a PI3K/mTORC2-modulating viral signature and enhanced B-cell/NAb responses in a viral infection model.</p>
<p>A link between viral T-cell escape and consequent immune modulation has been previously partially explored, including enhanced mutant HIV-1 epitope peptide binding to inhibitory MHC-I receptor on DCs impairing T cells (<xref ref-type="bibr" rid="c58">Lichterfeld et al., 2007</xref>) and decreased CTL-mediated lymph node immunopathology rather driving LCMV-specific antibody production (<xref ref-type="bibr" rid="c8">Battegay et al., 1993</xref>). Our results now evidence a new pattern of NAb responses bivalently shaped through viral interactions with both humoral and cellular immunity in AIDS virus infection. SIV<sub>mac239</sub> infection of macaques possessing MHC-I alleles associated with Nef-G63E mutation can be one unique model to analyze virus-host interaction for B cell maturation leading to NAb induction. The time frame of Nef-G63E mutant selection versus moment of NAb induction was variable in the inducers, for which we did not obtain a clear explanation. This may be influenced by certain basal competitive balance between humoral versus cellular adaptive immunity, as observed in certain vaccination settings (<xref ref-type="bibr" rid="c87">Querec et al., 2009</xref>).</p>
<p>Identification of the current Nef-G63E candidate phenotype adds one aspect to the wealth of evidence documenting the multifaceted impact of Nef in HIV/SIV infection (<xref ref-type="bibr" rid="c51">Kirchhoff et al., 1995</xref>; <xref ref-type="bibr" rid="c23">Gauduin et al., 2006</xref>; <xref ref-type="bibr" rid="c107">Stolp et al., 2012</xref>). It appeared unique that the current phenotype differed from decreased replication-related properties or generalized amelioration in immune impairment such as those documented in delta-Nef HIV/SIV infection (<xref ref-type="bibr" rid="c51">Kirchhoff et al., 1995</xref>; <xref ref-type="bibr" rid="c43">Johnson et al., 1997</xref>; <xref ref-type="bibr" rid="c23">Gauduin et al., 2006</xref>; <xref ref-type="bibr" rid="c22">Fukazawa et al., 2012</xref>). The SIV Nef N-terminal unstructured region comprising Nef-G63E is not conserved in HIV-1 (<xref ref-type="bibr" rid="c97">Schindler et al., 2004</xref>) and beyond this model study it remains to be addressed whether a mutant HIV-1 with a similar immunosignaling-affecting phenotype can be obtained and how much lentiviral conservation exists for such interactions. Cognate B-cell maturation analysis on cohort basis (<xref ref-type="bibr" rid="c31">Hau et al., 2022</xref>) may potentially assist this approach.</p>
<p>Obtained results on preferential Nef transfer to Env-specific B cells (<xref rid="fig5" ref-type="fig">Figure 5</xref>) implicate involvement of polarized cognate immune cell perturbation <italic>in vivo</italic>, best depicted for preferential infectivity of HIV-specific CD4<sup>+</sup> T cells (<xref ref-type="bibr" rid="c17">Douek et al., 2002</xref>) and HIV condensation to the dendritic cell-T-cell interface (<xref ref-type="bibr" rid="c68">McDonald et al., 2003</xref>). As cognate MHC class II interactions (<xref ref-type="bibr" rid="c115">Wülfing et al., 1998</xref>; <xref ref-type="bibr" rid="c25">Giltin et al., 2014</xref>) regularly occur between HIV/SIV-specific CD4<sup>+</sup> T cells and Env-specific B cells in the germinal center, results may show that Env-specific B-cell dysregulation stems from a negative consequence of exploited cognate T-cell/B-cell orchestration. Enhanced T-cell attachment and transfer of Nef to B cells <italic>in vitro</italic> by CD3 activation (<xref rid="fig6" ref-type="fig">Figure 6</xref>), mimicking peptide/MHC (pMHC) signaling, may facilitate recovery from viral T-cell cytoskeletal impairment (<xref ref-type="bibr" rid="c12">Campbell et al., 2004</xref>; <xref ref-type="bibr" rid="c44">Jolly et al., 2004</xref>; <xref ref-type="bibr" rid="c106">Stolp et al., 2009</xref>) antagonizing reduced motility (<xref ref-type="bibr" rid="c107">Stolp et al., 2012</xref>), resulting in <italic>in vivo</italic> “filtering” of enhanced cognate CD4<sup>+</sup> T-cell interaction with cognate B cells. Combined with recent <italic>in vivo</italic> detection of trogocytosed CD20-bearing follicular CD4<sup>+</sup> T cells positive for viral DNA and showing increase during SIV infection (<xref ref-type="bibr" rid="c93">Samer et al., 2023</xref>), results suggest occurrence of contact-dependent, polarized interactions facilitating Nef transfer to cognate B cells.</p>
<p>The major <italic>in vivo</italic> readout of this study is autologous neutralization of a highly difficult-to-neutralize SIV, differing from HIV-specific broadly neutralizing antibodies (bNAbs). Importantly, however, obtained signatures of enhanced IgG<sup>+</sup> Env-specific AFC B cells (class switch/terminal differentiation) and virus neutralization (hypermutation) directly evidence enhanced activity of activation-induced cytidine deaminase (AID), the canonical positive driver of B-cell fate, showing a strong conceptual continuity with bNAb regulation by AID.</p>
<p>Our results extracted an <italic>in vivo</italic> link between a decreased aberrant Nef-PI3K/mTORC2 interaction and major enhancement in B-cell responses. The relationship is indeed reciprocal to immunogenetic mechanisms of human PI3K gain-of-function mutations resulting in APDS with multiply impaired anti-viral B-cell responses. APDS occurs from germline mutations in leukocyte-intrinsic p110δ catalytic subunit-coding <italic>PIK3CD</italic> or the ubiquitous p85α regulatory subunit-coding <italic>PIK3R1</italic>, both deriving class IA PI3K gain-of-function residue substitutions (<xref ref-type="bibr" rid="c16">Dornan et al., 2017</xref>). Such mutations lead to immune cell-intrinsic perturbations with cognate B-cell blockade, manifesting as impaired class-switched B-cell responses and susceptibility against various infections (<xref ref-type="bibr" rid="c4">Angulo et al., 2013</xref>; <xref ref-type="bibr" rid="c62">Lucas et al., 2014</xref>; <xref ref-type="bibr" rid="c13">Coulter et al., 2017</xref>). In the current work, we conversely document a decrease in virally induced tonic PI3K drive, enhanced IgG class-switched cognate B-cell responses and NAb induction against a notably difficult-to-neutralize SIV. While the exact hierarchy of binding between Nef and PI3K/mTORC2 components (including PI3K isoforms) and its perturbation by Nef-G63E mutation remains to be investigated, PI3Kp85 did reasonably show the strongest Nef-binding index in PLA assay (<xref rid="fig4" ref-type="fig">Figure 4D</xref>) as Nef and PI3Kp85 possess SH3-binding PxxP and SH3 domains, respectively (<xref ref-type="bibr" rid="c92">Rickles et al., 1994</xref>). Binding decrease in canonical partner PI3Kp85 may domino-trigger decrease with others, resulting in quintuple PI3K/mTORC2 binding decrease and fragile downstream Akt signaling. Such domino-triggering is also observed from gain-of-function-mutated p85 to p110 evoking its activation (<xref ref-type="bibr" rid="c16">Dornan et al., 2017</xref>) similarly highlighting the fine-tuned nature of the pathway.</p>
<p>A limitation of this study is the use of retrospective samples, posing constraints for detecting exact temporal changes in tonic viral B-cell perturbation. Related with this, sampling of lymph node cells in animals belonging to the subgroup of interest at the optimal moment was unpredictable. Certain plasma and cellular samples were also unavailable in differing experiments. While partially addressed in <italic>in vitro</italic> reconstitution, much remains to be investigated for the observed polarity of Env-specific B-cell perturbation <italic>in vivo</italic>. Similarly, influence of the Nef-G63E phenotype on CD4<sup>+</sup> T cells <italic>in vivo</italic> and its consequence on B-cell modulation remains largely elusive, and in the current work we focused mainly on molecular properties of the NAb-correlating Nef-G63E mutant strain. As HIV/SIV infection uniquely shows a biphasic Tfh dysregulation of acute-phase destruction (<xref ref-type="bibr" rid="c67">Mattapallil et al., 2005</xref>; <xref ref-type="bibr" rid="c73">Moukambi et al., 2015</xref>; <xref ref-type="bibr" rid="c74">Moukambi et al., 2019</xref>) followed by dysregulated chronic-phase hyper-expansion (<xref ref-type="bibr" rid="c60">Lindqvist et al., 2012</xref>; <xref ref-type="bibr" rid="c85">Petrovas et al., 2012</xref>; <xref ref-type="bibr" rid="c14">Cubas et al., 2013</xref>; <xref ref-type="bibr" rid="c116">Xu et al., 2015</xref>), it is of interest how the PI3K drive-ameliorated and proapoptotic mutant influenced this axis post-<italic>in vivo</italic> selection, warranting further studies ahead. While influence on B cells appears to be stronger by unexplained reasons (<xref ref-type="bibr" rid="c5">Asano et al., 2018</xref>), it is noteworthy that PI3K gain-of-function also evokes basal dysregulation in peripheral CD4<sup>+</sup> T cells, locally recapitulating the consequence of immunodeficiency virus replication and implicating importance of this signaling axis in HIV/SIV infection. In any event, usage of specific animal models does help to depict a temporal cascade of <italic>in vivo</italic> events leading to NAb induction, assisting human immunology. As future extension of this study extracting the NAb-involved molecular axis, manipulation/reconstitution experiments shall be designed.</p>
<p>In conclusion, we exemplify in a non-human primate AIDS model that NAb induction against a highly resistant SIV occurs after selection of a CD8<sup>+</sup> T-cell escape variant reduced in excess PI3K/mTORC2 drive. These results provide an understanding of how immunodeficiency virus-specific NAb responses can be shaped by both wings of adaptive immune pressure and depicts that immune cell-intrinsic PI3K/mTORC2 manipulation may be pivotal for harnessing antiviral NAb responses. As human IEIs are increasingly becoming discovered with various immune-perturbing phenotypes and inheritance patterns (<xref ref-type="bibr" rid="c39">Jauch et al., 2023</xref>), search of other types of analogies between viral immune dysregulations and human IEIs may lead to identification of novel targets to modulate and harness immune responses in translational settings.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgments</title>
<p>This work was supported by Japanese Initiative for Progress of Research on Infectious Diseases for Global Epidemic (J-PRIDE) (JP19fm0208017 to H.Y.), Japan Program for Infectious Diseases Research and Infrastructure (Interdisciplinary Cutting-edge Research) (JP22wm0325006 to H.Y.), Research Programs on HIV/AIDS, Emerging and Re-emerging Infectious Diseases, and Global Health Issues (JP20fk0410022 and JP24fk0410066 to H.Y.; JP18fk0410003, JP20fk0410011, JP20fk0108125, JP20jm0110012, JP21fk0410035, and JP21jk0210002 to T.M.) from Japan Agency for Medical Research and Development, the Ministry of Education, Culture, Sports, Science, and Technology in Japan ([JSPS] KAKENHI Grants 17H02185, 18K07157 and 24K21287 to H.Y.; 21H02745 to T.M.), the Takeda Science Foundation (to H.Y.), the Imai Memorial Trust for AIDS Research (to H.Y.), and the Mitsui-Sumitomo Insurance Welfare Foundation (to H.Y.). We thank Fumiko Ono, Koji Hanari, Katsuhiko Komatsuzaki, Akio Hiyaoka, Hiromi Ogawa, Keiko Oto, Hirofumi Akari, Yasuhiro Yasutomi, Hiromi Sakawaki, Tomoyuki Miura and Yoshio Koyanagi for animal experiment assistance; Hiroyuki Kogure, Sayuri Seki and Julia R. Hirsiger for imaging cytometry technical assistance; Masako Nishizawa, Trang Thi Thu Hau, Shigeyoshi Harada, Takushi Nomura, Akiko Takeda, Taku Nakane, Nami Iwamoto, Taeko K. Naruse, Akinori Kimura and Mark S. de Souza for their help. H.Y. thanks Jun Abe, Shoi Shi, Bettina Stolp, Jens V. Stein, Makoto Yamagishi and Yusuke Yanagi for conceptual discussions, and Mike Recher for collaborative support.</p>
</ack>
<sec id="d1e1639">
<title>Author Contributions</title>
<p>H.Y. conceived/designed/performed study and wrote manuscript; T.M. provided animal cohort, co-edited manuscript and co-directed study.</p>
</sec>
<sec id="d1e1646">
<title>CRediT taxonomy</title>
<p>Conceptualization: HY</p>
<p>Methodology: HY</p>
<p>Validation: HY</p>
<p>Formal analysis: HY</p>
<p>Investigation: HY</p>
<p>Resources: HY, TM</p>
<p>Data curation: HY</p>
<p>Writing—original draft: HY</p>
<p>Writing—review &amp; editing: HY, TM</p>
<p>Visualization: HY</p>
<p>Supervision: HY, TM</p>
<p>Project administration: HY</p>
<p>Funding acquisition: HY, TM</p>
</sec>
<sec id="d1e1679">
<title>Declaration of Interests</title>
<p>The authors declare no competing interests.</p>
</sec>
<sec id="s4">
<title>Materials and methods</title>
<sec id="s4a">
<title>Material availability</title>
<p>This study did not generate new unique reagents.</p>
</sec>
<sec id="s4b">
<title>Data and code availability</title>
<p>Data were analyzed using existing computational packages. The accession number for the transcriptome data [wild-type SIV<sub>mac239</sub>-infected HSC-F cell line (<italic>n</italic> = 3), Nef-G63E SIV<sub>mac239</sub>-infected HSC-F cell line (<italic>n</italic> = 3) and uninfected HSC-F cell line (<italic>n</italic> = 3)] has been deposited under the accession number GenBank: GSE65806.</p>
</sec>
<sec id="s4c">
<title>Rhesus macaques retrospectively utilized for samples</title>
<p>Seventy Burmese rhesus macaques (<italic>macaca mulatta</italic>) (57 males and 13 females) were retrospectively analyzed in this study. Experiments were previously carried out (<xref ref-type="bibr" rid="c66">Matano et al., 2004</xref>; <xref ref-type="bibr" rid="c119">Yamamoto et al., 2007</xref>; <xref ref-type="bibr" rid="c36">Iseda et al., 2016</xref>; <xref ref-type="bibr" rid="c81">Nomura et al., 2012</xref>; <xref ref-type="bibr" rid="c37">Ishii et al., 2012</xref>; <xref ref-type="bibr" rid="c109">Takahashi et al., 2013</xref>; <xref ref-type="bibr" rid="c75">Nakane et al., 2013</xref>; <xref ref-type="bibr" rid="c101">Shi et al., 2013</xref>; <xref ref-type="bibr" rid="c38">Iwamoto et al., 2014</xref>; <xref ref-type="bibr" rid="c110">Terahara et al., 2014</xref>) in the Tsukuba Primate Research Center, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN) with the help of the Corporation for Production and Research of Laboratory Primates and the Institute for Frontier Life and Medical Sciences, Kyoto University (IFLMS-KU) after approval by the Committee on the Ethics of Animal Experiments of NIBIOHN and IFLMS-KU under the guidelines for animal experiments at NIBIOHN, IFLMS-KU and National Institute of Infectious Diseases in accordance with the Guidelines for Proper Conduct of Animal Experiments established by Science Council of Japan (<ext-link ext-link-type="uri" xlink:href="http://www.scj.go.jp/ja/info/kohyo/pdf/kohyo-20-k16-2e.pdf">http://www.scj.go.jp/ja/info/kohyo/pdf/kohyo-20-k16-2e.pdf</ext-link>). The experiments were in accordance with the “Weatherall report for the use of non-human primates in research” recommendations (<ext-link ext-link-type="uri" xlink:href="https://royalsociety.org/topics-policy/publications/2006/weatherall-report/">https://royalsociety.org/topics-policy/publications/2006/weatherall-report/</ext-link>). Animals were housed in adjoining individual primate cages allowing them to make sight and sound contact with one another for social interactions, where the temperature was kept at 25°C with light for 12 hours per day. Animals were fed with apples and commercial monkey diet (Type CMK-2, Clea Japan, Inc.). Blood collection and virus challenge were performed under ketamine anesthesia.</p>
</sec>
<sec id="s4d">
<title>Cells and viruses</title>
<p>MT4-R5 cells were maintained in RPMI1640 (Invitrogen) supplemented with 10% fetal bovine serum (FBS) (Clontech) and antibiotics. HSC-F cells (cynomolgus CD4<sup>+</sup> T-cell line) and HSR5.4 cells (rhesus macaque CD4<sup>+</sup> T-cell line) were maintained in RPMI1640 (Invitrogen) supplemented with 10% fetal bovine serum (FBS) (Clontech), human interleukin-2 (IL-2) (10 IU/ml, Roche), 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) (Invitrogen) and 2-mercaptoethanol (Gibco). SIV<sub>mac239</sub> molecular clone derivative was generated by mutagenesis PCR (Agilent Technologies) using the primers listed. For virus preparation, COS-1 cells were transfected with pBR<sub>mac239</sub> proviral DNA using FuGENE 6 (Promega). At 48 h post-transfection, culture supernatants were harvested, centrifuged and filtered through a 0.45-μm pore-size filter (Merck Millipore). To titrate infectivity, prepared viruses were serially diluted and infected on HSC-F cells in 96-well plates (Falcon) in quadruplicate. At 10 days post-infection, the endpoint was determined using SIV p27 antigen enzyme-linked immunosorbent assay (ELISA) kit (ABL), and virus infectivity was calculated as the 50 percent tissue culture infective dose (TCID<sub>50</sub>) according to the Reed-Muench method.</p>
</sec>
<sec id="s4e">
<title>Identification of SIV<sub>mac239</sub>-NAb inducers</title>
<p>Burmese rhesus macaques previously challenged with the highly pathogenic molecular clone virus SIV<sub>mac239</sub> (<italic>n</italic> = 70) were retrospectively examined approximately up to 2 years for their plasma NAb profiles. Animals were challenged intravenously with 1,000 TCID<sub>50</sub> of SIV<sub>mac239</sub>. In the current study, virological and immunological profiles were compared between the newly identified NAb inducers (<italic>n</italic> = 9) and representative NAb non-inducers (<italic>n</italic> = 19). Sex distribution of the NAb inducers (eight males and one female) did not significantly differ with the total non-inducers (49 males and 12 females, <italic>P</italic> = 0.99 by Fisher’s exact test). These NAb non-inducers and eight NAb inducers except R06-032 were previously partially reported for their plasma viral loads (<xref ref-type="bibr" rid="c119">Yamamoto et al., 2007</xref>; <xref ref-type="bibr" rid="c36">Iseda et al., 2016</xref>; <xref ref-type="bibr" rid="c81">Nomura et al., 2012</xref>; <xref ref-type="bibr" rid="c109">Takahashi et al., 2013</xref>; <xref ref-type="bibr" rid="c75">Nakane et al., 2013</xref>; <xref ref-type="bibr" rid="c38">Iwamoto et al., 2014</xref>) (<xref rid="fig1" ref-type="fig">Figure 1B</xref>). MHC-I haplotypes and alleles were determined by reference strand-mediated conformation analysis, PCR-SSP (PCR amplification utilizing sequence-specific priming) and cloning as described (<xref ref-type="bibr" rid="c76">Naruse et al., 2010</xref>). MHC-I binding prediction was made on April 27, 2013 using the IEDB analysis resource NetMHCpan tool (<xref ref-type="bibr" rid="c34">Hoof et al., 2009</xref>). Alleles of interest in the study have been previously identified in macaques (<xref ref-type="bibr" rid="c81">Nomura et al., 2012</xref>; <xref ref-type="bibr" rid="c18">Evans et al., 1999</xref>; <xref ref-type="bibr" rid="c99">Sette et al., 2012</xref>). Macaques R06-032, R03-015, R01-010 and R05-010 received a prime-boost vaccination (<xref ref-type="bibr" rid="c66">Matano et al., 2004</xref>) composed of a DNA prime/intranasal Sendai virus vector expressing SIV<sub>mac239</sub> Gag (SeV-Gag). R03-015, R06-019, R06-038 and R10-001 received 300 mg of non-specific rhesus IgG at day 7 post-SIV<sub>mac239</sub> challenge as an experimental control in our previous reports (<xref ref-type="bibr" rid="c119">Yamamoto et al., 2007</xref>; <xref ref-type="bibr" rid="c36">Iseda et al., 2016</xref>; <xref ref-type="bibr" rid="c75">Nakane et al., 2013</xref>).</p>
</sec>
<sec id="s4f">
<title>Plasma viral load quantitation</title>
<p>Plasma viral RNA samples were extracted with High Pure Viral RNA kit (Roche Diagnostics). Serial fivefold sample dilutions were amplified in quadruplicate by reverse transcription and nested PCR using SIV<sub>mac239</sub> <italic>gag</italic>-specific primers to determine end point via the Reed-Muench method as described previously (<xref ref-type="bibr" rid="c66">Matano et al., 2004</xref>; <xref ref-type="bibr" rid="c36">Iseda et al., 2016</xref>). The lower limit of detection is approximately 400 viral RNA copies/ml plasma. Viral loads have been previously partially reported (<xref ref-type="bibr" rid="c119">Yamamoto et al., 2007</xref>; <xref ref-type="bibr" rid="c81">Nomura et al., 2012</xref>; <xref ref-type="bibr" rid="c109">Takahashi et al., 2013</xref>; <xref ref-type="bibr" rid="c75">Nakane et al., 2013</xref>; <xref ref-type="bibr" rid="c38">Iwamoto et al., 2014</xref>).</p>
</sec>
<sec id="s4g">
<title>SIV<sub>mac239</sub>-specific neutralization assay</title>
<p>NAbs were titrated as described (<xref ref-type="bibr" rid="c119">Yamamoto et al., 2007</xref>; <xref ref-type="bibr" rid="c36">Iseda et al., 2016</xref>). Serial twofold dilutions of heat-inactivated plasma, or polyclonal IgG affinity-purified with Protein G Sepharose 4 Fast Flow (GE Healthcare) from heat-inactivated and filtered plasma were mixed with 10 TCID<sub>50</sub> of SIV<sub>mac239</sub> at a 1:1 ratio (5 μl:5 μl) in quadruplicate. After 45-min incubation at room temperature, the 10 μl mixtures were added into 5 x 10<sup>4</sup> MT4-R5 cells/well in 96-well plates. Progeny virus production in day 12 culture supernatants was examined by SIV p27 ELISA (ABL) to determine 100% neutralizing endpoint. The lower limit of titration is 1:2. Neutralization in three out of four wells at a dilution of 1:2 is defined as marginally NAb-positive (&lt; 1:2). Results were comparable when the same assay was performed with macaque HSC-F cells (<xref ref-type="bibr" rid="c2">Akari et al., 1996</xref>) as targets. NAb inducers R01-012, R02-004, R01-010, R02-007 and NAb non-inducer R01-011 were previously partially reported for their NAb titers measured with the same method using MT4 cells as targets (<xref ref-type="bibr" rid="c46">Kawada et al., 2007</xref>), which derived comparable results. For assessment of neutralizing activity in IgG, SIV<sub>mac239</sub>-specific IgGs purified from pools of plasma with SIV<sub>mac239</sub>-specific NAb titers were obtained from each animal as described (<xref ref-type="bibr" rid="c119">Yamamoto et al., 2007</xref>). After complement heat-inactivation at 56°C, 30 min and 0.45 μm filtration, IgGs were purified by Protein G Sepharose 4 Fast Flow (GE Healthcare) and concentrated by Amicon Ultra 4, MW 50,000 (Millipore) to 30 mg/ml and similarly examined for their 10 TCID<sub>50</sub> SIV<sub>mac239</sub> killing titers on MT4-R5 cells.</p>
</sec>
<sec id="s4h">
<title>SIV Env-specific IgG ELISA and immunoblotting</title>
<p>Plasma Env-specific IgG titers were measured as described (<xref ref-type="bibr" rid="c75">Nakane et al., 2013</xref>). SIV<sub>mac251</sub> Env gp120 (ImmunoDiagnostics) were coated on 96-well assay plates (BD) at 1000 ng/ml (100 μl/well). Wells were prewashed with phosphate-buffered saline (PBS), blocked with 0.5% bovine serum albumin (BSA)/PBS overnight and plasma samples were incubated at a 1:20 dilution (5 μl:95 μl) for 2 hours. Wells were washed with PBS and SIV Env-bound antibodies were detected with a horseradish peroxidase (HRP)-conjugated goat anti-monkey IgG (H+L) (Bethyl Laboratory) and SureBlue TMB 1-Component Microwell Peroxidase Substrate (KPL). Absorbance at 450 nm was measured. Samples from week 0 pre-challenge and month 3, month 6 and year 1 post-challenge were assessed in duplicate. Week 0 average values were subtracted from corresponding later time point values for calibration. For immunoblotting, SIV virion-specific IgGs in plasma were detected with a SIV<sub>mac239</sub>-cross-reactive western blotting system (ZeptoMetrix). In the NAb non-inducers, samples from those close to rapid progression (euthanized due to AIDS progression within approximately 1 year) known for low plasma anti-SIV reactivity (<xref ref-type="bibr" rid="c33">Hirsch et al., 2004</xref>; <xref ref-type="bibr" rid="c75">Nakane et al., 2013</xref>) were not included.</p>
</sec>
<sec id="s4i">
<title>Sequencing</title>
<p>Sequencing was performed as described (<xref ref-type="bibr" rid="c66">Matano et al., 2004</xref>; <xref ref-type="bibr" rid="c36">Iseda et al., 2016</xref>). Viral cDNA fragments spanning from nt (nucleotide) 4829 to nt 7000, nt 6843 to nt 8831 and nt 8677 to nt 10196 in SIV<sub>mac239</sub> (GenBank accession number MM33262) covering SIV <italic>env</italic> and <italic>nef</italic> were amplified from plasma viral RNA by nested RT-PCR using Prime-Script one-step RT-PCR kit v2 (TaKaRa) and KOD-Plus v2 (Toyobo). PCR products were either directly sequenced or subcloned with a TOP10-transforming TOPO blunt-end cloning system (Invitrogen). Sequencing was performed using dye terminator chemistry with an ABI 3730 DNA sequencer (Applied Biosystems). On average, 15 clones were obtained per sample and 20 clones were assessed when <italic>nef</italic> mutations of interest in early time points were subdominant.</p>
</sec>
<sec id="s4j">
<title>SIV<sub>mac239</sub>-specific CD8<sup>+</sup> T-cell responses</title>
<p>Virus-specific CD8<sup>+</sup> T-cell frequencies were measured as described (<xref ref-type="bibr" rid="c66">Matano et al., 2004</xref>; <xref ref-type="bibr" rid="c36">Iseda et al., 2016</xref>). Peripheral blood mononuclear cells (PBMCs) were cocultured for 6 hours with autologous herpesvirus papio-immortalized B lymphoblastoid cell lines (B-LCLs) pulsed with Nef peptides (Sigma-Aldrich Japan) at 1 μM concentration or as indicated otherwise under GolgiStop (monensin, BD) presence. Intracellular gamma interferon (IFN-γ) staining was performed using Cytofix/Cytoperm kit (BD) and the following conjugated anti-human monoclonal antibodies (mAbs): anti-CD4-FITC (M-T477, BD Pharmingen), anti-CD8-PerCP (SK1, BD Biosciences), anti-CD3-APC (SP34-2, BD Pharmingen) and anti-IFN-γ-PE (4S.B3, BioLegend). Specific CD8<sup>+</sup> T-cell frequencies were determined by subtracting nonspecific IFN-γ<sup>+</sup> CD8<sup>+</sup> T-cell frequencies from those after peptide-specific stimulation; frequencies beneath 100 cells/million PBMCs were considered negative. Cells acquired by FACS Canto II (BD) were analyzed by FACS Diva (BD) and FlowJo (Treestar). Approximately 1 x 10<sup>5</sup> PBMCs were gated per test.</p>
</sec>
<sec id="s4k">
<title>Nef-mediated signaling perturbation analysis</title>
<p>Virus supernatants obtained from COS-1 cells after transfection with wild-type or mutant SIV<sub>mac239</sub> molecular clones were used for infection of CD4<sup>+</sup> T-cell lines, cynomolgus macaque-derived HSC-F and rhesus macaque-derived HSR5.4 (<xref ref-type="bibr" rid="c2">Akari et al., 1996</xref>). QuikChange II XL site-directed mutagenesis kit (Agilent Technologies) was used to construct mutant SIV<sub>mac239</sub> molecular clones possessing <italic>nef</italic> mutations Nef-G63E (G-to-A mutation at nt 9520) and Nef-G63R (G-to-A mutation at nt 9519) from the wild-type SIV<sub>mac239</sub> molecular clone (<xref ref-type="bibr" rid="c48">Kestler et al., 1991</xref>) (nt number from GenBank accession number M33262). Cells (1 x 10<sup>5</sup> cells/well in U-bottomed 96-well culture plates [BD]) were infected with wild-type or mutant SIV<sub>mac239</sub> cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS) for indicated periods at MOI 0.1 (intracellular signaling analysis) or 0.001 (supernatant analysis). Culture supernatants were subjected to measurement of SIV capsid p27 concentrations by ELISA. Harvested cells were fixed and permeabilized with Cytofix/Cytoperm kit, washed twice and subjected to immunostaining. The following antibodies were used; anti-SIV<sub>mac251</sub> Gag p27 mAb (ABL) manually conjugated with Alexa 647 (Life Technologies), anti-SIV<sub>mac251</sub> Nef mAb (clone 17, epitope peptide corresponding to SIV<sub>mac239</sub> Nef 71-80 not including the residue G63: Thermo Fisher Scientific/Pierce) manually conjugated with Alexa 488 or Alexa 647, anti-human CD3-APC-Cy7 (SP34-2, BD Pharmingen), anti-human CD4-PerCP (L200, BD Pharmingen), anti-human HLA-ABC-FITC (G46-2.6, BD Pharmingen), anti-human CXCR4-APC (12G5, BioLegend), BST2-Alexa 647 (RS38E, BioLegend), Alexa 488-conjugated anti-phospho-Akt (Ser473) (D9E, CST) and Alexa 488-conjugated anti-phospho-Akt (Thr308) (C31E5E, CST). Cells acquired by FACS Canto II were analyzed by FACS Diva and FlowJo. Approximately 5 x 10<sup>4</sup> cells were gated for each test.</p>
</sec>
<sec id="s4l">
<title>Ferritin ELISA</title>
<p>Plasma ferritin levels in NAb inducers and control animals were analyzed by monkey ferritin sandwich ELISA kit (LS Bio) according to the manufacturer’s instructions.</p>
</sec>
<sec id="s4m">
<title>PI3K stimulation assay</title>
<p>5 x 10<sup>4</sup> HSC-F cells were infected with wild-type or Nef G63E mutant SIV<sub>mac239</sub> at MOI 0.2 and cultured for 1 day in medium supplemented with 10% (normal), 1% (1/10 starvation) or 0.1% (1/100 starvation) FBS. For ligand stimulation (<xref rid="figs4a" ref-type="fig">Figure 4-figure supplement 1C</xref>), cells at the end of 1-day culture were pulsed for 20 minutes with 40 ng/ml of recombinant human IFN-γ (Gibco/Thermo Fisher Scientific), 100 IU/ml of recombinant human IL-2 (Roche Diagnostics) or 10 μg/ml of SIV<sub>mac251</sub> Env gp130 (ImmunoDx). Cells were intracellularly stained using Cytofix/Cytoperm kit with anti-SIV<sub>mac251</sub> Nef mAb or anti-SIV<sub>mac251</sub> p27 mAb manually conjugated to Alexa 647 and PE-conjugated anti-human phospho-Akt (Ser473) (D9E, CST) or Alexa 488-conjugated anti-human phospho-Akt (Ser473). Cells acquired by FACS Canto II were analyzed by FACS Diva and FlowJo. Approximately 7 x 10<sup>4</sup> HSC-F cells were gated per test.</p>
</sec>
<sec id="s4n">
<title>Transcriptome analysis</title>
<p>Total RNAs were extracted using RNeasy Plus Mini kit (Qiagen) from 2 x 10<sup>6</sup> HSC-F cells 1 day after infection with wild-type or Nef G63E mutant SIV<sub>mac239</sub> at MOI 5. Negative control RNA samples were extracted from 2 x 10<sup>6</sup> uninfected HSC-F cells after culture with the same condition. Three sets of experiments were performed. Total RNA samples were subjected to a quality control (QC) analysis using an Agilent 2100 Bioanalyzer. The obtained amounts of total RNAs were: 12.37 ± 0.39 (uninfected), 8.80 ± 0.44 (wild-type) and 9.02 ± 0.17 (Nef G63E) μg (<italic>P</italic> = 0.66 for wild-type versus Nef G63E by unpaired t test). In all samples, two bands of 18S and 28S rRNA were confirmed and the RNA integrity number (RIN) was 10. 500 ng of total RNA samples were processed with GeneChip WT Plus reagent (Affymetrix/Thermo Fisher Scientific) to produce 150 μl of fragmented and labeled cDNA samples. These were incubated with a Human Gene 2.0 ST Array (Affymetrix/Thermo Fisher Scientific) for 16 hours, 60 rpm at 45°C using GeneChip hybridization oven 645 (Affymetrix/Thermo Fisher Scientific). Results were scanned with GeneChip Scanner 3000 7G (Affymetrix/Thermo Fisher Scientific) and processed with Affymetrix Expression Console Software (Affymetrix/Thermo Fisher Scientific) according to the manufacturer’s instructions. Expression values were normalized by the RMA method. Genes above mean background expression within the cognate sample and showing significant difference between wild-type and Nef G63E SIV (<italic>P</italic> &lt; 0.05 via unpaired t test for log<sub>2</sub>-transformed values, 768 candidates) were determined. Akt-related genes exhibiting a change of approximately 10% or more were representatively extracted and manually aligned by the authors.</p>
</sec>
<sec id="s4o">
<title>Peripheral CD4<sup>+</sup> T-cell surface staining</title>
<p>Cryopreserved/thawed PBMCs were stained for 30 minutes at 4°C with the following reagents or conjugated anti-human mAbs: Live/Dead Aqua (Life Technologies), anti-CD4-PerCP (L200, BD Pharmingen), anti-CD8-APC-Cy7 (RPA-T8, BD Pharmingen), anti-CD3-Alexa 700 (SP34-2, BD Pharmingen), anti-CD95-PE-Cy7 (DX2, eBioscience), anti-CXCR5-PE (87.1, eBioscience), anti-PD-1-Brilliant Violet 421 (EH12.2H7, BioLegend) and anti-CXCR3-Alexa 488 (G025H7, BioLegend). Cells acquired by FACS LSRII Fortessa (BD) were analyzed by FACS Diva and FlowJo. Approximately 1.5 x 10<sup>5</sup> PBMCs were gated per test.</p>
</sec>
<sec id="s4p">
<title>Proximity ligation assay (PLA)</title>
<p>A flow cytometry-based arrangement of proximity ligation assay (PLA) (<xref ref-type="bibr" rid="c7">Avin et al., 2017</xref>) was performed to quantitatively assess Nef binding to candidate interacting molecules. 1 x 10<sup>5</sup> HSC-F cells were infected with SIV<sub>mac239</sub> at MOI 0.05 in U-bottomed plates and permeated with Cytofix/Perm kit (BD Biosciences). After two washes, they were resuspended in 0.5% BSA/PBS for prevention of experimental procedure-related loss and stained with mouse anti-SIV<sub>mac251</sub> Nef mAb (clone 17, Thermo Fisher Scientific/Pierce) or mouse IgG1 isotype control mAb (P3.6.2.8.1, Abcam) in combination with either of the following rabbit antibodies: anti-GβL (86B8, CST), anti-mTOR (7C10, CST), polyclonal anti-human PI3K p85 (Merck Millipore), anti-PI3 Kinase p110α (C73F8, CST) or rabbit IgG1 isotype control mAb (DA1E, CST). Antibody-stained cells were subsequently probed with Duolink In Situ PLA Probe anti-mouse PLUS and anti-mouse MINUS probes (Sigma/Merck). Next, they were detected for intermolecular binding using Duolink flow PLA detection kit (Green) (Sigma/Merck) with a reaction time of 100 minutes for post-mouse/rabbit probe linking amplification. Finally, these PLA-subjected cells were additionally stained with anti-SIV<sub>mac251</sub> Gag p27 mAb manually conjugated with Alexa 647 and anti-CD4-PerCP for 30 minutes for 20 minutes at 4°C. Cells acquired by FACS Canto II were analyzed by FACS Diva and FlowJo. Approximately 1 x 10<sup>5</sup> cells were gated per test. Binding index (Y axis) was calculated by deriving the deviation from the summation of: {baseline P: (MFI of background reaction with mouse isotype control/rabbit isotype control) + anti-Nef antibody-derived background Q: [(MFI of reaction with mouse anti-Nef/rabbit isotype control) - (MFI of background reaction with mouse isotype control/rabbit isotype control)] + anti-binding partner antibody-derived background R:[(MFI of reaction with mouse isotype control/rabbit anti-binding partner molecule) - (MFI of background reaction with mouse isotype control/rabbit isotype control)]}.</p>
</sec>
<sec id="s4q">
<title>Co-immunoprecipitation analysis</title>
<p>1 x 10<sup>5</sup> HSC-F cells were infected with SIV<sub>mac239</sub> at MOI 0.05 in U-bottomed plates in quadruplicate for each SIV strain for three days and pooled for each for acquiring cell pellets. These pellets were lysed with Capturem IP &amp; Co-IP Kit lysis buffer (Takara) and portions for each were immunoprecipitated by anti-Sin1 mAb (D7G1A, CST) (1:50 dilution, 20 minutes, room temperature). Spin column membrane-bound immunoprecipitates were obtained by centrifugation with Capturem IP &amp; Co-IP Kit (Clontech/Takara). Whole cell lysates and Sin1-immunoprecipitated products were subjected to SDS-polyacrylamide gel electrophoresis separation on a Mini Protean TGX 4-15% gel (BioRad) and transferred to a Immun-Blot PVDF membrane (BioRad). Immunoblotting was performed by mouse anti-SIV<sub>mac251</sub> Nef mAb (clone 17, Thermo Fisher Scientific/Pierce) primary antibody probing (1:1000 dilution, 18 hours, 4°C) and Mouse TrueBlot ULTRA anti-mouse Ig HRP (eB144, Rockland Immunochemicals) secondary antibody incubation (1:1000 dilution, 30 minutes, room temperature). Nef-specific bands in infected controls were visualized by enhanced chemiluminescence using SuperSignal West Pico PLUS (Thermo Fisher Scientific). Bands auto-detectable by Image Lab software (BioRad) were analyzed for signal intensities. Uncropped images are provided as supplementary data.</p>
</sec>
<sec id="s4r">
<title>Cell death assay</title>
<p>Infected cell apoptosis was measured by methods previously described (<xref ref-type="bibr" rid="c39">Jauch et al., 2023</xref>). 1 x 10<sup>5</sup> HSC-F cells were infected with SIV<sub>mac239</sub> at MOI 0.1 in U-bottomed plates (six wells/control) for each SIV strain for three days. These cells were stained with CD4-FITC (M-T477, BD Pharmingen) for 15 minutes at room temperature, washed once and next stained with APC Annexin V (Biolegend) in Annexin V Binding Buffer (Biolegend) for 20 minutes at room temperature. Stained reactions were then diluted fivefold with Annexin V Binding Buffer and subjected to analysis. Cells acquired by FACS Lyric were analyzed by FACS Suite and FlowJo. Approximately 1 x 10<sup>4</sup> HSC-F cells were gated per test.</p>
</sec>
<sec id="s4s">
<title>Quantitative <italic>in vivo</italic> imaging flow cytometry</title>
<p>Cryopreserved/thawed lymph node cells (LNCs) from several persistently SIV-infected macaques used in previous experiments (<xref ref-type="bibr" rid="c75">Nakane et al., 2013</xref>; <xref ref-type="bibr" rid="c109">Takahashi et al., 2013</xref>; <xref ref-type="bibr" rid="c38">Iwamoto et al., 2014</xref>) were seeded in V-bottomed 96-well plates (Nunc) and blocked with 25 μg/ml of anti-human CD4 (clone L200: BD) in 100 μl volume for 15 minutes at 4°C. After three washes, they were stained with 10 μg/ml of recombinant SIV<sub>mac239</sub> Env gp140-biotin (Immune Technology) for 30 minutes at 4°C. Cells were then stained with anti-CD19-PC5.5 (J3-119, Beckman Coulter), Live/Dead Aqua (Invitrogen) and streptavidin-APC-Cy7 (BioLegend) for 30 minutes at 4°C. After two washes, cells were processed with Cytofix/Cytoperm kit (BD) for 20 minutes at 4°C, washed twice, and next intracellularly stained with PE-conjugated anti-human phospho-Akt (Ser473) (D9E, CST) and anti-SIV<sub>mac251</sub> Nef mAb (clone 17, Thermo Fisher Scientific/Pierce) manually conjugated with Alexa 488 or mouse IgG1 isotype control mAb (P3.6.2.8.1, Abcam) for 30 minutes at 4°C. After final two washes, cells were suspended in 0.8% PFA/PBS. All centrifugations for washing (1,200 x g, 2 minutes) were performed at 4°C. Cells were subjected to image acquisition with Image Stream X MKII imaging flow cytometer (Amnis/Merck Millipore/Luminex) and analyzed with IDEAS 6.3 software (Amnis/Merck Millipore/Luminex). Approximately 5 x 10<sup>5</sup> LNCs were acquired for analyses (<xref rid="fig5" ref-type="fig">Figure 5</xref>). A custom-implemented linear discriminant analysis-based machine learning module (Luminex) was utilized for verifying candidate Nef staining signal-related secondary parameters (<xref rid="fig5" ref-type="fig">Figure 5</xref> and <xref rid="figs5a" ref-type="fig">Figure 5-figure supplement 1A</xref>) for their efficacy of target population separation.</p>
</sec>
<sec id="s4t">
<title>B-cell Nef invasion <italic>in vitro</italic> assay</title>
<p>For Nef invasion assay, 5 x 10<sup>4</sup> HSC-F cells were infected at MOI 1 for 48 hours. These were then additionally cocultured with 7.5 x 10<sup>4</sup> Ramos B cells for 12 hours with or without addition of macaque T cell-stimulating anti-CD3 antibody (FN-18, Abcam) at 1 μg/ml. Cells were double-stained with Alexa 488-conjugated mouse anti-Nef (clone 17: Thermo Scientific/Pierce) and anti-CD19-PC-5.5 (J3-119, Beckman Coulter). For graphical visualization (<xref rid="fig6" ref-type="fig">Figure 6A</xref>), interacting Nef<sup>+</sup> infected cell-invaded B cell doublet images acquired with ImageStream X MKII (Amnis/Merck Millipore) were analyzed by IDEAS 6.3 (Amnis/Merck Millipore/Luminex) with the defined noise-cancelling gating (via gating Nef pixel signal contrast<sup>lo</sup>-Nef mean pixel per object<sup>hi</sup> cells). For Nef invasion modulation verification on conventional flow cytometry, the aforementioned culture condition was similarly used. Anti-CD3 antibody (FN-18, Abcam) addition at 1 μg/ml and phorbol 12-myristate 13-acetate (PMA, Sigma) plus ionomycin (Sigma) addition (10 ng/ml and 50 ng/ml, respectively) l were evaluated. Cells were stained with Alexa 647-conjugated mouse anti-Nef (clone 17: Thermo Scientific/Pierce), anti-CD19-PC-5.5 (J3-119, Beckman Coulter), anti-human phospho-Akt (Ser473)-Alexa 488 (D9E, CST) and Live/Dead Near-IR (Invitrogen) for dead cell exclusion. Dead cell frequencies were less than 3%. For viral phenotype evaluation, 1 x 10<sup>5</sup> HSC-F cells (surface CD40L<sup>+</sup>) were pre-infected at MOI 0.2 with wild type or Nef-G63E mutant SIV<sub>mac239</sub> six hours before coculture. 1.5 x 10<sup>5</sup> CD20<sup>+</sup> B cells, positively selected from fresh PBMCs of uninfected rhesus macaques via anti-CD20 microbeads (Miltenyi Biotec), were cocultured with these HSC-F cells at an E:T ratio of 2:3 for 3 days in the presence of 40 ng/ml carrier-free recombinant human IL-4 (R&amp;D Systems). Cells were surface-stained with anti-human CD20-PerCP (2H7, BioLegend) and intracellularly stained using Cytofix/Cytoperm kit with anti-SIV<sub>mac251</sub> Nef mAb manually conjugated to Alexa 488 and Alexa 647-conjugated anti-human phospho-Akt (Ser473) (D9E, CST). For <xref rid="fig6" ref-type="fig">Figure 6B</xref> and <xref rid="fig6" ref-type="fig">Figure 6C</xref>, Cells acquired by FACS Canto II were analyzed by FACS Diva and FlowJo. Approximately 5 x 10<sup>4</sup> CD20<sup>+</sup> primary B cells and 3 x 10<sup>4</sup> CD19<sup>+</sup> Ramos B cells were analyzed.</p>
</sec>
<sec id="s4u">
<title>Peripheral SIV Env-specific B-cell responses</title>
<p>Peripheral SIV Env gp140-specific memory B cells (B<sub>mem</sub>) and plasmablasts (PBs) were measured by flow cytometry with procedures modified from previous reports and our experience (<xref ref-type="bibr" rid="c103">Silveira et al., 2015</xref>; <xref ref-type="bibr" rid="c31">Hau et al., 2022</xref>). First, cryopreserved/thawed PBMCs seeded in V-bottomed 96-well plates (Nunc) were blocked with 25 μg/ml of anti-human CD4 (clone L200: BD) in 100 μl volume for 15 minutes at 4°C. This concentration attains blockade of promiscuous SIV Env binding to CD4 comparable to levels by magnetic depletion of CD3<sup>+</sup> T cells (data not shown). After three washes, they were next stained with 10 μg/ml of recombinant SIV<sub>mac239</sub> Env gp140-biotin (Immune Technology) for 30 minutes at 4°C. They were subsequently stained with the following anti-human antibodies and fluorochromes for 30 minutes at 4°C with combinations as follows; PB/B<sub>mem</sub>: anti-CD3-APC-Cy7 (SP34-2, BD Pharmingen), anti-CD8-APC-Cy7 (RPA-T8, BD Pharmingen), anti-CD14-APC-Cy7 (M5E2, BioLegend), anti-CD16-APC-Cy7 (3G8, BioLegend), streptavidin-Brilliant Violet 421 (BioLegend), anti-CD19-PC5.5 (J3-119, Beckman Coulter) and Live/Dead Aqua (Invitrogen); PB: anti-CD10-APC-Cy7 (HI10a, BioLegend), anti-CD11c-PE-Cy7 (3.9, BioLegend), anti-CD123-PE-Cy7 (6H6, BioLegend) and anti-HLA-DR-PE-Texas Red (TU36, Invitrogen); B<sub>mem</sub>: anti-CD27-PE/Dazzle 594 (M-T271, BioLegend), anti-CD10-PE-Cy7 (HI10a, BioLegend), anti-IgD-FITC (DaKo), anti-CD38-Alexa 647 (AT1, Santa Cruz Biotechnology), anti-IgG-Alexa 700 (G18-145, BD Pharmingen) and anti-CD138-PE (DL-101, eBioscience). After two washes, B<sub>mem</sub> samples were suspended in 0.8% PFA/PBS. For PB staining, surface-stained cells were further processed with Cytofix/Cytoperm kit (BD) for 20 minutes at 4°C, washed twice, and next intracellularly stained with 10 μg/ml of recombinant SIV<sub>mac239</sub> Env gp140-biotin (Immune Technology) for 30 minutes at 4°C. After three washes, they were next stained with anti-human IgG-PE (G18-145, BD), anti-human/mouse IRF4-eFluor 660 (3E4, eBioscience), anti-human Ki67-Alexa 700 (B56, BD Pharmingen) and streptavidin-Alexa 488 (BioLegend) for 30 minutes at 4°C. After final two washes, cells were suspended in 0.8% PFA/PBS. Cells acquired with FACS LSRII Fortessa were analyzed with FACS Diva and FlowJo. Approximately 1.5 x 10<sup>5</sup> PBMCs were acquired for B<sub>mem</sub> and 4 x 10<sup>5</sup> PBMCs were acquired for PB analyses (<xref rid="fig6" ref-type="fig">Figure 6</xref>). All centrifugations for washing (1,200 x g, 2 minutes) were performed at 4°C. Env-specific PB frequencies were 0 cells/million PBMCs for pre-challenge samples in all animals examined, ruling out background confounding for high-sensitivity quantitation of the population.</p>
</sec>
<sec id="s4v">
<title>Statistical Analysis</title>
<p>Analyses were performed via Prism 8 (GraphPad Software). <italic>P</italic> &lt; 0.05 were considered significant in two-tailed unpaired t tests, paired t tests, Mann Whitney U tests, Fisher’s exact tests, Wilcoxon signed-rank tests, one-way ANOVA with Tukey’s post-hoc multiple comparison tests and two-way ANOVA with Sidak’s post-hoc multiple comparison tests. For analysis of Nef-invaded B-cell pAkt levels, median fluorescence intensities (mFIs) were analyzed due to relatively small numbers of Nef<sup>+</sup> B cells. Analyses involving pAkt Ser473 levels all derived comparable results between mFI and MFI for wild type versus Nef G63E virus. Machine learning-based rating of Nef signal parameters was verified with IDEAS 6.3 Machine Learning Module (Luminex).</p>
</sec>
</sec>
<sec id="d1e9540">
<title>Supplemental Information</title>
<fig id="figs1a" position="float" orientation="portrait" fig-type="figure">
<label>Fig. 1-Supplement 1.</label>
<caption><title>Profile of SIV<sub>mac239</sub>-NAb non-inducer subgroup cohort.</title><p>Summary of a SIV<sub>mac239</sub>-NAb non-inducer subgroup cohort (<italic>n</italic> = 19), composed from previously partially characterized, MHC class I haplotype-balanced naïve animals. Symbols A+, B+, E+, J+ and D+ represent possession of MHC-I haplotypes <italic>90-120-Ia</italic>, <italic>90-120-Ib</italic>, <italic>90-010-Ie</italic>, <italic>90-088-Ij</italic> and <italic>90-010-Id</italic>, respectively. For the titers, - represents negative; +/-represents neutralization in three out of four wells in a quadruplicate test. Gray shadings indicate euthanasia due to AIDS progression. Mamu-A and Mamu-B alleles of interest in this study are listed. These NAb non-inducers were previously partially reported for their plasma viral loads and MHC-I alleles (<xref ref-type="bibr" rid="c81">Nomura et al., 2012</xref>; <xref ref-type="bibr" rid="c109">Takahashi et al., 2013</xref>; <xref ref-type="bibr" rid="c75">Nakane et al., 2013</xref>; <xref ref-type="bibr" rid="c38">Iwamoto et al., 2014</xref>). R01-011 was previously partially reported for NAb titers measured with the same method using MT4 cells as targets (<xref ref-type="bibr" rid="c46">Kawada et al., 2007</xref>), which derived comparable results.</p></caption>
<graphic xlink:href="537602v4_figs1a.tif" mime-subtype="tiff" mimetype="image"/>
</fig>
<fig id="figs1b" position="float" orientation="portrait" fig-type="figure">
<label>Fig. 1-Supplement 2.</label>
<caption><title>IgG class-switched NAbs in the inducers.</title>
<p>Titration of SIV<sub>mac239</sub>-neutralizing IgGs in the NAb inducers. SIV<sub>mac239</sub>-specific IgGs, purified from pools of plasma with SIV<sub>mac239</sub>-specific NAb titers, were obtained from each animal as described (<xref ref-type="bibr" rid="c119">Yamamoto et al., 2007</xref>) and examined for their neutralizing activity by 10 TCID<sub>50</sub> SIV<sub>mac239</sub> killing on MT4-R5 cells. NAb-negative anti-SIV IgG and control IgG were prepared from a representative animal (R01-011) with NAb-negative plasma and pooled plasma of uninfected rhesus macaques, respectively.</p></caption>
<graphic xlink:href="537602v4_figs1b.tif" mime-subtype="tiff" mimetype="image"/>
</fig>
<fig id="figs1c" position="float" orientation="portrait" fig-type="figure">
<label>Fig.1-Supplement 3.</label>
<caption><title>Anti-SIV binding IgG profiles in NAb inducers and non-inducers.</title>
<p>(A) Temporal changes in SIV<sub>mac251</sub> Env gp120-specific antibody titers in the NAb non-inducers without rapid progression [NAb-negative non-rapid progressors, NAb(-) non-RPs] (left, <italic>n</italic> = 11) and NAb inducers [NAb(+)] (right, <italic>n</italic> = 9). NAb non-inducers showing rapid progression (euthanized with AIDS onset within approximately 1 year) were not included except for macaque R10-001 (shown in the left for aligned comparison). Samples for non-RPs R06-001 and R10-002 were unavailable.</p><p>(B) Unpaired t test of log-transformed anti-SIV Env Ab titers in NAb(-) non-RPs and NAb inducers. Bars represent geometric mean absorbance within each group.</p><p>(C) Lysed SIV<sub>mac</sub> virion linear antigen-binding at year 1 p.i. in NAb(-) non-RPs (left, <italic>n</italic> = 12) and NAb inducers (right, <italic>n</italic> = 9). Plasma anti-SIV<sub>mac251</sub> IgGs were detected using a commercial western blotting system against the parental strain SIV<sub>mac251</sub> (ZeptoMetrix). White arrowheads indicate Env gp120-specific bands. Experiments were performed twice with comparable results.</p></caption>
<graphic xlink:href="537602v4_figs1c.tif" mime-subtype="tiff" mimetype="image"/>
</fig>
<fig id="figs1d" position="float" orientation="portrait" fig-type="figure">
<label>Fig. 1-Supplement 4.</label>
<caption><title>Env sequence variation pattern is not a major characteristic of NAb induction.</title>
<p>SIV<sub>mac239</sub> Env sequence variations before and after NAb induction. For each animal, the upper time point shows pre-induction and the lower time point (in purple) shows post-induction (first or second time point with NAb titer &gt; 1:2). Dominant residue changes are shown as follows: gp120 (gray), variable regions V1-V5 (blue), and gp41 (blue gray). Subdominant mutations are uncolored. Unlabeled gray and black shadings show subdominant and dominant deletion of residues. Parental SIV<sub>mac239</sub> sequence is listed for V1-V5. Residues mutated in multiple animals within V1-V5 are shown in red.</p></caption>
<graphic xlink:href="537602v4_figs1d.tif" mime-subtype="tiff" mimetype="image"/>
</fig>
<fig id="figs3a" position="float" orientation="portrait" fig-type="figure">
<label>Fig. 3-Supplement 1.</label>
<caption><title>Selection of Nef-G63E mutant SIV is linked with Nef<sub>62-70</sub>-specific CD8<sup>+</sup> T-cell response positivity.</title>
<p>(A) Nef<sub>62-70</sub>-specific CD8+ T-cell responses around week 20 post-SIV challenge in seven viremic NAb non-inducers possessing either of the MHC-I alleles Mamu-B*039:01, Mamu-B*004:01 or Mamu-A1*032:02.</p><p>(B) Temporal supernatant SIV p27 concentrations after wild type (WT) or Nef-G63E mutant SIV infection at multiplicity of infection (MOI) 0.001 on HSC-F cells. Data represent one of two independent experiments performed in triplicate. Bars: mean ± SEM.</p><p>(C) Comparison of plasma viral loads in Nef-G63E-selecting NAb non-inducers (<italic>n</italic> = 7) versus non-inducers at indicated time points post-SIV challenge. Bars represent geometric means. log10-transformed values are compared by unpaired t tests.</p></caption>
<graphic xlink:href="537602v4_figs3a.tif" mime-subtype="tiff" mimetype="image"/>
</fig>
<fig id="figs4a" position="float" orientation="portrait" fig-type="figure">
<label>Fig. 4-Supplement 1.</label>
<caption><title>Decreased Akt hyperactivation properties of Nef-G63E mutant SIV.</title>
<p><bold>(A)</bold> Plasma ferritin levels (ng/ml) in examined NAb non-inducers versus Nef-G63E mutant SIV-selecting NAb inducers around year 1 post-infection. Bars represent mean in each group. Log-transformed values compared by unpaired t test.</p><p><bold>(B)</bold> Relative levels of pAkt Ser473 (left panel) and threonine (Thr) 308 (right panel) in SIV Nef<sup>+</sup> HSR5.4 cells (MOI 0.1, 4 days p.i.).</p><p><bold>(C)</bold> Relative pAkt Ser473 levels in Nef<sup>+</sup> HSC-F cells without stimuli and transiently pulsed with IFN-γ, IL-2 or SIV<sub>mac</sub> Env gp130 after infection (MOI 0.2, 1 day).</p><p><bold>(D)</bold> Gene expression significantly differing between WT and Nef-G63E SIV infection (MOI 5, 1 day). Black bars show potentially Akt-related genes. Asterisks show dynamics concordant with the Nef-G63E phenotype (PI3K-pAkt Ser473 downstream downregulation or inhibition upregulation).</p><p><bold>(E)</bold> Representative flow cytometric gating (NAb inducer R01-012, wk 30 p.i.) of peripheral blood CXCR3<sup>-</sup>CXCR5<sup>+</sup>PD-1<sup>+</sup> memory follicular CD4+ T cells. Cells were gated as CD3<sup>+</sup>CD8<sup>-</sup> CD4<sup>+</sup>CD95<sup>+</sup>CXCR5<sup>+</sup>PD-1<sup>+</sup>CXCR3<sup>-</sup> live singlet PBMCs. Available samples of six NAb inducers showing peak Nef-G63E mutant selection around week 30 p.i. and thirteen viremic NAb non-inducers were tracked.</p><p><bold>(F)</bold> Comparison of peripheral CXCR3<sup>-</sup>CXCR5<sup>+</sup>PD-1<sup>+</sup> memory Tfh cell frequencies between pre-SIV infection and around week 30 post-infection in examined NAb non-inducers developing disease before week 60 (left: <italic>n</italic> = 5) and alive more than 70 weeks (middle: <italic>n</italic> = 8) and Nef-G63E-detected NAb inducers alive more than 70 weeks (right: <italic>n</italic> = 6). Analyzed by Wilcoxon signed-rank tests.</p><p>MFIs relative to those in uninfected controls (%) are shown. **: <italic>P</italic> &lt; 0.01, ***: <italic>P</italic> &lt; 0.001, n.s.: not significant between WT and Nef-G63E mutant by unpaired t tests (B-C). Data represent one of two (B, C) independent experiments performed in triplicate (C: unstimulated) or quadruplicate (B, C: PI3K-pulsed). Bars: mean ± SEM.</p></caption>
<graphic xlink:href="537602v4_figs4a.tif" mime-subtype="tiff" mimetype="image"/>
</fig>
<fig id="figs4b" position="float" orientation="portrait" fig-type="figure">
<label>Fig. 4-Supplement 2.</label>
<caption><title>Nef-G63R mutant SIV properties.</title>
<p><bold>(A)</bold> Comparison of frequencies of macaques selecting for Nef-G63R mutant in plasma between NAb non-inducers and inducers. Compared by Fisher’s exact test.</p><p><bold>(B)</bold> Temporal relationship of Nef G63R frequencies in plasma virus in a NAb non-inducer macaque R06-034 preferentially selecting for Nef-G63R but not Nef-G63E mutant. Black boxes (left Y axis) show log<sub>2</sub> NAb titers; red triangles and blue diamonds (right Y axis) show percentage of G63E and G63R mutations detected by subcloning (15 clones/point on average), respectively.</p><p><bold>(C)</bold> Left: representative histograms of relative pAkt serine (Ser) 473 levels in p27<sup>+</sup> subpopulations after WT, Nef-G63E or Nef-G63R mutant SIV infection at MOI 0.1 on HSC-F cells. Numbers show pAkt Ser473 mean fluorescence intensities (MFIs) for each. Right: Deviation of pAkt Ser473 MFIs in p27<sup>+</sup> HSC-F cells compared with mean MFI of uninfected cells. Analyzed by one-way ANOVA with Tukey’s post-hoc multiple comparison tests. Data represent one of two independent experiments performed in quadruplicate with similar results.</p></caption>
<graphic xlink:href="537602v4_figs4b.tif" mime-subtype="tiff" mimetype="image"/>
</fig>
<fig id="figs5a" position="float" orientation="portrait" fig-type="figure">
<label>Fig. 5-Supplement 1.</label>
<caption><title>Machine learning-verified morphological gating of Nef-invaded B cells <italic>in vivo</italic>.</title>
<p><bold>(A)</bold> Representative gating strategy plus schematic of inguinal lymph node Nef<sup>+</sup>CD19<sup>+</sup> B cells of an SIV<sub>mac239</sub>-infected rhesus macaque analyzed by ImageStreamX MK II imaging flow cytometry (R10-012, week 160 p.i.). First-step incorporation of Live/Dead staining gates out CD19<sup>+</sup> B cells staining positive for Nef potentially due to pre-experimental membrane permeation (e.g., image #246896, #248952 and #71859). Second-step dual gating for intracellular Nef signal pixel Haralick variance mean (H Variance mean, X axis), a textural feature calculated from a gray level co-occurrence matrix (GLCM) for each image representing adjacent pixel signal strength heterogeneity and Nef signal intensity threshold (Y axis) gates out CD19<sup>+</sup> B cells showing potentially non-specific, strong intracellular binary clustered staining pixels for Nef deriving a large variance (X axis), and/or cells stained overtly strong for Nef and hence becoming void for feasible image verification (high threshold) (Y axis), both likely originating stochastically from post-experimental rupturing procedures including membrane permeation (e.g. image #18541). This two-step noise cancellation results in acquisition of a Live/Dead<sup>-</sup>-Nef signal Haralick variance mean<sup>lo</sup>-Nef signal intensity threshold<sup>lo</sup>-Nef<sup>+</sup>CD19<sup>+</sup> B-cell population (e.g. image #116318, #116250 and #132927) with a pericellular Nef<sup>int-lo</sup> staining, biologically concordant with Nef membrane anchoring, resembling Nef<sup>+</sup> cells experimentally generated <italic>in vitro</italic> and showed the highest score in IDEAS6.3 machine learning module scoring for segregation of typical void vs. valid images (upper right). This gating was implemented for counting and analysis of Env-specific B-cell Nef invasion <italic>in vivo</italic> (<xref rid="fig5" ref-type="fig">Figure 5</xref>).</p><p><bold>(B)</bold> Detection of contact-dependent Nef invasion from SIV-infected HSC-F CD4<sup>+</sup> T cells to cocultured Ramos B cells <italic>in vitro</italic>. One typical image of an intercellular conduit (SSC, purple) with Nef (green) protrusions from infected HSC-F cells to CD19<sup>+</sup> (red) Ramos B cells from two independent experiments are shown.</p></caption>
<graphic xlink:href="537602v4_figs5a.tif" mime-subtype="tiff" mimetype="image"/>
</fig>
<fig id="figs7a" position="float" orientation="portrait" fig-type="figure">
<label>Fig. 7-Supplement 1.</label>
<caption><title>Full gating strategy of SIV<sub>mac239</sub> Env gp140-specific B-cell responses.</title>
<p>Full gating (R02-004, week 32 p.i.) of SIV Env gp140-specific memory B cells (B<sub>mem</sub>) and plasmablasts (PBs) shown in <xref rid="fig7" ref-type="fig">Figure 7</xref>.</p></caption>
<graphic xlink:href="537602v4_figs7a.tif" mime-subtype="tiff" mimetype="image"/>
</fig>
<table-wrap id="tbl1" orientation="portrait" position="float">
<graphic xlink:href="537602v4_utbl1.tif" mime-subtype="tiff" mimetype="image"/>
<graphic xlink:href="537602v4_utbl1a.tif" mime-subtype="tiff" mimetype="image"/>
<graphic xlink:href="537602v4_utbl1b.tif" mime-subtype="tiff" mimetype="image"/>
<graphic xlink:href="537602v4_utbl1c.tif" mime-subtype="tiff" mimetype="image"/>
<graphic xlink:href="537602v4_utbl1d.tif" mime-subtype="tiff" mimetype="image"/>
<graphic xlink:href="537602v4_utbl1e.tif" mime-subtype="tiff" mimetype="image"/>
<graphic xlink:href="537602v4_utbl1f.tif" mime-subtype="tiff" mimetype="image"/>
<graphic xlink:href="537602v4_utbl1g.tif" mime-subtype="tiff" mimetype="image"/>
<graphic xlink:href="537602v4_utbl1h.tif" mime-subtype="tiff" mimetype="image"/>
<graphic xlink:href="537602v4_utbl1i.tif" mime-subtype="tiff" mimetype="image"/>
<graphic xlink:href="537602v4_utbl1j.tif" mime-subtype="tiff" mimetype="image"/>
<graphic xlink:href="537602v4_utbl1k.tif" mime-subtype="tiff" mimetype="image"/>
</table-wrap>
</sec>
<ref-list>
<title>References</title>
<ref id="c1"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Adnan</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Reeves</surname>, <given-names>R.K.</given-names></string-name>, <string-name><surname>Gillis</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Wong</surname>, <given-names>F.E.</given-names></string-name>, <string-name><surname>Yu</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Camp</surname>, <given-names>J.V.</given-names></string-name>, <string-name><surname>Li</surname>, <given-names>Q.</given-names></string-name>, <string-name><surname>Connole</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Li</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Piatak</surname>, <given-names>M.</given-names></string-name> Jr., <etal>et al.</etal></person-group> (<year>2016</year>). <article-title>Persistent low-level replication of SIVΔnef drives maturation of antibody and CD8 T cell responses to induce protective immunity against vaginal SIV infection</article-title>. <source>PLoS Pathog</source>. <volume>12</volume>, <fpage>e1006104</fpage>.</mixed-citation></ref>
<ref id="c2"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Akari</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Mori</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Terao</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Otani</surname>, <given-names>I.</given-names></string-name>, <string-name><surname>Fukasawa</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Mukai</surname>, <given-names>R.</given-names></string-name>, and <string-name><surname>Yoshikawa</surname>, <given-names>Y.</given-names></string-name></person-group> (<year>1996</year>). <article-title>In vitro immortalization of Old World monkey T lymphocytes with Herpesvirus saimiri: its susceptibility to infection with simian immunodeficiency viruses</article-title>. <source>Virology</source> <volume>218</volume>, <fpage>382</fpage>–<lpage>388</lpage>.</mixed-citation></ref>
<ref id="c3"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Al Qureshah</surname>, <given-names>F.</given-names></string-name>, <string-name><surname>Sagadiev</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Thouvenel</surname>, <given-names>C.D.</given-names></string-name>, <string-name><surname>Liu</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Hua</surname>, <given-names>Z.</given-names></string-name>, <string-name><surname>Hou</surname>, <given-names>B.</given-names></string-name>, <string-name><surname>Acharya</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>James</surname>, <given-names>R.G.</given-names></string-name>, and <string-name><surname>Rawlings</surname>, <given-names>D.J.</given-names></string-name></person-group> (<year>2021</year>). <article-title>Activated PI3Kδ signals compromise plasma cell survival via limiting autophagy and increasing ER stress</article-title>. <source>J. Exp. Med</source>. <volume>218</volume>, <fpage>e20211035</fpage>.</mixed-citation></ref>
<ref id="c4"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Angulo</surname>, <given-names>I.</given-names></string-name>, <string-name><surname>Vadas</surname>, <given-names>O.</given-names></string-name>, <string-name><surname>Garçon</surname>, <given-names>F.</given-names></string-name>, <string-name><surname>Banham-Hall</surname>, <given-names>E.</given-names></string-name>, <string-name><surname>Plagnol</surname>, <given-names>V.</given-names></string-name>, <string-name><surname>Leahy</surname>, <given-names>T.R.</given-names></string-name>, <string-name><surname>Baxendale</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Coulter</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Curtis</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Wu</surname>, <given-names>C.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2013</year>). <article-title>Phosphoinositide 3-kinase δ gene mutation predisposes to respiratory infection and airway damage</article-title>. <source>Science</source> <volume>342</volume>, <fpage>866</fpage>–<lpage>871</lpage>.</mixed-citation></ref>
<ref id="c5"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Asano</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Okada</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Tsumura</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Yeh</surname>, <given-names>T.W.</given-names></string-name>, <string-name><surname>Mitsui-Sekinaka</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Tsujita</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Ichinose</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Shimada</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Hashimoto</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Wada</surname>, <given-names>T.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2018</year>). <article-title>Enhanced AKT phosphorylation of circulating B cells in patients with activated PI3Kδ syndrome</article-title>. <source>Front. Immunol</source>. <volume>9</volume>, <fpage>568</fpage>.</mixed-citation></ref>
<ref id="c6"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Avery</surname>, <given-names>D.T.</given-names></string-name>, <string-name><surname>Kane</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Nguyen</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Lau</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Nguyen</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Lenthall</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Payne</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Shi</surname>, <given-names>W.</given-names></string-name>, <string-name><surname>Brigden</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>French</surname>, <given-names>E.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2018</year>). <article-title>Germline-activating mutations in PIK3CD compromise B cell development and function</article-title>. <source>J. Exp. Med</source>. <volume>215</volume>, <fpage>2073</fpage>–<lpage>2095</lpage>.</mixed-citation></ref>
<ref id="c7"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Avin</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Levy</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Porat</surname>, <given-names>Z.</given-names></string-name>, and <string-name><surname>Abramson</surname>, <given-names>J.</given-names></string-name></person-group> (<year>2017</year>) <article-title>Quantitative analysis of protein-protein interactions and post-translational modifications in rare immune populations</article-title>. <source>Nat. Commun</source>. <volume>8</volume>, <fpage>1524</fpage>.</mixed-citation></ref>
<ref id="c8"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Battegay</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Moskophidis</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Waldner</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Bründler</surname>, <given-names>M.A.</given-names></string-name>, <string-name><surname>Fung-Leung</surname>, <given-names>W.P.</given-names></string-name>, <string-name><surname>Mak</surname>, <given-names>T.W.</given-names></string-name>, <string-name><surname>Hengartner</surname>, <given-names>H.</given-names></string-name>, and <string-name><surname>Zinkernagel</surname>, <given-names>R.M.</given-names></string-name></person-group> (<year>1993</year>). <article-title>Impairment and delay of neutralizing antiviral antibody responses by virus-specific cytotoxic T cells</article-title>. <source>J. Immunol</source>. <volume>151</volume>, <fpage>5408</fpage>–<lpage>5415</lpage>.</mixed-citation></ref>
<ref id="c9"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Baumjohann</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Preite</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Reboldi</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Ronchi</surname>, <given-names>F.</given-names></string-name>, <string-name><surname>Ansel</surname>, <given-names>K.M.</given-names></string-name>, <string-name><surname>Lanzavecchia</surname>, <given-names>A.</given-names></string-name>, and <string-name><surname>Sallusto</surname>, <given-names>F.</given-names></string-name></person-group> (<year>2013</year>). <article-title>Persistent antigen and germinal center B cells sustain T follicular helper cell responses and phenotype</article-title>. <source>Immunity</source> <volume>38</volume>, <fpage>596</fpage>–<lpage>605</lpage>.</mixed-citation></ref>
<ref id="c10"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bradley</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Peppa</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Pedroza-Pacheco</surname>, <given-names>I.</given-names></string-name>, <string-name><surname>Li</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Cain</surname>, <given-names>D.W.</given-names></string-name>, <string-name><surname>Henao</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Venkat</surname>, <given-names>V.</given-names></string-name>, <string-name><surname>Hora</surname>, <given-names>B.</given-names></string-name>, <string-name><surname>Chen</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Vandergrift</surname>, <given-names>N.A.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2018</year>). <article-title>RAB11FIP5 Expression and Altered Natural Killer Cell Function Are Associated with Induction of HIV Broadly Neutralizing Antibody Responses</article-title>. <source>Cell</source> <volume>175</volume>, <fpage>387</fpage>–<lpage>399.e17</lpage>.</mixed-citation></ref>
<ref id="c11"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Burns</surname>, <given-names>D.P.</given-names></string-name>, <string-name><surname>Collignon</surname>, <given-names>C.</given-names></string-name>, and <string-name><surname>Desrosiers</surname>, <given-names>R.C.</given-names></string-name></person-group> (<year>1993</year>). <article-title>Simian immunodeficiency virus mutants resistant to serum neutralization arise during persistent infection of rhesus monkeys</article-title>. <source>J. Virol</source>. <volume>67</volume>, <fpage>4104</fpage>–<lpage>4113</lpage>.</mixed-citation></ref>
<ref id="c12"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Campbell</surname>, <given-names>E.M.</given-names></string-name>, <string-name><surname>Nunez</surname>, <given-names>R.</given-names></string-name>, and <string-name><surname>Hope</surname>, <given-names>T.J.</given-names></string-name></person-group> (<year>2004</year>). <article-title>Disruption of the actin cytoskeleton can complement the ability of Nef to enhance human immunodeficiency virus type 1 infectivity</article-title>. <source>J. Virol</source>. <volume>78</volume>, <fpage>5745</fpage>–<lpage>5755</lpage>.</mixed-citation></ref>
<ref id="c13"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Coulter</surname>, <given-names>T.I.</given-names></string-name>, <string-name><surname>Chandra</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Bacon</surname>, <given-names>C.M.</given-names></string-name>, <string-name><surname>Babar</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Curtis</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Screaton</surname>, <given-names>N.</given-names></string-name>, <string-name><surname>Goodlad</surname>, <given-names>J.R.</given-names></string-name>, <string-name><surname>Farmer</surname>, <given-names>G.</given-names></string-name>, <string-name><surname>Steele</surname>, <given-names>C.L.</given-names></string-name>, <string-name><surname>Leahy</surname>, <given-names>T.R.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2017</year>). <article-title>Clinical spectrum and features of activated phosphoinositide 3-kinase δ syndrome: A large patient cohort study</article-title>. <source>J. Allergy Clin. Immunol</source>. <volume>139</volume>, <fpage>597</fpage>–<lpage>606.e4</lpage>.</mixed-citation></ref>
<ref id="c14"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cubas</surname>, <given-names>R.A.</given-names></string-name>, <string-name><surname>Mudd</surname>, <given-names>J.C.</given-names></string-name>, <string-name><surname>Savoye</surname>, <given-names>A.L.</given-names></string-name>, <string-name><surname>Perreau</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>van Grevenynghe</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Metcalf</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Connick</surname>, <given-names>E.</given-names></string-name>, <string-name><surname>Meditz</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Freeman</surname>, <given-names>G.J.</given-names></string-name>, <string-name><surname>Abesada-Terk</surname>, <given-names>G.</given-names></string-name> Jr., <etal>et al.</etal></person-group> (<year>2013</year>). <article-title>Inadequate T follicular cell help impairs B cell immunity during HIV infection</article-title>. <source>Nat. Med</source>. <volume>19</volume>, <fpage>494</fpage>–<lpage>499</lpage>.</mixed-citation></ref>
<ref id="c15"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cumont</surname>, <given-names>M.C.</given-names></string-name>, <string-name><surname>Diop</surname>, <given-names>O.</given-names></string-name>, <string-name><surname>Vaslin</surname>, <given-names>B.</given-names></string-name>, <string-name><surname>Elbim</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Viollet</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Monceaux</surname>, <given-names>V.</given-names></string-name>, <string-name><surname>Lay</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Silvestri</surname>, <given-names>G.</given-names></string-name>, <string-name><surname>Le Grand</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Müller-Trutwin</surname>, <given-names>M.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2008</year>). <article-title>Early divergence in lymphoid tissue apoptosis between pathogenic and nonpathogenic simian immunodeficiency virus infections of nonhuman primates</article-title>. <source>J. Virol</source>. <volume>82</volume>, <fpage>1175</fpage>–<lpage>1184</lpage>.</mixed-citation></ref>
<ref id="c16"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Dornan</surname>, <given-names>G.L.</given-names></string-name>, <string-name><surname>Siempelkamp</surname>, <given-names>B.D.</given-names></string-name>, <string-name><surname>Jenkins</surname>, <given-names>M.L.</given-names></string-name>, <string-name><surname>Vadas</surname>, <given-names>O.</given-names></string-name>, <string-name><surname>Lucas</surname>, <given-names>C.L.</given-names></string-name>, and <string-name><surname>Burke</surname>, <given-names>J.E.</given-names></string-name></person-group> (<year>2017</year>). <article-title>Conformational disruption of PI3Kδ regulation by immunodeficiency mutations in PIK3CD and PIK3R1</article-title>. <source>Proc. Natl. Acad. Sci. USA</source> <volume>114</volume>, <fpage>1982</fpage>–<lpage>1987</lpage>.</mixed-citation></ref>
<ref id="c17"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Douek</surname>, <given-names>D.C.</given-names></string-name>, <string-name><surname>Brenchley</surname>, <given-names>J.M.</given-names></string-name>, <string-name><surname>Betts</surname>, <given-names>M.R.</given-names></string-name>, <string-name><surname>Ambrozak</surname>, <given-names>D.R.</given-names></string-name>, <string-name><surname>Hill</surname>, <given-names>B.J.</given-names></string-name>, <string-name><surname>Okamoto</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Casazza</surname>, <given-names>J.P.</given-names></string-name>, <string-name><surname>Kuruppu</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Kunstman</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Wolinsky</surname>, <given-names>S.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2002</year>). <article-title>HIV preferentially infects HIV-specific CD4<sup>+</sup> T cells</article-title>. <source>Nature</source> <volume>417</volume>, <fpage>95</fpage>–<lpage>98</lpage>.</mixed-citation></ref>
<ref id="c18"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Evans</surname>, <given-names>D.T.</given-names></string-name>, <string-name><surname>O’Connor</surname>, <given-names>D.H.</given-names></string-name>, <string-name><surname>Jing</surname>, <given-names>P.</given-names></string-name>, <string-name><surname>Dzuris</surname>, <given-names>J.L.</given-names></string-name>, <string-name><surname>Sidney</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>da Silva</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Allen</surname>, <given-names>T.M.</given-names></string-name>, <string-name><surname>Horton</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Venham</surname>, <given-names>J.E.</given-names></string-name>, <string-name><surname>Rudersdorf</surname>, <given-names>R.A.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>1999</year>). <article-title>Virus-specific cytotoxic T-lymphocyte responses select for amino-acid variation in simian immunodeficiency virus Env and Nef</article-title>. <source>Nat. Med</source>. <volume>5</volume>, <fpage>1270</fpage>–<lpage>1276</lpage>.</mixed-citation></ref>
<ref id="c19"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Fallet</surname>, <given-names>B.</given-names></string-name>, <string-name><surname>Narr</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Ertuna</surname>, <given-names>Y.I.</given-names></string-name>, <string-name><surname>Remy</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Sommerstein</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Cornille</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Kreutzfeldt</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Page</surname>, <given-names>N.</given-names></string-name>, <string-name><surname>Zimmer</surname>, <given-names>G.</given-names></string-name>, <string-name><surname>Geier</surname>, <given-names>F.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2016</year>). <article-title>Interferon-driven deletion of antiviral B cells at the onset of chronic infection</article-title>. <source>Sci. Immunol</source>. <volume>1</volume>, pii: <fpage>eaah6817</fpage>.</mixed-citation></ref>
<ref id="c20"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>François</surname>, <given-names>F.</given-names></string-name>, and <string-name><surname>Klotman</surname>, <given-names>M.E.</given-names></string-name></person-group> (<year>2003</year>). <article-title>Phosphatidylinositol 3-kinase regulates human immunodeficiency virus type 1 replication following viral entry in primary CD4+ T lymphocytes and macrophages</article-title>. <source>J. Virol</source>. <volume>77</volume>, <fpage>2539</fpage>–<lpage>2549</lpage>.</mixed-citation></ref>
<ref id="c21"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Fruman</surname>, <given-names>D.A.</given-names></string-name>, <string-name><surname>Snapper</surname>, <given-names>S.B.</given-names></string-name>, <string-name><surname>Yballe</surname>, <given-names>C.M.</given-names></string-name>, <string-name><surname>Davidson</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Yu</surname>, <given-names>J.Y.</given-names></string-name>, <string-name><surname>Alt</surname>, <given-names>F.W.</given-names></string-name>, and <string-name><surname>Cantley</surname>, <given-names>L.C.</given-names></string-name></person-group> (<year>1999</year>). <article-title>Impaired B cell development and proliferation in absence of phosphoinositide 3-kinase p85alpha</article-title>. <source>Science</source> <volume>283</volume>, <fpage>393</fpage>–<lpage>397</lpage>.</mixed-citation></ref>
<ref id="c22"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Fukazawa</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Park</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Cameron</surname>, <given-names>M.J.</given-names></string-name>, <string-name><surname>Lefebvre</surname>, <given-names>F.</given-names></string-name>, <string-name><surname>Lum</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Coombes</surname>, <given-names>N.</given-names></string-name>, <string-name><surname>Mahyari</surname>, <given-names>E.</given-names></string-name>, <string-name><surname>Hagen</surname>, <given-names>S.I.</given-names></string-name>, <string-name><surname>Bae</surname>, <given-names>J.Y.</given-names></string-name>, <string-name><surname>Reyes</surname>, <given-names>M.D.</given-names> <suffix>3rd</suffix></string-name>., <etal>et al.</etal></person-group> (<year>2012</year>). <article-title>Lymph node T cell responses predict the efficacy of live attenuated SIV vaccines</article-title>. <source>Nat. Med</source>. <volume>18</volume>, <fpage>1673</fpage>–<lpage>1681</lpage>.</mixed-citation></ref>
<ref id="c23"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gauduin</surname>, <given-names>M.C.</given-names></string-name>, <string-name><surname>Yu</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Barabasz</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Carville</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Piatak</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Lifson</surname>, <given-names>J.D.</given-names></string-name>, <string-name><surname>Desrosiers</surname>, <given-names>R.C.</given-names></string-name>, and <string-name><surname>Johnson</surname>, <given-names>R.P.</given-names></string-name></person-group> (<year>2006</year>). <article-title>Induction of a virus-specific effector-memory CD4+ T cell response by attenuated SIV infection</article-title>. <source>J. Exp. Med</source>. <volume>203</volume>, <fpage>2661</fpage>–<lpage>2672</lpage>.</mixed-citation></ref>
<ref id="c24"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Geyer</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Fackler</surname>, <given-names>O.T.</given-names></string-name>, and <string-name><surname>Peterlin</surname>, <given-names>B.M.</given-names></string-name></person-group> (<year>2001</year>). <article-title>Structure--function relationships in HIV-1 Nef</article-title>. <source>EMBO Rep</source>. <volume>2</volume>, <fpage>580</fpage>–<lpage>585</lpage>.</mixed-citation></ref>
<ref id="c25"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gitlin</surname>, <given-names>A.D.</given-names></string-name>, <string-name><surname>Shulman</surname>, <given-names>Z.</given-names></string-name> and <string-name><surname>Nussenzweig</surname>, <given-names>M.C.</given-names></string-name></person-group> (<year>2014</year>). <article-title>Clonal selection in the germinal centre by regulated proliferation and hypermutation</article-title>. <source>Nature</source> <volume>509</volume>, <fpage>637</fpage>–<lpage>640</lpage>.</mixed-citation></ref>
<ref id="c26"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gray</surname>, <given-names>E.S.</given-names></string-name>, <string-name><surname>Madiga</surname>, <given-names>M.C.</given-names></string-name>, <string-name><surname>Hermanus</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Moore</surname>, <given-names>P.L.</given-names></string-name>, <string-name><surname>Wibmer</surname>, <given-names>C.K.</given-names></string-name>, <string-name><surname>Tumba</surname>, <given-names>N.L.</given-names></string-name>, <string-name><surname>Werner</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Mlisana</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Sibeko</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Williamson</surname>, <given-names>C.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2011</year>). <article-title>The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection</article-title>. <source>J. Virol</source>. <volume>85</volume>, <fpage>4828</fpage>–<lpage>4840</lpage>.</mixed-citation></ref>
<ref id="c27"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Haigwood</surname>, <given-names>N.L.</given-names></string-name>, <string-name><surname>Watson</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Sutton</surname>, <given-names>W.F.</given-names></string-name>, <string-name><surname>McClure</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Lewis</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Ranchalis</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Travis</surname>, <given-names>B.</given-names></string-name>, <string-name><surname>Voss</surname>, <given-names>G.</given-names></string-name>, <string-name><surname>Letvin</surname>, <given-names>N.L.</given-names></string-name>, <string-name><surname>Hu</surname>, <given-names>S.L.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>1996</year>). <article-title>Passive immune globulin therapy in the SIV/macaque model: early intervention can alter disease profile</article-title>. <source>Immunol. Lett</source>. <volume>51</volume>, <fpage>107</fpage>–<lpage>114</lpage>.</mixed-citation></ref>
<ref id="c28"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Haralick</surname>, <given-names>R.M.</given-names></string-name>, <string-name><surname>Shanmugam</surname>, <given-names>K.</given-names></string-name>, and <string-name><surname>Dinstein</surname>, <given-names>I.</given-names></string-name></person-group> (<year>1973</year>) <article-title>Textural features for image classification. <italic>IEEE Transactions on Systems</italic></article-title>, <source>Man, and Cybernetics SMC</source>-<volume>3</volume>, <fpage>610</fpage>–<lpage>621</lpage>.</mixed-citation></ref>
<ref id="c29"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Harris</surname>, <given-names>R.S.</given-names></string-name>, <string-name><surname>Bishop</surname>, <given-names>K.N.</given-names></string-name>, <string-name><surname>Sheehy</surname>, <given-names>A.M.</given-names></string-name>, <string-name><surname>Craig</surname>, <given-names>H.M.</given-names></string-name>, <string-name><surname>Petersen-Mahrt</surname>, <given-names>S.K.</given-names></string-name>, <string-name><surname>Watt</surname>, <given-names>I.N.</given-names></string-name>, <string-name><surname>Neuberger</surname>, <given-names>M.S.</given-names></string-name>, and <string-name><surname>Malim</surname>, <given-names>M.H.</given-names></string-name></person-group> (<year>2003</year>). <article-title>DNA deamination mediates innate immunity to retroviral infection</article-title>. <source>Cell</source> <volume>113</volume>, <fpage>803</fpage>–<lpage>809</lpage>.</mixed-citation></ref>
<ref id="c30"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hashimoto</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Bhuyan</surname>, <given-names>F.</given-names></string-name>, <string-name><surname>Hiyoshi</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Noyori</surname>, <given-names>O.</given-names></string-name>, <string-name><surname>Nasser</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Miyazaki</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Saito</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Kondoh</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Osada</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Kimura</surname>, <given-names>S.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2016</year>). <article-title>Potential role of the formation of tunneling nanotubes in HIV-1 spread in macrophages</article-title>. <source>J. Immunol</source>. <volume>196</volume>, <fpage>1832</fpage>–<lpage>1841</lpage>.</mixed-citation></ref>
<ref id="c31"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hau</surname>, <given-names>T.T.T.</given-names></string-name>, <string-name><surname>Nishizawa</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Harada</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Phan</surname>, <given-names>M.H.</given-names></string-name>, <string-name><surname>Kanno</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Nomura</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Matsuoka</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Kawana-Tachikawa</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Hall</surname>, <given-names>W.W.</given-names></string-name>, <string-name><surname>Matano</surname>, <given-names>T.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2022</year>). <article-title>Association of envelope-specific B-cell differentiation and viral selective pressure signatures in HIV-1 CRF01_AE infection</article-title>. <source>AIDS</source> <volume>36</volume>, <fpage>1629</fpage>–<lpage>1641</lpage>.</mixed-citation></ref>
<ref id="c32"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Havenar-Daughton</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Carnathan</surname>, <given-names>D.G.</given-names></string-name>, <string-name><surname>Torrents de la Peña</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Pauthner</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Briney</surname>, <given-names>B.</given-names></string-name>, <string-name><surname>Reiss</surname>, <given-names>S.M.</given-names></string-name>, <string-name><surname>Wood</surname>, <given-names>J.S.</given-names></string-name>, <string-name><surname>Kaushik</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>van Gils</surname>, <given-names>M.J.</given-names></string-name>, <string-name><surname>Rosales</surname>, <given-names>S.L.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2016</year>). <article-title>Direct Probing of Germinal Center Responses Reveals Immunological Features and Bottlenecks for Neutralizing Antibody Responses to HIV Env Trimer</article-title>. <source>Cell Rep</source>. <volume>17</volume>, <fpage>2195</fpage>–<lpage>2209</lpage>.</mixed-citation></ref>
<ref id="c33"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hirsch</surname>, <given-names>V.M.</given-names></string-name>, <string-name><surname>Santra</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Goldstein</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Plishka</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Buckler-White</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Seth</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Ourmanov</surname>, <given-names>I.</given-names></string-name>, <string-name><surname>Brown</surname>, <given-names>C.R.</given-names></string-name>, <string-name><surname>Engle</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Montefiori</surname>, <given-names>D.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2004</year>). <article-title>Immune failure in the absence of profound CD4+ T-lymphocyte depletion in simian immunodeficiency virus-infected rapid progressor macaques</article-title>. <source>J. Virol</source>. <volume>78</volume>, <fpage>275</fpage>–<lpage>284</lpage>.</mixed-citation></ref>
<ref id="c34"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hoof</surname>, <given-names>I.</given-names></string-name>, <string-name><surname>Peters</surname>, <given-names>B.</given-names></string-name>, <string-name><surname>Sidney</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Pedersen</surname>, <given-names>L.E.</given-names></string-name>, <string-name><surname>Sette</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Lund</surname>, <given-names>O.</given-names></string-name>, <string-name><surname>Buus</surname>, <given-names>S.</given-names></string-name>, and <string-name><surname>Nielsen</surname>, <given-names>M.</given-names></string-name></person-group>. (<year>2009</year>). <article-title>NetMHCpan, a method for MHC class I binding prediction beyond humans</article-title>. <source>Immunogenetics</source> <volume>61</volume>, <fpage>1</fpage>–<lpage>13</lpage>.</mixed-citation></ref>
<ref id="c35"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hunziker</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Recher</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Macpherson</surname>, <given-names>A.J.</given-names></string-name>, <string-name><surname>Ciurea</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Freigang</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Hengartner</surname>, <given-names>H.</given-names></string-name>, and <string-name><surname>Zinkernagel</surname>, <given-names>R.M.</given-names></string-name></person-group> (<year>2003</year>). <article-title>Hypergammaglobulinemia and autoantibody induction mechanisms in viral infections</article-title>. <source>Nat. Immunol</source>. <volume>4</volume>, <fpage>343</fpage>–<lpage>349</lpage>.</mixed-citation></ref>
<ref id="c36"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Iseda</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Takahashi</surname>, <given-names>N.</given-names></string-name>, <string-name><surname>Poplimont</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Nomura</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Seki</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Nakane</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Nakamura</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Shi</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Ishii</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Furukawa</surname>, <given-names>S.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2016</year>). <article-title>Biphasic CD8+ T-cell defense in simian immunodeficiency virus control by acute-phase passive neutralizing antibody immunization</article-title>. <source>J. Virol</source>. <volume>90</volume>, <fpage>6276</fpage>–<lpage>6290</lpage>.</mixed-citation></ref>
<ref id="c37"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ishii</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Kawada</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Tsukamoto</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Yamamoto</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Matsuoka</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Shiino</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Takeda</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Inoue</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Iida</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Hara</surname>, <given-names>H.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2012</year>). <article-title>Impact of vaccination on cytotoxic T lymphocyte immunodominance and cooperation against simian immunodeficiency virus replication in rhesus macaques</article-title>. <source>J. Virol</source>. <volume>86</volume>, <fpage>738</fpage>–<lpage>745</lpage>.</mixed-citation></ref>
<ref id="c38"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Iwamoto</surname>, <given-names>N.</given-names></string-name>, <string-name><surname>Takahashi</surname>, <given-names>N.</given-names></string-name>, <string-name><surname>Seki</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Nomura</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Yamamoto</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Inoue</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Shu</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Naruse</surname>, <given-names>T.K.</given-names></string-name>, <string-name><surname>Kimura</surname>, <given-names>A.</given-names></string-name>, and <string-name><surname>Matano</surname>, <given-names>T.</given-names></string-name></person-group> (<year>2014</year>). <article-title>Control of simian immunodeficiency virus replication by vaccine-induced Gag-and Vif-specific CD8<sup>+</sup> T cells</article-title>. <source>J. Virol</source>. <volume>88</volume>, <fpage>425</fpage>–<lpage>433</lpage>.</mixed-citation></ref>
<ref id="c39"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Jauch</surname>, <given-names>A.J.</given-names></string-name>, <string-name><surname>Bignucolo</surname>, <given-names>O.</given-names></string-name>, <string-name><surname>Seki</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Ghraichy</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Delmonte</surname>, <given-names>O.M.</given-names></string-name>, <string-name><surname>von Niederhäusern</surname>, <given-names>V.</given-names></string-name>, <string-name><surname>Higgins</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Ghosh</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Nishizawa</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Tanaka</surname>, <given-names>M.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2023</year>). <article-title>Autoimmunity and immunodeficiency associated with monoallelic LIG4 mutations via haploinsufficiency</article-title>. <source>J. Allergy Clin. Immunol</source>. <volume>152</volume>, <fpage>500</fpage>–<lpage>516</lpage>.</mixed-citation></ref>
<ref id="c40"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Jia</surname>, <given-names>B.</given-names></string-name>, <string-name><surname>Serra-Moreno</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Neidermyer</surname>, <given-names>W.</given-names></string-name>, <string-name><surname>Rahmberg</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Mackey</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Fofana</surname>, <given-names>I.B.</given-names></string-name>, <string-name><surname>Johnson</surname>, <given-names>W.E.</given-names></string-name>, <string-name><surname>Westmoreland</surname>, <given-names>S.</given-names></string-name>, and <string-name><surname>Evans</surname>, <given-names>D.T.</given-names></string-name></person-group> (<year>2009</year>). <article-title>Species-specific activity of SIV Nef and HIV-1 Vpu in overcoming restriction by tetherin/BST2</article-title>. <source>PLoS Pathog</source>. <volume>5</volume>, <fpage>e1000429</fpage>.</mixed-citation></ref>
<ref id="c41"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Joas</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Parrish</surname>, <given-names>E.H.</given-names></string-name>, <string-name><surname>Gnanadurai</surname>, <given-names>C.W.</given-names></string-name>, <string-name><surname>Lump</surname>, <given-names>E.</given-names></string-name>, <string-name><surname>Stürzel</surname>, <given-names>C.M.</given-names></string-name>, <string-name><surname>Parrish</surname>, <given-names>N.F.</given-names></string-name>, <string-name><surname>Learn</surname>, <given-names>G.H.</given-names></string-name>, <string-name><surname>Sauermann</surname>, <given-names>U.</given-names></string-name>, <string-name><surname>Neumann</surname>, <given-names>B.</given-names></string-name>, <string-name><surname>Rensing</surname>, <given-names>K.M.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2018</year>) <article-title>Species-specific host factors rather than virus-intrinsic virulence determine primate lentiviral pathogenicity</article-title>. <source>Nat. Commun</source>. <volume>9</volume>, <fpage>1371</fpage>.</mixed-citation></ref>
<ref id="c42"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Joas</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Sauermann</surname>, <given-names>U.</given-names></string-name>, <string-name><surname>Roshani</surname>, <given-names>B.</given-names></string-name>, <string-name><surname>Klippert</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Daskalaki</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Mätz-Rensing</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Stolte-Leeb</surname>, <given-names>N.</given-names></string-name>, <string-name><surname>Heigele</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Tharp</surname>, <given-names>G.K.</given-names></string-name>, <string-name><surname>Gupta</surname>, <given-names>P.M.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2020</year>). <article-title>Nef-Mediated CD3-TCR Downmodulation Dampens Acute Inflammation and Promotes SIV Immune Evasion</article-title>. <source>Cell Rep</source>. <volume>30</volume>, <fpage>2261</fpage>–<lpage>2274.e7</lpage>.</mixed-citation></ref>
<ref id="c43"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Johnson</surname>, <given-names>R.P.</given-names></string-name>, <string-name><surname>Glickman</surname>, <given-names>R.L.</given-names></string-name>, <string-name><surname>Yang</surname>, <given-names>J.Q.</given-names></string-name>, <string-name><surname>Kaur</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Dion</surname>, <given-names>J.T.</given-names></string-name>, <string-name><surname>Mulligan</surname>, <given-names>M.J.</given-names></string-name>, and <string-name><surname>Desrosiers</surname>, <given-names>R.C.</given-names></string-name></person-group> (<year>1997</year>). <article-title>Induction of vigorous cytotoxic T-lymphocyte responses by live attenuated simian immunodeficiency virus</article-title>. <source>J. Virol</source>. <volume>71</volume>, <fpage>7711</fpage>–<lpage>7718</lpage>.</mixed-citation></ref>
<ref id="c44"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Jolly</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Kashefi</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Hollinshead</surname>, <given-names>M.</given-names></string-name>, and <string-name><surname>Sattentau</surname>, <given-names>Q.J.</given-names></string-name></person-group> (<year>2004</year>). <article-title>HIV-1 cell to cell transfer across an Env-induced, actin-dependent synapse</article-title>. <source>J. Exp. Med</source>. <volume>199</volume>, <fpage>283</fpage>–<lpage>293</lpage>.</mixed-citation></ref>
<ref id="c45"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Junt</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Moseman</surname>, <given-names>E.A.</given-names></string-name>, <string-name><surname>Iannacone</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Massberg</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Lang</surname>, <given-names>P.A.</given-names></string-name>, <string-name><surname>Boes</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Fink</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Henrickson</surname>, <given-names>S.E.</given-names></string-name>, <string-name><surname>Shayakhmetov</surname>, <given-names>D.M.</given-names></string-name>, <string-name><surname>Di Paolo</surname>, <given-names>N.C.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2007</year>). <article-title>Subcapsular sinus macrophages in lymph nodes clear lymph-borne viruses and present them to antiviral B cells</article-title>. <source>Nature</source> <volume>450</volume>, <fpage>110</fpage>–<lpage>114</lpage>.</mixed-citation></ref>
<ref id="c46"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kawada</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Tsukamoto</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Yamamoto</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Takeda</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Igarashi</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Watkins</surname>, <given-names>D.I.</given-names></string-name>, and <string-name><surname>Matano</surname>, <given-names>T.</given-names></string-name></person-group> (<year>2007</year>). <article-title>Long-term control of simian immunodeficiency virus replication with central memory CD4+ T-cell preservation after nonsterile protection by a cytotoxic T-lymphocyte-based vaccine</article-title>. <source>J. Virol</source>. <volume>81</volume>, <fpage>5202</fpage>–<lpage>5211</lpage>.</mixed-citation></ref>
<ref id="c47"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kennedy</surname>, <given-names>S.G.</given-names></string-name>, <string-name><surname>Wagner</surname>, <given-names>A.J.</given-names></string-name>, <string-name><surname>Conzen</surname>, <given-names>S.D.</given-names></string-name>, <string-name><surname>Jordán</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Bellacosa</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Tsichlis</surname>, <given-names>P.N.</given-names></string-name>, and <string-name><surname>Hay</surname>, <given-names>N.</given-names></string-name></person-group> (<year>1997</year>). <article-title>The PI 3-kinase/Akt signaling pathway delivers an anti-apoptotic signal</article-title>. <source>Genes Dev</source>. <volume>11</volume>, <fpage>701</fpage>–<lpage>713</lpage>.</mixed-citation></ref>
<ref id="c48"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kestler</surname>, <given-names>H.W.</given-names></string-name> 3rd, <string-name><surname>Ringler</surname>, <given-names>D.J.</given-names></string-name>, <string-name><surname>Mori</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Panicali</surname>, <given-names>D.L.</given-names></string-name>, <string-name><surname>Sehgal</surname>, <given-names>P.K.</given-names></string-name>, <string-name><surname>Daniel</surname>, <given-names>M.D.</given-names></string-name>, and <string-name><surname>Desrosiers</surname>, <given-names>R.C.</given-names></string-name></person-group> (<year>1991</year>). <article-title>Importance of the nef gene for maintenance of high virus loads and for development of AIDS</article-title>. <source>Cell</source> <volume>65</volume>, <fpage>651</fpage>–<lpage>662</lpage>.</mixed-citation></ref>
<ref id="c49"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Khan</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Sumner</surname>, <given-names>R.P.</given-names></string-name>, <string-name><surname>Rasaiyaah</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Tan</surname>, <given-names>C.P.</given-names></string-name>, <string-name><surname>Rodriguez-Plata</surname>, <given-names>M.T.</given-names></string-name>, <string-name><surname>Van Tulleken</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Fink</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Zuliani-Alvarez</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Thorne</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Stirling</surname>, <given-names>D.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2020</year>). <article-title>HIV-1 Vpr antagonizes innate immune activation by targeting karyopherin-mediated NF-κB/IRF3 nuclear transport</article-title>. <source>Elife</source> <volume>9</volume>, <fpage>e60821</fpage>.</mixed-citation></ref>
<ref id="c50"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kim</surname>, <given-names>D.H.</given-names></string-name>, <string-name><surname>Sarbassov</surname>, <given-names>D.D.</given-names></string-name>, <string-name><surname>Ali</surname>, <given-names>S.M.</given-names></string-name>, <string-name><surname>Latek</surname>, <given-names>R.R.</given-names></string-name>, <string-name><surname>Guntur</surname>, <given-names>K.V.</given-names></string-name>, <string-name><surname>Erdjument-Bromage</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Tempst</surname>, <given-names>P.</given-names></string-name>, and <string-name><surname>Sabatini</surname>, <given-names>D.M.</given-names></string-name></person-group> (<year>2003</year>). <article-title>GbetaL, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR</article-title>. <source>Mol. Cell</source> <volume>11</volume>, <fpage>895</fpage>–<lpage>904</lpage>.</mixed-citation></ref>
<ref id="c51"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kirchhoff</surname>, <given-names>F.</given-names></string-name>, <string-name><surname>Greenough</surname>, <given-names>T.C.</given-names></string-name>, <string-name><surname>Brettler</surname>, <given-names>D.B.</given-names></string-name>, <string-name><surname>Sullivan</surname>, <given-names>L.L.</given-names></string-name> and <string-name><surname>Desrosiers</surname>, <given-names>R.C.</given-names></string-name></person-group> (<year>1995</year>). <article-title>Absence of intact nef sequences in a long-term, nonprogressing survivor of HIV-1 infection</article-title>. <source>N. Engl. J. Med</source>. <volume>332</volume>, <fpage>228</fpage>–<lpage>232</lpage>.</mixed-citation></ref>
<ref id="c52"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kumar</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Abbas</surname>, <given-names>W.</given-names></string-name>, <string-name><surname>Colin</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Khan</surname>, <given-names>K.A.</given-names></string-name>, <string-name><surname>Bouchat</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Varin</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Larbi</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Gatot</surname>, <given-names>J.S.</given-names></string-name>, <string-name><surname>Kabeya</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Vanhulle</surname>, <given-names>C.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2016</year>). <article-title>Tuning of AKT-pathway by Nef and its blockade by protease inhibitors results in limited recovery in latently HIV infected T-cell line</article-title>. <source>Sci. Rep</source>. <volume>6</volume>, <fpage>24090</fpage>.</mixed-citation></ref>
<ref id="c53"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kumar</surname>, <given-names>V.</given-names></string-name>, <string-name><surname>Scandella</surname>, <given-names>E.</given-names></string-name>, <string-name><surname>Danuser</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Onder</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Nitschké</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Fukui</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Halin</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Ludewig</surname>, <given-names>B.</given-names></string-name>, and <string-name><surname>Stein</surname>, <given-names>J.V.</given-names></string-name></person-group> (<year>2010</year>). <article-title>Global lymphoid tissue remodeling during a viral infection is orchestrated by a B cell-lymphotoxin-dependent pathway</article-title>. <source>Blood</source> <volume>115</volume>, <fpage>4725</fpage>–<lpage>4733</lpage>.</mixed-citation></ref>
<ref id="c54"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Laguette</surname>, <given-names>N.</given-names></string-name>, <string-name><surname>Sobhian</surname>, <given-names>B.</given-names></string-name>, <string-name><surname>Casartelli</surname>, <given-names>N.</given-names></string-name>, <string-name><surname>Ringeard</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Chable-Bessia</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Ségéral</surname>, <given-names>E.</given-names></string-name>, <string-name><surname>Yatim</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Emiliani</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Schwartz</surname>, <given-names>O.</given-names></string-name>, and <string-name><surname>Benkirane</surname>, <given-names>M.</given-names></string-name></person-group> (<year>2011</year>). <article-title>SAMHD1 is the dendritic-and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx</article-title>. <source>Nature</source> <volume>474</volume>, <fpage>654</fpage>–<lpage>657</lpage>.</mixed-citation></ref>
<ref id="c55"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Langer</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Hammer</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Hopfensperger</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Klein</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Hotter</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>De Jesus</surname>, <given-names>P.D.</given-names></string-name>, <string-name><surname>Herbert</surname>, <given-names>K.M.</given-names></string-name>, <string-name><surname>Pache</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Smith</surname>, <given-names>N.</given-names></string-name>, <string-name><surname>van der Merwe</surname>, <given-names>J.A.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2019</year>) <article-title>HIV-1 Vpu is a potent transcriptional suppressor of NF-κB-elicited antiviral immune responses</article-title>. <source>Elife</source> <volume>8</volume>, <fpage>e41930</fpage>.</mixed-citation></ref>
<ref id="c56"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Leuchowius</surname>, <given-names>K.J.</given-names></string-name>, <string-name><surname>Weibrecht</surname>, <given-names>I.</given-names></string-name>, <string-name><surname>Landegren</surname>, <given-names>U.</given-names></string-name>, <string-name><surname>Gedda</surname>, <given-names>L.</given-names></string-name>, and <string-name><surname>Söderberg</surname>, <given-names>O.</given-names></string-name></person-group> (<year>2009</year>). <article-title>Flow cytometric in situ proximity ligation analyses of protein interactions and post-translational modification of the epidermal growth factor receptor family</article-title>. <source>Cytometry A</source> <volume>75</volume>, <fpage>833</fpage>–<lpage>839</lpage>.</mixed-citation></ref>
<ref id="c57"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Levesque</surname>, <given-names>M.C.</given-names></string-name>, <string-name><surname>Moody</surname>, <given-names>M.A.</given-names></string-name>, <string-name><surname>Hwang</surname>, <given-names>K.K.</given-names></string-name>, <string-name><surname>Marshall</surname>, <given-names>D.J.</given-names></string-name>, <string-name><surname>Whitesides</surname>, <given-names>J.F.</given-names></string-name>, <string-name><surname>Amos</surname>, <given-names>J.D.</given-names></string-name>, <string-name><surname>Gurley</surname>, <given-names>T.C.</given-names></string-name>, <string-name><surname>Allgood</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Haynes</surname>, <given-names>B.B.</given-names></string-name>, <string-name><surname>Vandergrift</surname>, <given-names>N.A.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2009</year>). <article-title>Polyclonal B cell differentiation and loss of gastrointestinal tract germinal centers in the earliest stages of HIV-1 infection</article-title>. <source>PLoS Med</source>. <volume>6</volume>, <fpage>e1000107</fpage>.</mixed-citation></ref>
<ref id="c58"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lichterfeld</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Kavanagh</surname>, <given-names>D.G.</given-names></string-name>, <string-name><surname>Williams</surname>, <given-names>K.L.</given-names></string-name>, <string-name><surname>Moza</surname>, <given-names>B.</given-names></string-name>, <string-name><surname>Mui</surname>, <given-names>S.K.</given-names></string-name>, <string-name><surname>Miura</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Sivamurthy</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Allgaier</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Pereyra</surname>, <given-names>F.</given-names></string-name>, <string-name><surname>Trocha</surname>, <given-names>A.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2007</year>). <article-title>A viral CTL escape mutation leading to immunoglobulin-like transcript 4-mediated functional inhibition of myelomonocytic cells</article-title>. <source>J. Exp. Med</source>. <volume>204</volume>, <fpage>2813</fpage>–<lpage>2824</lpage>.</mixed-citation></ref>
<ref id="c59"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Limon</surname>, <given-names>J.J.</given-names></string-name>, <string-name><surname>So</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Jellbauer</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Chiu</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Corado</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Sykes</surname>, <given-names>S.M.</given-names></string-name>, <string-name><surname>Raffatellu</surname>, <given-names>M.</given-names></string-name>, and <string-name><surname>Fruman</surname>, <given-names>D.A.</given-names></string-name></person-group> (<year>2014</year>). <article-title>mTOR kinase inhibitors promote antibody class switching via mTORC2 inhibition</article-title>. <source>Proc. Natl. Acad. Sci. USA</source> <volume>111</volume>, <fpage>E5076</fpage>–<lpage>5085</lpage>.</mixed-citation></ref>
<ref id="c60"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lindqvist</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>van Lunzen</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Soghoian</surname>, <given-names>D.Z.</given-names></string-name>, <string-name><surname>Kuhl</surname>, <given-names>B.D.</given-names></string-name>, <string-name><surname>Ranasinghe</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Kranias</surname>, <given-names>G.</given-names></string-name>, <string-name><surname>Flanders</surname>, <given-names>M.D.</given-names></string-name>, <string-name><surname>Cutler</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Yudanin</surname>, <given-names>N.</given-names></string-name>, <string-name><surname>Muller</surname>, <given-names>M.I.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2012</year>). <article-title>Expansion of HIV-specific T follicular helper cells in chronic HIV infection</article-title>. <source>J. Clin. Invest</source>. <volume>122</volume>, <fpage>3271</fpage>–<lpage>3280</lpage>.</mixed-citation></ref>
<ref id="c61"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Locci</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Havenar-Daughton</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Landais</surname>, <given-names>E.</given-names></string-name>, <string-name><surname>Wu</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Kroenke</surname>, <given-names>M.A.</given-names></string-name>, <string-name><surname>Arlehamn</surname>, <given-names>C.L.</given-names></string-name>, <string-name><surname>Su</surname>, <given-names>L.F.</given-names></string-name>, <string-name><surname>Cubas</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Davis</surname>, <given-names>M.M.</given-names></string-name>, <string-name><surname>Sette</surname>, <given-names>A.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2013</year>). <article-title>Human circulating PD-1<sup>+</sup>CXCR3<sup>-</sup>CXCR5<sup>+</sup> memory Tfh cells are highly functional and correlate with broadly neutralizing HIV antibody responses</article-title>. <source>Immunity</source> <volume>39</volume>, <fpage>758</fpage>–<lpage>769</lpage>.</mixed-citation></ref>
<ref id="c62"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lucas</surname>, <given-names>C.L.</given-names></string-name>, <string-name><surname>Kuehn</surname>, <given-names>H.S.</given-names></string-name>, <string-name><surname>Zhao</surname>, <given-names>F.</given-names></string-name>, <string-name><surname>Niemela</surname>, <given-names>J.E.</given-names></string-name>, <string-name><surname>Deenick</surname>, <given-names>E.K.</given-names></string-name>, <string-name><surname>Palendira</surname>, <given-names>U.</given-names></string-name>, <string-name><surname>Avery</surname>, <given-names>D.T.</given-names></string-name>, <string-name><surname>Moens</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Cannons</surname>, <given-names>J.L.</given-names></string-name>, <string-name><surname>Biancalana</surname>, <given-names>M.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2014</year>). <article-title>Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110δ result in T cell senescence and human immunodeficiency</article-title>. <source>Nat. Immunol</source>. <volume>15</volume>, <fpage>88</fpage>–<lpage>97</lpage>.</mixed-citation></ref>
<ref id="c63"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Luo</surname>, <given-names>W.</given-names></string-name>, <string-name><surname>Hawse</surname>, <given-names>W.</given-names></string-name>, <string-name><surname>Conter</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Trivedi</surname>, <given-names>N.</given-names></string-name>, <string-name><surname>Weisel</surname>, <given-names>F.</given-names></string-name>, <string-name><surname>Wikenheiser</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Cattley</surname>, <given-names>R.T.</given-names></string-name>, and <string-name><surname>Shlomchik</surname>, <given-names>M.J.</given-names></string-name></person-group> (<year>2019</year>). <article-title>The AKT kinase signaling network is rewired by PTEN to control proximal BCR signaling in germinal center B cells</article-title>. <source>Nat. Immunol</source>. <volume>20</volume>, <fpage>736</fpage>–<lpage>746</lpage>.</mixed-citation></ref>
<ref id="c64"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Marzec</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Liu</surname>, <given-names>X.</given-names></string-name>, <string-name><surname>Kasprzycka</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Witkiewicz</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Raghunath</surname>, <given-names>P.N.</given-names></string-name>, <string-name><surname>El-Salem</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Robertson</surname>, <given-names>E.</given-names></string-name>, <string-name><surname>Odum</surname>, <given-names>N.</given-names></string-name>, and <string-name><surname>Wasik</surname>, <given-names>M.A.</given-names></string-name></person-group> (<year>2008</year>). <article-title>IL-2-and IL-15-induced activation of the rapamycin-sensitive mTORC1 pathway in malignant CD4+ T lymphocytes</article-title>. <source>Blood</source> <volume>111</volume>, <fpage>2181</fpage>–<lpage>2189</lpage>.</mixed-citation></ref>
<ref id="c65"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mason</surname>, <given-names>R.D.</given-names></string-name>, <string-name><surname>Welles</surname>, <given-names>H.C.</given-names></string-name>, <string-name><surname>Adams</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Chakrabarti</surname>, <given-names>B.K.</given-names></string-name>, <string-name><surname>Gorman</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Zhou</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Nguyen</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>O’Dell</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Lusvarghi</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Bewley</surname>, <given-names>C.A.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2016</year>). <article-title>Targeted Isolation of Antibodies Directed against Major Sites of SIV Env Vulnerability</article-title>. <source>PLoS Pathog</source>. <volume>12</volume>, <fpage>e1005537</fpage>.</mixed-citation></ref>
<ref id="c66"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Matano</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Kobayashi</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Igarashi</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Takeda</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Nakamura</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Kano</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Sugimoto</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Mori</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Iida</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Hirata</surname>, <given-names>T.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2004</year>). <article-title>Cytotoxic T lymphocyte-based control of simian immunodeficiency virus replication in a preclinical AIDS vaccine trial</article-title>. <source>J. Exp. Med</source>. <volume>199</volume>, <fpage>1709</fpage>– <lpage>1718</lpage>.</mixed-citation></ref>
<ref id="c67"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mattapallil</surname>, <given-names>J.J.</given-names></string-name>, <string-name><surname>Douek</surname>, <given-names>D.C.</given-names></string-name>, <string-name><surname>Hill</surname>, <given-names>B.</given-names></string-name>, <string-name><surname>Nishimura</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Martin</surname>, <given-names>M.</given-names></string-name>, and <string-name><surname>Roederer</surname>, <given-names>M.</given-names></string-name></person-group> (<year>2005</year>). <article-title>Massive infection and loss of memory CD4+ T cells in multiple tissues during acute SIV infection</article-title>. <source>Nature</source> <volume>434</volume>, <fpage>1093</fpage>–<lpage>1097</lpage>.</mixed-citation></ref>
<ref id="c68"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>McDonald</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Wu</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Bohks</surname>, <given-names>S.M.</given-names></string-name>, <string-name><surname>KewalRamani</surname>, <given-names>V.N.</given-names></string-name>, <string-name><surname>Unutmaz</surname>, <given-names>D.</given-names></string-name>, and <string-name><surname>Hope</surname>, <given-names>T.J.</given-names></string-name></person-group> (<year>2003</year>). <article-title>Recruitment of HIV and its receptors to dendritic cell-T cell junctions</article-title>. <source>Science</source> <volume>300</volume>, <fpage>1295</fpage>–<lpage>1297</lpage>.</mixed-citation></ref>
<ref id="c69"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mikell</surname>, <given-names>I.</given-names></string-name>, <string-name><surname>Sather</surname>, <given-names>D.N.</given-names></string-name>, <string-name><surname>Kalams</surname>, <given-names>S.A.</given-names></string-name>, <string-name><surname>Altfeld</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Alter</surname>, <given-names>G.</given-names></string-name>, and <string-name><surname>Stamatatos</surname>, <given-names>L.</given-names></string-name></person-group> (<year>2011</year>). <article-title>Characteristics of the earliest cross-neutralizing antibody response to HIV-1</article-title>. <source>PLoS Pathog</source>. <volume>7</volume>, <fpage>e1001251</fpage>.</mixed-citation></ref>
<ref id="c70"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Moir</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Malaspina</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Ogwaro</surname>, <given-names>K.M.</given-names></string-name>, <string-name><surname>Donoghue</surname>, <given-names>E.T.</given-names></string-name>, <string-name><surname>Hallahan</surname>, <given-names>C.W.</given-names></string-name>, <string-name><surname>Ehler</surname>, <given-names>L.A.</given-names></string-name>, <string-name><surname>Liu</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Adelsberger</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Lapointe</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Hwu</surname>, <given-names>P.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2001</year>). <article-title>HIV-1 induces phenotypic and functional perturbations of B cells in chronically infected individuals</article-title>. <source>Proc. Natl. Acad. Sci. USA</source> <volume>98</volume>, <fpage>10362</fpage>–<lpage>10367</lpage>.</mixed-citation></ref>
<ref id="c71"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Moody</surname>, <given-names>M.A.</given-names></string-name>, <string-name><surname>Pedroza-Pacheco</surname>, <given-names>I.</given-names></string-name>, <string-name><surname>Vandergrift</surname>, <given-names>N.A.</given-names></string-name>, <string-name><surname>Chui</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Lloyd</surname>, <given-names>K.E.</given-names></string-name>, <string-name><surname>Parks</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Soderberg</surname>, <given-names>K.A.</given-names></string-name>, <string-name><surname>Ogbe</surname>, <given-names>A.T.</given-names></string-name>, <string-name><surname>Cohen</surname>, <given-names>M.S.</given-names></string-name>, <string-name><surname>Liao</surname>, <given-names>H.X.</given-names></string-name>, <string-name><surname>Gao</surname>, <given-names>F.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2016</year>). <article-title>Immune perturbations in HIV-1-infected individuals who make broadly neutralizing antibodies</article-title>. <source>Sci. Immunol</source>. <volume>1</volume>, <fpage>aag0851</fpage>.</mixed-citation></ref>
<ref id="c72"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Moore</surname>, <given-names>P.L.</given-names></string-name>, <string-name><surname>Gray</surname>, <given-names>E.S.</given-names></string-name>, <string-name><surname>Wibmer</surname>, <given-names>C.K.</given-names></string-name>, <string-name><surname>Bhiman</surname>, <given-names>J.N.</given-names></string-name>, <string-name><surname>Nonyane</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Sheward</surname>, <given-names>D.J.</given-names></string-name>, <string-name><surname>Hermanus</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Bajimaya</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Tumba</surname>, <given-names>N.L.</given-names></string-name>, <string-name><surname>Abrahams</surname>, <given-names>M.R.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2012</year>). <article-title>Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape</article-title>. <source>Nat. Med</source>. <volume>18</volume>, <fpage>1688</fpage>–<lpage>1692</lpage>.</mixed-citation></ref>
<ref id="c73"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Moukambi</surname>, <given-names>F.</given-names></string-name>, <string-name><surname>Rabezanahary</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Rodrigues</surname>, <given-names>V.</given-names></string-name>, <string-name><surname>Racine</surname>, <given-names>G.</given-names></string-name>, <string-name><surname>Robitaille</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Krust</surname>, <given-names>B.</given-names></string-name>, <string-name><surname>Andreani</surname>, <given-names>G.</given-names></string-name>, <string-name><surname>Soundaramourty</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Silvestre</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Laforge</surname>, <given-names>M.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2015</year>). <article-title>Early loss of splenic Tfh cells in SIV-infected rhesus macaques</article-title>. <source>PLoS Pathog</source>. <volume>11</volume>, <fpage>e1005287</fpage>.</mixed-citation></ref>
<ref id="c74"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Moukambi</surname>, <given-names>F.</given-names></string-name>, <string-name><surname>Rabezanahary</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Fortier</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Rodrigues</surname>, <given-names>V.</given-names></string-name>, <string-name><surname>Clain</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Benmadid-Laktout</surname>, <given-names>G.</given-names></string-name>, <string-name><surname>Zghidi-Abouzid</surname>, <given-names>O.</given-names></string-name>, <string-name><surname>Soundaramourty</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Laforge</surname>, <given-names>M.</given-names></string-name>, and <string-name><surname>Estaquier</surname>, <given-names>J.</given-names></string-name></person-group> (<year>2019</year>) <article-title>Mucosal T follicular helper cells in SIV-infected rhesus macaques: contributing role of IL-27</article-title>. <source>Mucosal Immunol</source>. <volume>12</volume>, <fpage>1038</fpage>–<lpage>1054</lpage>.</mixed-citation></ref>
<ref id="c75"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Nakane</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Nomura</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Shi</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Nakamura</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Naruse</surname>, <given-names>T.K.</given-names></string-name>, <string-name><surname>Kimura</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Matano</surname>, <given-names>T.</given-names></string-name>, and <string-name><surname>Yamamoto</surname>, <given-names>H.</given-names></string-name></person-group> (<year>2013</year>). <article-title>Limited impact of passive non-neutralizing antibody immunization in acute SIV infection on viremia control in rhesus macaques</article-title>. <source>PLoS ONE</source> <volume>8</volume>, <fpage>e73453</fpage>.</mixed-citation></ref>
<ref id="c76"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Naruse</surname>, <given-names>T.K.</given-names></string-name>, <string-name><surname>Chen</surname>, <given-names>Z.</given-names></string-name>, <string-name><surname>Yanagida</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Yamashita</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Saito</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Mori</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Akari</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Yasutomi</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Miyazawa</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Matano</surname>, <given-names>T.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2010</year>). <article-title>Diversity of MHC class I genes in Burmese-origin rhesus macaques</article-title>. <source>Immunogenetics</source> <volume>62</volume>, <fpage>601</fpage>–<lpage>611</lpage>.</mixed-citation></ref>
<ref id="c77"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Neil</surname>, <given-names>S.J.</given-names></string-name>, <string-name><surname>Zang</surname>, <given-names>T.</given-names></string-name>, and <string-name><surname>Bieniasz</surname>, <given-names>P.D.</given-names></string-name></person-group> (<year>2008</year>). <article-title>Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu</article-title>. <source>Nature</source> <volume>451</volume>, <fpage>425</fpage>–<lpage>430</lpage>.</mixed-citation></ref>
<ref id="c78"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ng</surname>, <given-names>C.T.</given-names></string-name>, <string-name><surname>Jaworski</surname>, <given-names>J.P.</given-names></string-name>, <string-name><surname>Jayaraman</surname>, <given-names>P.</given-names></string-name>, <string-name><surname>Sutton</surname>, <given-names>W.F.</given-names></string-name>, <string-name><surname>Delio</surname>, <given-names>P.</given-names></string-name>, <string-name><surname>Kuller</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Anderson</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Landucci</surname>, <given-names>G.</given-names></string-name>, <string-name><surname>Richardson</surname>, <given-names>B.A.</given-names></string-name>, <string-name><surname>Burton</surname>, <given-names>D.R.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2010</year>). <article-title>Passive neutralizing antibody controls SHIV viremia and enhances B cell responses in infant macaques</article-title>. <source>Nat. Med</source>. <volume>16</volume>, <fpage>1117</fpage>– <lpage>1119</lpage>.</mixed-citation></ref>
<ref id="c79"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Nguyen</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Ramana</surname>, <given-names>C.V.</given-names></string-name>, <string-name><surname>Bayes</surname>, <given-names>J.</given-names></string-name>, and <string-name><surname>Stark</surname>, <given-names>G.R.</given-names></string-name></person-group> (<year>2001</year>). <article-title>Roles of phosphatidylinositol 3-kinase in interferon-gamma-dependent phosphorylation of STAT1 on serine 727 and activation of gene expression</article-title>. <source>J. Biol. Chem</source>. <volume>276</volume>, <fpage>33361</fpage>–<lpage>33368</lpage>.</mixed-citation></ref>
<ref id="c80"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Nishimura</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Gautam</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Chun</surname>, <given-names>T.W.</given-names></string-name>, <string-name><surname>Sadjadpour</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Foulds</surname>, <given-names>K.E.</given-names></string-name>, <string-name><surname>Shingai</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Klein</surname>, <given-names>F.</given-names></string-name>, <string-name><surname>Gazumyan</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Golijanin</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Donaldson</surname>, <given-names>M.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2017</year>). <article-title>Early antibody therapy can induce long-lasting immunity to SHIV</article-title>. <source>Nature</source> <volume>543</volume>, <fpage>559</fpage>–<lpage>563</lpage>.</mixed-citation></ref>
<ref id="c81"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Nomura</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Yamamoto</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Shiino</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Takahashi</surname>, <given-names>N.</given-names></string-name>, <string-name><surname>Nakane</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Iwamoto</surname>, <given-names>N.</given-names></string-name>, <string-name><surname>Ishii</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Tsukamoto</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Kawada</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Matsuoka</surname>, <given-names>S.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2012</year>). <article-title>Association of major histocompatibility complex class I haplotypes with disease progression after simian immunodeficiency virus challenge in Burmese rhesus macaques</article-title>. <source>J. Virol</source>. <volume>86</volume>, <fpage>6481</fpage>–<lpage>6490</lpage>.</mixed-citation></ref>
<ref id="c82"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Nutt</surname>, <given-names>S.L.</given-names></string-name>, <string-name><surname>Hodgkin</surname>, <given-names>P.D.</given-names></string-name>, <string-name><surname>Tarlinton</surname>, <given-names>D.M.</given-names></string-name>, and <string-name><surname>Corcoran</surname>, <given-names>L.M.</given-names></string-name></person-group> (<year>2015</year>). <article-title>The generation of antibody-secreting plasma cells</article-title>. <source>Nat. Rev. Immunol</source>. <volume>15</volume>, <fpage>160</fpage>–<lpage>171</lpage>.</mixed-citation></ref>
<ref id="c83"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Omori</surname>, <given-names>S.A.</given-names></string-name>, <string-name><surname>Cato</surname>, <given-names>M.H.</given-names></string-name>, <string-name><surname>Anzelon-Mills</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Puri</surname>, <given-names>K.D.</given-names></string-name>, <string-name><surname>Shapiro-Shelef</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Calame</surname>, <given-names>K.</given-names></string-name>, and <string-name><surname>Rickert</surname>, <given-names>R.C.</given-names></string-name></person-group> (<year>2006</year>). <article-title>Regulation of class-switch recombination and plasma cell differentiation by phosphatidylinositol 3-kinase signaling</article-title>. <source>Immunity</source> <volume>25</volume>, <fpage>545</fpage>–<lpage>557</lpage>.</mixed-citation></ref>
<ref id="c84"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Perfetto</surname>, <given-names>S.P.</given-names></string-name>, <string-name><surname>Chattopadhyay</surname>, <given-names>P.K.</given-names></string-name>, <string-name><surname>Lamoreaux</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Nguyen</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Ambrozak</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Koup</surname>, <given-names>R.A.</given-names></string-name>, and <string-name><surname>Roederer</surname>, <given-names>M.</given-names></string-name></person-group> (<year>2006</year>). <article-title>Amine reactive dyes: an effective tool to discriminate live and dead cells in polychromatic flow cytometry</article-title>. <source>J. Immunol. Methods</source> <volume>313</volume>, <fpage>199</fpage>–<lpage>208</lpage>.</mixed-citation></ref>
<ref id="c85"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Petrovas</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Yamamoto</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Gerner</surname>, <given-names>M.Y.</given-names></string-name>, <string-name><surname>Boswell</surname>, <given-names>K.L.</given-names></string-name>, <string-name><surname>Wloka</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Smith</surname>, <given-names>E.C.</given-names></string-name>, <string-name><surname>Ambrozak</surname>, <given-names>D.R.</given-names></string-name>, <string-name><surname>Sandler</surname>, <given-names>N.G.</given-names></string-name>, <string-name><surname>Timmer</surname>, <given-names>K.J.</given-names></string-name>, <string-name><surname>Sun</surname>, <given-names>X.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2012</year>). <article-title>CD4 T follicular helper cell dynamics during SIV infection</article-title>. <source>J. Clin. Invest</source>. <volume>122</volume>, <fpage>3281</fpage>–<lpage>3294</lpage>.</mixed-citation></ref>
<ref id="c86"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Qiao</surname>, <given-names>X.</given-names></string-name>, <string-name><surname>He</surname>, <given-names>B.</given-names></string-name>, <string-name><surname>Chiu</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Knowles</surname>, <given-names>D.M.</given-names></string-name>, <string-name><surname>Chadburn</surname>, <given-names>A.</given-names></string-name>, and <string-name><surname>Cerutti</surname>, <given-names>A.</given-names></string-name></person-group> (<year>2006</year>). <article-title>Human immunodeficiency virus 1 Nef suppresses CD40-dependent immunoglobulin class switching in bystander B cells</article-title>. <source>Nat. Immunol</source>. <volume>7</volume>, <fpage>302</fpage>–<lpage>310</lpage>.</mixed-citation></ref>
<ref id="c87"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Querec</surname>, <given-names>T.D.</given-names></string-name>, <string-name><surname>Akondy</surname>, <given-names>R.S.</given-names></string-name>, <string-name><surname>Lee</surname>, <given-names>E.K.</given-names></string-name>, <string-name><surname>Cao</surname>, <given-names>W.</given-names></string-name>, <string-name><surname>Nakaya</surname>, <given-names>H.I.</given-names></string-name>, <string-name><surname>Teuwen</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Pirani</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Gernert</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Deng</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Marzolf</surname>, <given-names>B.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2009</year>). <article-title>Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans</article-title>. <source>Nat. Immunol</source>. <volume>10</volume>, <fpage>116</fpage>–<lpage>125</lpage>.</mixed-citation></ref>
<ref id="c88"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ray</surname>, <given-names>J.P.</given-names></string-name>, <string-name><surname>Staron</surname>, <given-names>M.M.</given-names></string-name>, <string-name><surname>Shyer</surname>, <given-names>J.A.</given-names></string-name>, <string-name><surname>Ho</surname>, <given-names>P.C.</given-names></string-name>, <string-name><surname>Marshall</surname>, <given-names>H.D.</given-names></string-name>, <string-name><surname>Gray</surname>, <given-names>S.M.</given-names></string-name>, <string-name><surname>Laidlaw</surname>, <given-names>B.J.</given-names></string-name>, <string-name><surname>Araki</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Ahmed</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Kaech</surname>, <given-names>S.M.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2015</year>). <article-title>The interleukin-2-mTORc1 kinase axis defines the signaling, differentiation, and metabolism of T helper 1 and follicular B helper T cells</article-title>. <source>Immunity</source> <volume>43</volume>, <fpage>690</fpage>–<lpage>702</lpage>.</mixed-citation></ref>
<ref id="c89"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Recher</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Lang</surname>, <given-names>K.S.</given-names></string-name>, <string-name><surname>Hunziker</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Freigang</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Eschli</surname>, <given-names>B.</given-names></string-name>, <string-name><surname>Harris</surname>, <given-names>N.L.</given-names></string-name>, <string-name><surname>Navarini</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Senn</surname>, <given-names>B.M.</given-names></string-name>, <string-name><surname>Fink</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Lötscher</surname>, <given-names>M.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2004</year>). <article-title>Deliberate removal of T cell help improves virus-neutralizing antibody production</article-title>. <source>Nat. Immunol</source>. <volume>5</volume>, <fpage>934</fpage>–<lpage>942</lpage>.</mixed-citation></ref>
<ref id="c90"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Recher</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Lang</surname>, <given-names>K.S.</given-names></string-name>, <string-name><surname>Navarini</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Hunziker</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Lang</surname>, <given-names>P.A.</given-names></string-name>, <string-name><surname>Fink</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Freigang</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Georgiev</surname>, <given-names>P.</given-names></string-name>, <string-name><surname>Hangartner</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Zellweger</surname>, <given-names>R.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2007</year>). <article-title>Extralymphatic virus sanctuaries as a consequence of potent T-cell activation</article-title>. <source>Nat. Med</source>. <volume>13</volume>, <fpage>1316</fpage>–<lpage>1323</lpage>.</mixed-citation></ref>
<ref id="c91"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Reuschl</surname>, <given-names>A.K.</given-names></string-name>, <string-name><surname>Mesner</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Shivkumar</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Whelan</surname>, <given-names>M.V.X.</given-names></string-name>, <string-name><surname>Pallett</surname>, <given-names>L.J.</given-names></string-name>, <string-name><surname>Guerra-Assunção</surname>, <given-names>J.A.</given-names></string-name>, <string-name><surname>Madansein</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Dullabh</surname>, <given-names>K.J.</given-names></string-name>, <string-name><surname>Sigal</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Thornhill</surname>, <given-names>J.P.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2022</year>). <article-title>HIV-1 Vpr drives a tissue residency-like phenotype during selective infection of resting memory T cells</article-title>. <source>Cell Rep</source>. <volume>39</volume>, <fpage>110650</fpage>.</mixed-citation></ref>
<ref id="c92"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Rickles</surname>, <given-names>R.J.</given-names></string-name>, <string-name><surname>Botfield</surname>, <given-names>M.C.</given-names></string-name>, <string-name><surname>Weng</surname>, <given-names>Z.</given-names></string-name>, <string-name><surname>Taylor</surname>, <given-names>J.A.</given-names></string-name>, <string-name><surname>Green</surname>, <given-names>O.M.</given-names></string-name>, <string-name><surname>Brugge</surname>, <given-names>J.S.</given-names></string-name>, and <string-name><surname>Zoller</surname>, <given-names>M.J.</given-names></string-name></person-group> (<year>1994</year>). <article-title>Identification of Src, Fyn, Lyn, PI3K and Abl SH3 domain ligands using phage display libraries</article-title>. <source>EMBO J</source>. <volume>13</volume>, <fpage>5598</fpage>–<lpage>5604</lpage>.</mixed-citation></ref>
<ref id="c93"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Samer</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Chowdhury</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Wiche Salinas</surname>, <given-names>T.R.</given-names></string-name>, <string-name><surname>Estrada</surname>, <given-names>P.M.D.R.</given-names></string-name>, <string-name><surname>Reuter</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Tharp</surname>, <given-names>G.</given-names></string-name>, <string-name><surname>Bosinger</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Cervasi</surname>, <given-names>B.</given-names></string-name>, <string-name><surname>Auger</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Gill</surname>, <given-names>K.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2023</year>). <article-title>Lymph-Node-based CD3<sup>+</sup> CD20<sup>+</sup> cells emerge from membrane exchange between T follicular helper cells and B cells and increase their frequency following simian immunodeficiency virus infection</article-title>. <source>J. Virol</source>. <volume>97</volume>, <fpage>e0176022</fpage>.</mixed-citation></ref>
<ref id="c94"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sammicheli</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Kuka</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Di Lucia</surname>, <given-names>P.</given-names></string-name>, <string-name><surname>de Oya</surname>, <given-names>N.J.</given-names></string-name>, <string-name><surname>De Giovanni</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Fioravanti</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Cristofani</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Maganuco</surname>, <given-names>C.G.</given-names></string-name>, <string-name><surname>Fallet</surname>, <given-names>B.</given-names></string-name>, <string-name><surname>Ganzer</surname>, <given-names>L.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2016</year>). <article-title>Inflammatory monocytes hinder antiviral B cell responses</article-title>. <source>Sci. Immunol</source>. <volume>1</volume>, pii: <fpage>eaah6789</fpage>.</mixed-citation></ref>
<ref id="c95"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sander</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Chu</surname>, <given-names>V.T.</given-names></string-name>, <string-name><surname>Yasuda</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Franklin</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Graf</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Calado</surname>, <given-names>D.P.</given-names></string-name>, <string-name><surname>Li</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Imami</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Selbach</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Di Virgilio</surname>, <given-names>M.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2015</year>). <article-title>PI3 kinase and FOXO1 transcription factor activity differentially control B cells in the germinal center light and dark zones</article-title>. <source>Immunity</source> <volume>43</volume>, <fpage>1075</fpage>–<lpage>1086</lpage>.</mixed-citation></ref>
<ref id="c96"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sarbassov</surname>, <given-names>D.D.</given-names></string-name>, <string-name><surname>Guertin</surname>, <given-names>D.A.</given-names></string-name>, <string-name><surname>Ali</surname>, <given-names>S.M.</given-names></string-name>, and <string-name><surname>Sabatini</surname>, <given-names>D.M.</given-names></string-name></person-group> (<year>2005</year>) <article-title>Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex</article-title>. <source>Science</source> <volume>307</volume>, <fpage>1098</fpage>–<lpage>1101</lpage>.</mixed-citation></ref>
<ref id="c97"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Schindler</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Münch</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Brenner</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Stahl-Hennig</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Skowronski</surname>, <given-names>J.</given-names></string-name>, and <string-name><surname>Kirchhoff</surname>, <given-names>F.</given-names></string-name></person-group> (<year>2004</year>). <article-title>Comprehensive analysis of nef functions selected in simian immunodeficiency virus-infected macaques</article-title>. <source>J. Virol</source>. <volume>78</volume>, <fpage>10588</fpage>–<lpage>10597</lpage>.</mixed-citation></ref>
<ref id="c98"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Schindler</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Münch</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Kutsch</surname>, <given-names>O.</given-names></string-name>, <string-name><surname>Li</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Santiago</surname>, <given-names>M.L.</given-names></string-name>, <string-name><surname>Bibollet-Ruche</surname>, <given-names>F.</given-names></string-name>, <string-name><surname>Müller-Trutwin</surname>, <given-names>M.C.</given-names></string-name>, <string-name><surname>Novembre</surname>, <given-names>F.J.</given-names></string-name>, <string-name><surname>Peeters</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Courgnaud</surname>, <given-names>V.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2006</year>). <article-title>Nef-mediated suppression of T cell activation was lost in a lentiviral lineage that gave rise to HIV-1</article-title>. <source>Cell</source> <volume>125</volume>, <fpage>1055</fpage>–<lpage>1067</lpage>.</mixed-citation></ref>
<ref id="c99"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sette</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Sidney</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Southwood</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Moore</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Berry</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Dow</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Bradley</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Hoof</surname>, <given-names>I.</given-names></string-name>, <string-name><surname>Lewis</surname>, <given-names>M.G.</given-names></string-name>, <string-name><surname>Hildebrand</surname>, <given-names>W.H.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2012</year>). <article-title>A shared MHC supertype motif emerges by convergent evolution in macaques and mice, but is totally absent in human MHC molecules</article-title>. <source>Immunogenetics</source> <volume>64</volume>, <fpage>421</fpage>–<lpage>434</lpage>.</mixed-citation></ref>
<ref id="c100"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sheehy</surname>, <given-names>A.M.</given-names></string-name>, <string-name><surname>Gaddis</surname>, <given-names>N.C.</given-names></string-name>, <string-name><surname>Choi</surname>, <given-names>J.D.</given-names></string-name>, and <string-name><surname>Malim</surname>, <given-names>M.H.</given-names></string-name></person-group> (<year>2002</year>). <article-title>Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein</article-title>. <source>Nature</source> (2002) <volume>418</volume>, <fpage>646</fpage>– <lpage>650</lpage>.</mixed-citation></ref>
<ref id="c101"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Shi</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Seki</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Matano</surname>, <given-names>T.</given-names></string-name>, and <string-name><surname>Yamamoto</surname>, <given-names>H.</given-names></string-name></person-group> (<year>2013</year>). <article-title>IL-21-producer CD4<sup>+</sup> T cell kinetics during primary simian immunodeficiency virus infection</article-title>. <source>Microbes Infect</source>. <volume>15</volume>, <fpage>697</fpage>–<lpage>707</lpage>.</mixed-citation></ref>
<ref id="c102"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Shulman</surname>, <given-names>Z.</given-names></string-name>, <string-name><surname>Gitlin</surname>, <given-names>A.D.</given-names></string-name>, <string-name><surname>Weinstein</surname>, <given-names>J.S.</given-names></string-name>, <string-name><surname>Lainez</surname>, <given-names>B.</given-names></string-name>, <string-name><surname>Esplugues</surname>, <given-names>E.</given-names></string-name>, <string-name><surname>Flavell</surname>, <given-names>R.A.</given-names></string-name>, <string-name><surname>Craft</surname>, <given-names>J.E.</given-names></string-name>, and <string-name><surname>Nussenzweig</surname>, <given-names>M.C.</given-names></string-name></person-group> (<year>2014</year>). <article-title>Dynamic signaling by T follicular helper cells during germinal center B cell selection</article-title>. <source>Science</source> <volume>345</volume>, <fpage>1058</fpage>–<lpage>1062</lpage>.</mixed-citation></ref>
<ref id="c103"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Silveira</surname>, <given-names>E.L.</given-names></string-name>, <string-name><surname>Kasturi</surname>, <given-names>S.P.</given-names></string-name>, <string-name><surname>Kovalenkov</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Rasheed</surname>, <given-names>A.U.</given-names></string-name>, <string-name><surname>Yeiser</surname>, <given-names>P.</given-names></string-name>, <string-name><surname>Jinnah</surname>, <given-names>Z.S.</given-names></string-name>, <string-name><surname>Legere</surname>, <given-names>T.H.</given-names></string-name>, <string-name><surname>Pulendran</surname>, <given-names>B.</given-names></string-name>, <string-name><surname>Villinger</surname>, <given-names>F.</given-names></string-name>, and <string-name><surname>Wrammert</surname>, <given-names>J.</given-names></string-name></person-group> (<year>2015</year>). <article-title>Vaccine-induced plasmablast responses in rhesus macaques: phenotypic characterization and a source for generating antigen-specific monoclonal antibodies</article-title>. <source>J. Immunol. Methods</source> <volume>416</volume>, <fpage>69</fpage>–<lpage>83</lpage>.</mixed-citation></ref>
<ref id="c104"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sommerstein</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Flatz</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Remy</surname>, <given-names>M.M.</given-names></string-name>, <string-name><surname>Malinge</surname>, <given-names>P.</given-names></string-name>, <string-name><surname>Magistrelli</surname>, <given-names>G.</given-names></string-name>, <string-name><surname>Fischer</surname>, <given-names>N.</given-names></string-name>, <string-name><surname>Sahin</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Bergthaler</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Igonet</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Ter Meulen</surname>, <given-names>J.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2015</year>). <article-title>Arenavirus glycan shield promotes neutralizing antibody evasion and protracted infection</article-title>. <source>PLoS Pathog</source>. <volume>11</volume>, <fpage>e1005276</fpage>.</mixed-citation></ref>
<ref id="c105"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Srinivasan</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Sasaki</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Calado</surname>, <given-names>D.P.</given-names></string-name>, <string-name><surname>Zhang</surname>, <given-names>B.</given-names></string-name>, <string-name><surname>Paik</surname>, <given-names>J.H.</given-names></string-name>, <string-name><surname>DePinho</surname>, <given-names>R.A.</given-names></string-name>, <string-name><surname>Kutok</surname>, <given-names>J.L.</given-names></string-name>, <string-name><surname>Kearney</surname>, <given-names>J.F.</given-names></string-name>, <string-name><surname>Otipoby</surname>, <given-names>K.L.</given-names></string-name>, and <string-name><surname>Rajewsky</surname>, <given-names>K.</given-names></string-name></person-group> (<year>2009</year>). <article-title>PI3 kinase signals BCR-dependent mature B cell survival</article-title>. <source>Cell</source> <volume>139</volume>, <fpage>573</fpage>–<lpage>586</lpage>.</mixed-citation></ref>
<ref id="c106"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Stolp</surname>, <given-names>B.</given-names></string-name>, <string-name><surname>Reichman-Fried</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Abraham</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Pan</surname>, <given-names>X.</given-names></string-name>, <string-name><surname>Giese</surname>, <given-names>S.I.</given-names></string-name>, <string-name><surname>Hannemann</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Goulimari</surname>, <given-names>P.</given-names></string-name>, <string-name><surname>Raz</surname>, <given-names>E.</given-names></string-name>, <string-name><surname>Grosse</surname>, <given-names>R.</given-names></string-name>, and <string-name><surname>Fackler</surname>, <given-names>O.T.</given-names></string-name></person-group> (<year>2009</year>). <article-title>HIV-1 Nef interferes with host cell motility by deregulation of Cofilin</article-title>. <source>Cell Host Microbe</source> <volume>6</volume>, <fpage>174</fpage>–<lpage>186</lpage>.</mixed-citation></ref>
<ref id="c107"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Stolp</surname>, <given-names>B.</given-names></string-name>, <string-name><surname>Imle</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Coelho</surname>, <given-names>F.M.</given-names></string-name>, <string-name><surname>Hons</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Gorina</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Lyck</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Stein</surname>, <given-names>J.V.</given-names></string-name>, and <string-name><surname>Fackler</surname>, <given-names>O.T.</given-names></string-name></person-group> (<year>2012</year>). <article-title>HIV-1 Nef interferes with T-lymphocyte circulation through confined environments in vivo</article-title>. <source>Proc. Natl. Acad. Sci. USA</source> <volume>109</volume>, <fpage>18541</fpage>–<lpage>18546</lpage>.</mixed-citation></ref>
<ref id="c108"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Swingler</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Zhou</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Swingler</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Dauphin</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Greenough</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Jolicoeur</surname>, <given-names>P.</given-names></string-name>, and <string-name><surname>Stevenson</surname>, <given-names>M.</given-names></string-name></person-group> (<year>2008</year>). <article-title>Evidence for a pathogenic determinant in HIV-1 Nef involved in B cell dysfunction in HIV/AIDS</article-title>. <source>Cell Host Microbe</source> <volume>4</volume>, <fpage>63</fpage>–<lpage>76</lpage>.</mixed-citation></ref>
<ref id="c109"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Takahashi</surname>, <given-names>N.</given-names></string-name>, <string-name><surname>Nomura</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Takahara</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Yamamoto</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Shiino</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Takeda</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Inoue</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Iida</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Hara</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Shu</surname>, <given-names>T.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2013</year>). <article-title>A novel protective MHC-I haplotype not associated with dominant Gag-specific CD8<sup>+</sup> T-cell responses in SIV<sub>mac239</sub> infection of Burmese rhesus macaques</article-title>. <source>PLoS ONE</source> <volume>8</volume>, <fpage>e54300</fpage>.</mixed-citation></ref>
<ref id="c110"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Terahara</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Ishii</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Nomura</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Takahashi</surname>, <given-names>N.</given-names></string-name>, <string-name><surname>Takeda</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Shiino</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Tsunetsugu-Yokota</surname>, <given-names>Y.</given-names></string-name>, and <string-name><surname>Matano</surname>, <given-names>T.</given-names></string-name></person-group> (<year>2014</year>). <article-title>Vaccine-induced CD107a<sup>+</sup> CD4<sup>+</sup> T cells are resistant to depletion following AIDS virus infection</article-title>. <source>J. Virol</source>. <volume>88</volume>, <fpage>14232</fpage>–<lpage>14240</lpage>.</mixed-citation></ref>
<ref id="c111"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tomaras</surname>, <given-names>G.D.</given-names></string-name>, <string-name><surname>Yates</surname>, <given-names>N.L.</given-names></string-name>, <string-name><surname>Liu</surname>, <given-names>P.</given-names></string-name>, <string-name><surname>Qin</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Fouda</surname>, <given-names>G.G.</given-names></string-name>, <string-name><surname>Chavez</surname>, <given-names>L.L.</given-names></string-name>, <string-name><surname>Decamp</surname>, <given-names>A.C.</given-names></string-name>, <string-name><surname>Parks</surname>, <given-names>R.J.</given-names></string-name>, <string-name><surname>Ashley</surname>, <given-names>V.C.</given-names></string-name>, <string-name><surname>Lucas</surname>, <given-names>J.T.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2008</year>). <article-title>Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia</article-title>. <source>J. Virol</source>. <volume>82</volume>, <fpage>12449</fpage>–<lpage>12463</lpage>.</mixed-citation></ref>
<ref id="c112"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Volcic</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Sparrer</surname>, <given-names>K.M.J.</given-names></string-name>, <string-name><surname>Koepke</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Hotter</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Sauter</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Stürzel</surname>, <given-names>C.M.</given-names></string-name>, <string-name><surname>Scherer</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Stamminger</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Hofmann</surname>, <given-names>T.G.</given-names></string-name>, <string-name><surname>Arhel</surname>, <given-names>N.J.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2020</year>). <article-title>Vpu modulates DNA repair to suppress innate sensing and hyper-integration of HIV-1</article-title>. <source>Nat. Microbiol</source>. <volume>5</volume>, <fpage>1247</fpage>–<lpage>1261</lpage>.</mixed-citation></ref>
<ref id="c113"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Sohn</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Sun</surname>, <given-names>G.</given-names></string-name>, <string-name><surname>Milner</surname>, <given-names>J.D.</given-names></string-name> and <string-name><surname>Pierce</surname>, <given-names>S.K.</given-names></string-name></person-group> (<year>2014</year>). <article-title>The autoinhibitory C-terminal SH2 domain of phospholipase C-γ2 stabilizes B cell receptor signalosome assembly</article-title>. <source>Sci. Signal</source>. <volume>7</volume>, <elocation-id>ra89</elocation-id>.</mixed-citation></ref>
<ref id="c114"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Whitney</surname>, <given-names>J.B.</given-names></string-name>, <string-name><surname>Hill</surname>, <given-names>A.L.</given-names></string-name>, <string-name><surname>Sanisetty</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Penaloza-MacMaster</surname>, <given-names>P.</given-names></string-name>, <string-name><surname>Liu</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Shetty</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Parenteau</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Cabral</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Shields</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Blackmore</surname>, <given-names>S.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2014</year>). <article-title>Rapid seeding of the viral reservoir prior to SIV viraemia in rhesus monkeys</article-title>. <source>Nature</source> <volume>512</volume>, <fpage>74</fpage>–<lpage>77</lpage>.</mixed-citation></ref>
<ref id="c115"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wülfing</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Sjaastad</surname>, <given-names>M.D.</given-names></string-name>, and <string-name><surname>Davis</surname>, <given-names>M.M.</given-names></string-name></person-group> (<year>1998</year>). <article-title>Visualizing the dynamics of T cell activation: intracellular adhesion molecule 1 migrates rapidly to the T cell/B cell interface and acts to sustain calcium levels</article-title>. <source>Proc. Natl. Acad. Sci. USA</source> <volume>95</volume>, <fpage>6302</fpage>–<lpage>6307</lpage>.</mixed-citation></ref>
<ref id="c116"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Xu</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Wang</surname>, <given-names>X.</given-names></string-name>, <string-name><surname>Malam</surname>, <given-names>N.</given-names></string-name>, <string-name><surname>Aye</surname>, <given-names>P.P.</given-names></string-name>, <string-name><surname>Alvarez</surname>, <given-names>X.</given-names></string-name>, <string-name><surname>Lackner</surname>, <given-names>A.A.</given-names></string-name>, and <string-name><surname>Veazey</surname>, <given-names>R.S.</given-names></string-name></person-group> (<year>2015</year>). <article-title>Persistent simian immunodeficiency virus infection drives differentiation, aberrant accumulation, and latent infection of germinal center follicular T helper cells</article-title>. <source>J. Virol</source>. <volume>90</volume>,<fpage>1578</fpage>– <lpage>1587</lpage>.</mixed-citation></ref>
<ref id="c117"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Xu</surname>, <given-names>W.</given-names></string-name>, <string-name><surname>Santini</surname>, <given-names>P.A.</given-names></string-name>, <string-name><surname>Sullivan</surname>, <given-names>J.S.</given-names></string-name>, <string-name><surname>He</surname>, <given-names>B.</given-names></string-name>, <string-name><surname>Shan</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Ball</surname>, <given-names>S.C.</given-names></string-name>, <string-name><surname>Dyer</surname>, <given-names>W.B.</given-names></string-name>, <string-name><surname>Ketas</surname>, <given-names>T.J.</given-names></string-name>, <string-name><surname>Chadburn</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Cohen-Gould</surname>, <given-names>L.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2009</year>). <article-title>HIV-1 evades virus-specific IgG2 and IgA responses by targeting systemic and intestinal B cells via long-range intercellular conduits</article-title>. <source>Nat. Immunol</source>. <volume>10</volume>, <fpage>1008</fpage>–<lpage>1017</lpage>.</mixed-citation></ref>
<ref id="c118"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yamada</surname>, <given-names>E.</given-names></string-name>, <string-name><surname>Nakaoka</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Klein</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Reith</surname>, <given-names>E.</given-names></string-name>, <string-name><surname>Langer</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Hopfensperger</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Iwami</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Schreiber</surname>, <given-names>G.</given-names></string-name>, <string-name><surname>Kirchhoff</surname>, <given-names>F.</given-names></string-name>, <string-name><surname>Koyanagi</surname>, <given-names>Y.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2018</year>) <article-title>Human-specific adaptations in Vpu conferring anti-tetherin activity are critical for efficient early HIV-1 replication in vivo</article-title>. <source>Cell Host Microbe</source> <volume>23</volume>, <fpage>110</fpage>–<lpage>120.e7</lpage>.</mixed-citation></ref>
<ref id="c119"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yamamoto</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Kawada</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Takeda</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Igarashi</surname>, <given-names>H.</given-names></string-name> and <string-name><surname>Matano</surname>, <given-names>T.</given-names></string-name></person-group> (<year>2007</year>). <article-title>Post-infection immunodeficiency virus control by neutralizing antibodies</article-title>. <source>PLoS ONE</source> <volume>2</volume>, <fpage>e540</fpage>.</mixed-citation></ref>
<ref id="c120"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yan</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Shun</surname>, <given-names>M.C.</given-names></string-name>, <string-name><surname>Zhang</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Hao</surname>, <given-names>C.</given-names></string-name>, and <string-name><surname>Skowronski</surname>, <given-names>J.</given-names></string-name></person-group> (<year>2019</year>). <article-title>HIV-1 Vpr counteracts HLTF-mediated restriction of HIV-1 infection in T cells</article-title>. <source>Proc. Natl. Acad. Sci. USA</source>. <volume>116</volume>, <fpage>9568</fpage>– <lpage>9577</lpage>.</mixed-citation></ref>
<ref id="c121"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhang</surname>, <given-names>F.</given-names></string-name>, <string-name><surname>Wilson</surname>, <given-names>S.J.</given-names></string-name>, <string-name><surname>Landford</surname>, <given-names>W.C.</given-names></string-name>, <string-name><surname>Virgen</surname>, <given-names>B.</given-names></string-name>, <string-name><surname>Gregory</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Johnson</surname>, <given-names>M.C.</given-names></string-name>, <string-name><surname>Munch</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Kirchhoff</surname>, <given-names>F.</given-names></string-name>, <string-name><surname>Bieniasz</surname>, <given-names>P.D.</given-names></string-name>, and <string-name><surname>Hatziioannou</surname>, <given-names>T.</given-names></string-name></person-group> (<year>2009</year>). <article-title>Nef proteins from simian immunodeficiency viruses are tetherin antagonists</article-title>. <source>Cell Host Microbe</source> <volume>6</volume>, <fpage>54</fpage>–<lpage>67</lpage>.</mixed-citation></ref>
<ref id="c122"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zotos</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Coquet</surname>, <given-names>J.M.</given-names></string-name>, <string-name><surname>Zhang</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Light</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>D’Costa</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Kallies</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Corcoran</surname>, <given-names>L.M.</given-names></string-name>, <string-name><surname>Godfrey</surname>, <given-names>D.I.</given-names></string-name>, <string-name><surname>Toellner</surname>, <given-names>K.M.</given-names></string-name>, <string-name><surname>Smyth</surname>, <given-names>M.J.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2010</year>). <article-title>IL-21 regulates germinal center B cell differentiation and proliferation through a B cell-intrinsic mechanism</article-title>. <source>J. Exp. Med</source>. <volume>207</volume>, <fpage>365</fpage>– <lpage>378</lpage>.</mixed-citation></ref>
</ref-list>
</back>
<sub-article id="sa0" article-type="editor-report">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.88849.2.sa2</article-id>
<title-group>
<article-title>eLife Assessment</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Kirchhoff</surname>
<given-names>Frank</given-names>
</name>
<role specific-use="editor">Reviewing Editor</role>
<aff>
<institution-wrap>
<institution>Ulm University Medical Center</institution>
</institution-wrap>
<city>Ulm</city>
<country>Germany</country>
</aff>
</contrib>
</contrib-group>
<kwd-group kwd-group-type="evidence-strength">
<kwd>Convincing</kwd>
</kwd-group>
<kwd-group kwd-group-type="claim-importance">
<kwd>Important</kwd>
</kwd-group>
</front-stub>
<body>
<p>Yamamoto and Matano provide <bold>convincing</bold> evidence that a G63E CD8+ T-cell escape mutation in the accessory viral protein Nef facilitates the induction of neutralizing antibody (nAb) responses in rhesus macaques infected with SIVmac239. Functional analyses support that this mutation specifically impairs Nef`s ability to stimulate PI3K/Akt/mTORC2 signalling. This <bold>important</bold> study suggests that the accessory viral Nef protein impairs B cell function and effective humoral immune responses and is of interest for researchers and physicians interested in HIV/AIDS and vaccine development.</p>
</body>
</sub-article>
<sub-article id="sa1" article-type="referee-report">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.88849.2.sa1</article-id>
<title-group>
<article-title>Reviewer #1 (Public review):</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<anonymous/>
<role specific-use="referee">Reviewer</role>
</contrib>
</contrib-group>
</front-stub>
<body>
<p>Human and simian immunodeficiency viruses (HIV and SIV, respectively) evolved numerous mechanisms to compromise effective immune responses but the underlying mechanisms remain incompletely understood. Here, Yamamoto and Matano examined the humoral immune response in a large number of rhesus macaques infected with the difficult-to-neutralize SIVmac239 strain and identified a subgroup of animals showing significant neutralizing Ab responses. Sequence analyses revealed that in most of these animals (7/9) but only a minority in the control group (2/19) SIVmac variants containing a CD8+ T-cell escape mutation of G63E/R in the viral Nef gene emerged. Functional analyses revealed that this change attenuates the ability of Nef to stimulate PI3K/Akt/mTORC2 signalling. The authors propose that this improved induction of SIVmac239 nAb is reciprocal to antibody dysregulation caused by a previously identified human PI3K gain-of-function mutation associated with impaired anti-viral B-cell responses. Altogether, the results suggest that PI3K signalling plays a role in B-cell maturation and generation of effective nAb responses. Preliminary data indicate that Nef might be transferred from infected T cells to B cells by direct contact. However, the exact mechanism and the relevance for vaccine development requires further studies</p>
<p>Strengths of the study are that the authors analyzed a large number of SIVmac-infected macaques to unravel the biological significance of the known effect of the interaction of Nef with PI3K/Akt/mTORC2 signaling. This is interesting and may provide a novel means to improve humoral immune responses to HIV. In the revised version the authors made an effort to address previous concerns. Especially, they provide data supporting that Nef might be transferred to B cells by direct cell-cell contact. In addition, the provide some evidence that G63R that also emerged in most animals does not share the disruptive effect of G63G although experimental examination and discussion why G63R might emerge remains poor. Another weakness that remains is that some effects of the G63E mutation are modest and effects were not compared to SIVmac constructs lacking Nef entirely. The evidence for a role of Nef G63E mutation on PI3K and the association with improved nAb responses was largely convincing and it is appreciated that the authors provide additional evidence for a potential impact of &quot;soluble&quot; Nef on neighboring B cells. However, the experimental set-up and the results are difficult to comprehend. It seems that direct cell-cell contact is required and membranes are exchanged. Since Nef is associated with cellular membranes this might lead to some transfer of Nef to B cells. However, the immunological and functional consequences of this remain largely elusive. Alternatively, Nef-mediated manipulation of helper CD4 T cells might also impact B cell function and effective humoral immune responses. As previously noted, the presentation of the results and conclusions was in part very convoluted and difficult to comprehend. While the authors made attempts to improve the writing parts of the manuscript are still challenging to follow. This applies even more to the rebuttal (complex words combined with poor grammar), which made it difficult to assess which concerns have been satisfactory addressed.</p>
</body>
</sub-article>
<sub-article id="sa2" article-type="author-comment">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.88849.2.sa0</article-id>
<title-group>
<article-title>Author response:</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Yamamoto</surname>
<given-names>Hiroyuki</given-names>
</name>
<role specific-use="author">Author</role>
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-0708-9373</contrib-id></contrib>
<contrib contrib-type="author">
<name>
<surname>Matano</surname>
<given-names>Tetsuro</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
</contrib-group>
</front-stub>
<body>
<p>The following is the authors’ response to the original reviews.</p>
<disp-quote content-type="editor-comment">
<p><bold>Reviewer #1 (Public Review):</bold></p>
<p>This work describes the induction of SIV-specific NAb responses in rhesus macaques infected with SIVmac239, a neutralization-resistant virus. Typically, host NAb responses are not detected in animals infected with SIVmac239. In this work, seventy SIVmac239-infected macaques were retrospectively screened for NAb responses and a subset of nine animals were identified as NAb-inducers. The viral genomes from 7/9 animals that induced NAb responses were found to encode nonsynonymous mutation in the Nef gene (amino acid G63E). In contrast, Nef G63E mutation was found only in 2/19 NAb non-inducers - implicating that the Nef G63E mutation is selected in NAb inducers. Measurement of Nef G63E frequencies in plasma viruses suggested that Nef G63E selection preceded NAb induction. Nef G63E mutation was found to mediate escape from Nef-specific CD8+ T-cell responses. To examine the functional phenotype of Nef G63E mutant, its effect on downmodulation of Nef-interacting host proteins was examined. Infection of rhesus and cynomolgus macaque CD4+ T cell lines with WT or Nef G63E mutant SIV suggested that Nef mutant reduces S473 phosphorylation of AKT. Using flow cytometry-based proximity ligation assay, it was shown that Nef G63E mutation reduced binding of Nef to PI3K p85/p110 and mTORC2 GβL/mLST8 and MTOR components - kinase complex responsible AKT-S473 phosphorylation. In vitro B-cell Nef invasion and in vivo imaging/flow cytometry-based assays were employed to suggest that Nef from infected cells can target Env-specific B cells. Lastly, it was determined that NAb inducers have significantly higher Env-specific B-cells responses after Nef G63E selection when compared to NAb non-inducers. Finally, a corollary was drawn between the Nef G63E-associated B-cell/NAb induction phenotype and activated PI3K delta syndrome (APDS), which is caused by activating GOF mutations in PI3K, to suggest that Nef G63E-meidated induction of NAb response is reciprocal to APDS.</p>
<p>Strengths:</p>
<p>This study aims to understand the viral-host interaction that governs NAb induction in SIVmac239-infected macaques - this could enable identification of determinants important for induction of NAb responses against hard-to-neutralize tier-2/3 HIV variants. The finding that SIV-specific B-cell responses are induced following Nef G63E CD8+ T-cell escape mutant selection argue for an evolutionary trade-off between CTL escape and NAb induction. Exploitation of such a cellular-humoral immune axis could be important for HIV/AIDS vaccine efforts.</p>
<p>Although more validation and mechanistic basis are needed, the corollary between PI3K hyperactive signaling during autoimmune disorders and Nef-mediated abrogated PI3K signaling could help identify novel targets and modalities for targeting immune disorders and viral infections.</p>
</disp-quote>
<p>We are grateful for the supportive and insightful comments. The work did seem to unintendedly highlight a conceptual link between extrinsic and intrinsic immune perturbations. We will keep working on both wings, aiming to evoke synergisms.</p>
<disp-quote content-type="editor-comment">
<p>Weaknesses:</p>
<p>Although the paper does have strengths in principle, the weaknesses of the paper are that the mechanistic basis of Nef-mediated induction of NAb responses are not directly examined. For example, it remains unclear whether SIVmac239 with engineered G63E mutation in Nef would induce faster and potent NAb responses. A macaque challenge study is needed to address this point.</p>
</disp-quote>
<p>We appreciate the point. We do have certain difficulties in availability of macaques for <italic>de novo</italic> experiments. As partially discussed in ver1, the identified Nef phenotype selected post-acute infection confers an enhanced CD4+ T cell-killing effect (revised Fig 4F), and it is likely that <italic>de novo</italic> infection with the mutant would redirect the trajectory of infection to rapid disease/AIDS progression accompanying generalized immune failure by boosting acute-phase CD4 destruction. In other words, mutant <italic>de novo</italic> infection may not necessarily be directly discussable as an attempt for reconstitution. It appears equally critical to understand the mutant <italic>in vitro</italic> on an immunosignaling basis, and in the current work we have focused on depicting this as the first step. We will work on reconstitution experiments with emphasis on pharmacology in our future study.</p>
<disp-quote content-type="editor-comment">
<p>As presented, the central premise of the paper involves infected cell-generated Nef (WT or G63E mutant) being targeted to adjacent Env-specific B cells. However, it remains unclear how this is transfer takes place. A direct evidence demonstrating CD4+ T cell-associated and/or cell-free Nef being transferred to B-cell is needed to address this concern.</p>
</disp-quote>
<p>We appreciate the point, also pointed out by Reviewers 2 and 3. We have performed three sets of <italic>in vitro</italic> reconstitution experiments graphically/functionally addressing how Nef transfer from CD4+ T cells to B cells can be modulated (new Fig 6) and edited text accordingly.</p>
<disp-quote content-type="editor-comment">
<p>The interaction between Nef and PI3K signaling components (p85, p110, GβL/mLST8, and MTOR) has been explored using PLA assay, however, this requires validation using additional biochemical and/or immunoprecipitation-based approaches. For example, is Nef (WT or mutant form) sufficient to affect PI3K-induced phosphorylation of Akt in an in vitro kinase assay? Moreover, the details regarding the binding events of WT vs mutant Nef with PI3K signaling components is lacking in this study. Lastly, it is unclear whether the interaction of Nef with PI3K signaling components is a conserved function of all primate lentiviruses or is this SIV-specific phenotype.</p>
</disp-quote>
<p>We appreciate the point. Co-immunoprecipitation analysis via pulldown with the mTORC2-intrinsic cofactor Sin1 (revised Fig 4E), showing decreased G63E-Nef binding, should confer robustness to the statement combined with initial manipulation results (Fig 4C). As Sin1 is mTORC2- and not mTORC1-intrinsic, results should be strengthened. Phosflow may be a standard readout nowadays for pAkt itself. Related with sequence variation, conservation will be addressed in studies ahead. We concisely mentioned on this in the revision (Lines 390-391).</p>
<disp-quote content-type="editor-comment">
<p>It has been previously reported that the region of Nef encoding glycine at position 63 is not conserved in HIV-1 (Schindler et al, Journal of Virology 2004). Thus, does HIV-1 Nef also function in induction of NAb responses in humans? or the observed phenotype specific to SIV?</p>
</disp-quote>
<p>We appreciate the point, and do not have an answer at the moment. We will explore in our HIV-1-infected patient cohort (Hau et al, <italic>AIDS</italic> 2022) and other occasions whether corresponding phenotypes may exist. We have mentioned on this point in the revised manuscript (Line 392-393).</p>
<disp-quote content-type="editor-comment">
<p><bold>Reviewer #2 (Public Review):</bold></p>
<p>It is well known that human and simian immunodeficiency viruses (HIV and SIV, respectively) evolved numerous mechanisms to compromise effective immune responses but the underlying mechanisms remain incompletely understood. Here, Yamamoto and Matano examined the humoral immune response in a large number of rhesus macaques infected with the difficult-to-neutralize SIVmac239 strain. They identified a subgroup of animals that showed significant neutralizing Ab responses. Sequence analyses revealed that in most of these animals (7/9) but only a minority in the control group (2/19) SIVmac variants containing a CD8+ T-cell escape mutation of G63E/R in the viral Nef gene emerged. They further show that this change attenuates the ability of Nef to stimulate PI3K/Akt/mTORC2 signaling. The authors propose that this induction of SIVmac239 nAb induction is reciprocal to antibody dysregulation caused by a previously identified human PI3K gain-of-function (Ref). Altogether, the results suggest that PI3K signaling plays a key role in B-cell maturation and generation of effective nAb responses.</p>
<p>Strengths of the study are that the authors analyzed a large number of SIVmac-infected macaques to unravel the biological significance of the known effect of the interaction of Nef with PI3K/Akt/mTORC2 signaling. This is interesting and may provide a novel means to improve humoral immune responses to HIV. Weaknesses are that only G63E and not G63R that also emerged in most animals was examined in most functional assays. Some effects of the G63E mutation seem modest and comparison to a grossly nef-defective SIVmac construct would be desirable to better assess to impact of the mutation of Nef-mediated stimulation of PI3K. While the impact of this Nef mutations on PI3K and the association with improved nAb responses is largely convincing, the results on the potential impact of soluble Nef on neighboring B cells is much less clear. SIVmac239 infects and manipulates helper CD4 T cells and these are essential for the activation and differentiation of B cells into antibody-producing plasma cells and effective humoral immune responses. Without additional functional evidence that Nef indeed specifically targets and manipulated B cells these results and conclusions should be made with much greater caution. Finally, the presentation of the results and conclusions is partly very convoluted and difficult to comprehend. Editing to improve clarity is highly recommended.</p>
</disp-quote>
<p>We are very grateful for the supportive and visionary review and suggestions. Experiments have been performed to improve the points raised. This work inevitably involved interdisciplinary factors to even hit on the schematic (NAbs, B cells, CD4+T, CD8+T, viral escape, immunosignaling, IEI as extrapolation &amp; microscopy implementations) and convoluted sections should have existed. We attempted streamlining of certain portions and edited writing throughout, and hope that it became more straightforward.</p>
<disp-quote content-type="editor-comment">
<p><bold>Reviewer #2 (Recommendations For The Authors):</bold></p>
<p>As outlined in the public review, I found the results potentially very interesting but parts of the manuscript much more complex and confusing than necessary. In addition, the methods on the potential impact of soluble Nef on neighboring B cells in vivo was difficult to assess but altogether this part was not convincing. Have the following specific suggestions:</p>
</disp-quote>
<p>We are very grateful for the scholarly review, and encouraging and suggestive comments on this orphan work. In the revision we designed experiments to address the properties of Nef transfer to append understanding on the <italic>in vivo</italic> B-cell data. Recommendations have been addressed as follows.</p>
<disp-quote content-type="editor-comment">
<p>(1) Title: &quot;AIDS virus-neutralizing antibody induction reciprocal to a PI3K gain-of-function disease&quot;. Think this title hardly reflects the data; SIVmac cause simian AIDS and is not the &quot;AIDS virus&quot; the 2nd part is more appropriate for discussion than for the title (and the abstract).</p>
</disp-quote>
<p>We appreciate the point. The original intent of the title was to conceptually bridge two differing fields of virus-host interaction and inborn errors of immunity/immunosignaling on an original article basis. Certain papers (Mudd et al, <italic>Nature</italic> 2012 etc) do utilize the term AIDS virus, and we similarly chose the term for simplification to non-virologists at initial submission.</p>
<p>That being said, we understand the scholarly point raised, and feel that the initial aim can be well attained by retaining the key host effector PI3K in the title, as in the revised submission titled “SIV-specific neutralizing antibody induction following selection of a PI3K drive-attenuated <italic>nef</italic> variant”.</p>
<disp-quote content-type="editor-comment">
<p>(2) Abstract and throughout: As the authors show, SIVmac is not generally &quot;neutralization resistant&quot;; difficult to neutralize is more appropriate and should be used throughout. Also, the abstract and other parts are more complicated than necessary.</p>
</disp-quote>
<p>We appreciate the point. HIV/SIV Env immunology work utilizes “neutralization-resistant” for SIVmac239 (e.g., Mason et al, <italic>PLoS Pathog</italic> 2016), and autologous titer positivity of ~10% at this size of examination does appear low amongst lentiviruses. Nevertheless, as recommended, “difficult-to-neutralize” better describes the nature, and we have switched the term accordingly.</p>
<p>Linked with title modification, we reflected the comment on abstract structure and switched the main introductory sentence (Here we…) to a more data-based one instead of depicting extrapolation, and have modified phrasings in the latter half.</p>
<disp-quote content-type="editor-comment">
<p>(3) The intro seems a bit biased. Immune evasion due to mutations and proviral integration that play key roles in viral persistence are not mentioned. nAbs are not known to efficiently control HIV or SIV replication in vivo (not even in the present study). Thus, a more &quot;balanced&quot; presentation of the role of nAbs in vivo is desirable.</p>
</disp-quote>
<p>We agree with the comment. Introduction in ver1 submission was compressed to just display humoral immune perturbation examples across persistence-prone viral infections, and indeed it should be much better to layout the multiscale strategies of lentiviruses in manifesting viral persistence. We have appended two sets of texts, one on the fundamental integrating retroviral life cycle and another on the wide spectrum of accessory protein-driven perturbation. As pointed out, the current endogenous induction is of course not early enough to exert suppressive impact on replication as like in exogenous Ab passive infusions. We have accordingly modulated text to improve the balance.</p>
<disp-quote content-type="editor-comment">
<p>(4) Lines 73-76: rephrase for clarity.</p>
</disp-quote>
<p>We acknowledge the comment and have rephrased accordingly.</p>
<disp-quote content-type="editor-comment">
<p>(5) Line 92: &quot;linked with sustained Env-specific B-cell responses after the mutant Nef selection&quot;. After or during in one case; the time frame varies enormously and this should be discussed.</p>
</disp-quote>
<p>We appreciate the comment. The six Nef-G63E mutant-selecting NAb inducers subjected to B-cell analysis were the ones that showed precedence in Fig 2D (mutant before induction). That being said, we modified text as suggested (Line 104 in revised uploaded text). Text related to temporal deviation has been appended (Lines 378-383 in revised uploaded text).</p>
<disp-quote content-type="editor-comment">
<p>(6) The authors should discuss G63R and include it in the functional analyses.</p>
</disp-quote>
<p>We appreciate the comment. Discussion on Nef-G63R in ver1 submission was kept minimal because statistical significance for selection was marginal. We generated a Nef-G63R mutant and results are appended in Fig 4-Figure Supplement 2.</p>
<disp-quote content-type="editor-comment">
<p>(7) Lines 124/5: conservation only applies to SIVsmm/mac Nefs and this region is also frequently deleted/length-variable in primary HIV-1 Nefs.</p>
</disp-quote>
<p>We appreciate the comment. We modified description of the region accordingly (Lines 139-141 in revised text).</p>
<disp-quote content-type="editor-comment">
<p>(8) Lines 153-155: Statement doesn't seem to make sense. The triple mutant Nef SIVmac construct was not attenuated for replication but specifically disrupted in CD3 down-modulation.</p>
</disp-quote>
<p>We acknowledge the comment. It had meant that the consequent plasma viral load showed a trend of decrease (as in the Graphical Abstract of the work) which should (in a simplistic view) influence antigenicity for humoral immune responses. Yet it is very true that virological replicative capacity was comparable with wild-type as in Fig.1. We have taken down the related text and rephrased it (Ref remains cited in introduction).</p>
<disp-quote content-type="editor-comment">
<p>(9) Lines 178/9: levels in PI3K gain-of-function mice &quot;with full disease phenotype (Avery et al., 2018)&quot;. This needs more information, e.g. what disease exactly are they talking about?</p>
</disp-quote>
<p>We are grateful for the correction, and have appended text and introduced the mentioned congenital disease in the Introduction section in advance. In-detail description is also appended in the Discussion section.</p>
<disp-quote content-type="editor-comment">
<p>(10) Lines 186/7: &quot;Env-stimulating high-MOI infection also accelerated phenotype appearance, with enhanced 50% reduction (Figure 4C, right)&quot;. Modify text and corresponding figure for clarity.</p>
</disp-quote>
<p>We acknowledge the comment. We revised as: “A high-MOI SIV infection, comprising higher initial concentration of extracellular Env stimuli, also accelerated phenotype appearance from day 3 to day 1 post-infection with stronger pAkt reduction”.</p>
<disp-quote content-type="editor-comment">
<p>(11) The validity of the results described in the section &quot;Targeting of lymph node Env-specific B cells by Nef in vivo&quot; was difficult to assess. Altogether, however, I didn't find them convincing, especially since a negative control (e.g. macaques infected with nef-deleted SIVmac) are missing.</p>
</disp-quote>
<p>We acknowledge the comment. As a pure experimental control, whole-Nef deletion may assist for subtracted baselines. Within this work, the staining per se at least should be highly specific (mAb multiply verified in other applications and cytometry panel also designed for minimal spillover into AF488 channel). On <italic>in vivo</italic> basis, direct comparison may be somewhat frustrated by the fact that reduction in other pleiotropic effects of Nef seem to more dominate upon Nef deletion, as a set of reduced viremia, robust CD8 responses, killer CD4 responses and increased binding Ab titers (Johnson et al, <italic>J Virol</italic> 1997, Gauduin et al, <italic>J Exp Med</italic> 2006, Fukazawa et al, <italic>Nat Med</italic> 2012, Adnan et al, <italic>PLoS Pathog</italic> 2016 etc) leading to altered trajectory. We promise that we will work on refinement of the methodology in studies ahead.</p>
<disp-quote content-type="editor-comment">
<p>(12) Lines 309-319: This paragraph made little sense to me (as did lines 328-331).</p>
</disp-quote>
<p>We acknowledge the comment and have edited both sections.</p>
<disp-quote content-type="editor-comment">
<p><bold>Reviewer #3 (Additional Reviewer):</bold></p>
<p>In this manuscript, Hiroyuki Yamamoto et al examined virus-specific antibody responses and identified a subgroup of nine individuals, out of seventy SIVmac239 rhesus macaques of Burmese origin infected with SIVmac239, that develop neutralizing antibodies (NAb). The authors propose the emergence of a nef mutant (Nef-G63E) that impacts on B cell maturation resulting in PI3K gain-of-function.</p>
<p>My major concerns are:</p>
<p>The authors by different aspect addressed the role of the emergence of Nef-G63E mutant in individuals developing NAb. The manuscript is confused and the rational not always clearly stated. This reflects the two aspects of the manuscript (i) NAb identification in a subgroup of macaque and (2) the identification this nef mutation.</p>
</disp-quote>
<p>We are grateful for the comprehensive and scholarly comments. As pointed out, the work did need to confront potential bifurcation of the influence of the obtained viral immunosignaling phenotype for CD4-intrinsic (which might be your specialty) and B-cell-intrinsic impact. Based on your suggestions we have acquired additional data and revised the manuscript as attached.</p>
<disp-quote content-type="editor-comment">
<p>The authors used both males (n=57) and females (n=13). However, there is no indication related to the sex regarding NAb inducers versus non-NAb Inducers. The notion of &quot;highly pathogenic&quot; is certainly not correct (see the introduction). Pathogenicity is also depending on monkey origin. Thus, cynomolgus are less sensitive to SIVmac239 or SIVmac251 compared to rhesus macaques (Ling B Aids 2002; Reimann KA, J Virol 2005; Cumont MC, J Virol 2008), or to pigtails used in US. Indeed, the authors used Burmese macaques, and therefore the dynamics of pathogenicity is different to rhesus macaque (Indian origin) housed in US. How many animals have been sacrificed out of the 61 animals? Herein, the animals are surviving longer (more than one year), and therefore the notion of &quot;highly pathogenic&quot; merits to be modulated.</p>
</disp-quote>
<p>We appreciate the comment. We have accordingly appended sex information (M/F: 8/1 versus 49/12 in NAb inducers vs non-inducers, <italic>p</italic> &gt; 0.99 by Fisher’s exact test) in the methods section. As pointed out there are differences in the frequency and rate of AIDS progression among macaques of differing origin, whereas we have also previously reported reproducible AIDS progression dependent on MHC-I genotypes in the Burmese rhesus macaques utilized (Nomura, Yamamoto et al., <italic>J Virol</italic> 2012). Adhering to advice, we have attenuated the term to “pathogenic” in the revised manuscript and appended one reference showing pathogenesis gradation from a cell-death perspective (Cumont 2008).</p>
<disp-quote content-type="editor-comment">
<p>Furthermore, no indication is provided regarding CD4 T cell dynamics, or CD8 T cells. In particular, the extent of T cell immunodeficiency may compromise humoral response. Therefore, this data needs to be shown. Indeed, previous reports have indicated that early CD4 T cell depletion is associated with defective humoral response. Furthermore, Tfh cell depletion was reported in several immune tissues, which are essential for B cell immune response like the spleen. Thus, this should be discussed as an alternative mechanism to the absence of NAb. Indeed, the authors found higher and persistent env-specific plasmablast cells in NAb inducers than that observed in non-NAb inducers figure 6. Why to have selected twelve individuals out of 61 individuals for assessing anti-env response (Supplemental S3 for figure 1, panel 1), and only eleven for western blots. The explanation in the text is absent. This requires to be clearly stated. See lines 108-110.</p>
</disp-quote>
<p>We appreciate the comment. As in other sections, this study utilized available cryopreserved samples from a retrospective cohort, also having heterogeneity in data acquisition along the way. We acknowledge that some supplemental data are particularly limited in information, which is also a reason they are presented in SI. We felt that one important core was to secure samples for Nef-G63E-selecting NAb inducers versus viremic non-inducers, for which we acquired six versus twelve in the B-cell analysis.</p>
<p>We (Nakane et al, <italic>PLoS ONE</italic> 2013) and others (Hirsch et al, <italic>J Virol</italic> 2004) have already reported on western blotting-basis that SIV-infected rapid progressors tend to manifest serological failure (impaired binding Ab-WB bands). Therefore, to compare quantitative traits at this basal stage (Fig 1), we judged that NAb inducer comparison with more non-rapid-progressing (&gt;60 wk survival) non-inducers would be a criterion. We have mentioned on this in the revised manuscript (results/methods). Additionally, we have replaced the immunoblotting result with one more non-inducer (<italic>n</italic> = 12) to enhance results. Please note that there are lot deviations in strip-coated antigen (e.g., gp160) but the result is comparable (now covers 12/13 of animals with &gt;60-wk survival).</p>
<disp-quote content-type="editor-comment">
<p>The authors indicated the frequencies of Nef-G63E mutant in figure 2 panel C. However. no information is indicated in the legend about the number of NAb non-inducers used to calculate this frequency. The authors indicated line 127, &quot;only in two of the nineteen NAb non-inducers, including one rapid progressor&quot;. Thus, different numbers of individuals are used through the manuscript. For the readers, this is clearly a statement that needs to be clarify and to refer to what. This is not homogeneous along the text and the analyses performed.</p>
</disp-quote>
<p>We appreciate the comment, and have appended the number in the revised Fig 2C. As aforementioned, heterogeneity of sample number in different sections is indeed a limitation of the work, and have mentioned this in the Discussion.</p>
<disp-quote content-type="editor-comment">
<p>The rational related to the sentence lines 140-142. Please clarify.. &quot;NAb induction is not associated with these MHC-I genotypes (P = 0.25 by Fisher's exact test, data not shown) but with the Nef-G63E mutation itself&quot;.</p>
</disp-quote>
<p>We appreciate the comment. We have rephrased it as:</p>
<p>“Ten of nineteen NAb non-inducers also had either of these alleles (Figure 1-figure supplement 1). This did not significantly differ with the NAb inducer group (P = 0.25 by Fisher’s exact test, data not shown), indicating that NAb induction was not simply linked with possession of these MHC-I genotypes but instead required furthermore specific selection of the Nef-G63E mutation.” (Lines 159-162).</p>
<disp-quote content-type="editor-comment">
<p>In supplemental figure 3, only 7 individuals have been tested, while the authors indicated &quot;Ten of nineteen NAb non-inducers also had either of these alleles&quot;. Why only seven? In NAb Burmese monkeys, the authors indicate specific T cells capable to recognize WT nef peptide, but not G63E peptide mutant. Thus, nef is immunogenic in vivo generating T cells despite to be mutated.</p>
<p>In contrary, non-NAb-inducers demonstrate the absence of nef specific T cells (supplemental figure 3, excepted R01-011 panel A). Although, the authors propose an escape mutant for CD8 T cells, this is not associated with the absence of immunogenicity and not with a difference in viral load in comparison to NAb inducers (panel C). Therefore, the conclusions merit to be revised. Thus, this part of the manuscript is confusing. Please clarify the rational to link NAb and Nef specific CD8 T cells.</p>
</disp-quote>
<p>We appreciate the comment. 7 out of 8 non-inducers positive for the allele and not selecting for the Nef-G63E mutant was available for analysis. The relative contribution of this single Nef62-70 epitope-specific CTL response is speculated not to be largely impacting viral control, among the many induced. This is basally discussed in a previous paper (Nomura, Yamamoto et al., <italic>J Virol</italic> 2012), more suggestive of an MHC-I haplotype-level correlation with plasma viral load. We assume that the CTL pressure-driven selection of Nef-G63E mutant was a rather pure immunosignaling trigger under persistent viremia. We appended this in the revised text (Line 172).</p>
<disp-quote content-type="editor-comment">
<p>In the next part of the manuscript, the authors assessed the function of this Nef-G63E mutant. The rational to introduce Ferritin in this part of the document is not clear for the reader. Furthermore, a subgroup for each (NAb+ versus NAb-) is shown: 4 for NAbneg versus 6 for NAbpos.</p>
</disp-quote>
<p>We appreciate the point. As introduced, Swingler et al <italic>Cell Host Microbe</italic> 2008 reported HIV-infected macrophage-derived ferritin as a potentially B cell-disrupting factor. In that paper, viral load, ferritin and binding antibody titers positively correlated. Current data shows that SIVmac239-specific NAb induction is distinct from such kinetics already versus viral load (Fig 3-Supplement 1C), and ferritin levels were measured for some available samples more simply for confirmation. We appended three more available samples in the NAb- group. (The six NAb+/G63E animals correspond to the ones with B-cell data in Figure 7.) Statistical results appear unaffected and robust, as shown in this version. The revised manuscript incorporates appended explanation for the former.</p>
<disp-quote content-type="editor-comment">
<p>Similarly, whereas the authors observed a role of nef mutant on pAkt Ser473 (less induced) in comparison to WT, the authors suggest that this may have an impact on T cell survival.</p>
</disp-quote>
<p>We appreciate the point. In the first submission we obtained peripheral memory Tfh decrease, whereas it is true that this is indirect. In the current revision we have addressed apoptotic cell death, shown to increase with Nef-G63E mutation (Figure 4F).</p>
<disp-quote content-type="editor-comment">
<p>The rational to analyze CXCR3-CXCR5+PD-1+ memory follicular Th (Tfh) is not clear. Moreover, the references used are not the adequately cited. Indeed, these papers show an expansion. See the literature for a depletion (Xu H, J Immunol. 2015; Moukambi F, PLoS Pathog. 2015; Yamamoto T, Sci Transl Med. 2015; Xu H, J Immunol. 2018 Moukambi F, Mucosal Immunol. 2019).</p>
</disp-quote>
<p>We appreciate these points on <italic>in vivo</italic> CD4+ T cells.</p>
<p>Peripheral memory Tfh was reported to correlate with Ab cross-reactivity in one human cohort (Locci et al, <italic>Immunity</italic> 2013) and we concisely examined the subset in the current NAb induction. We mentioned this in the revised manuscript.</p>
<p>Moukambi F et al, <italic>PLoS Pathog</italic> 2015 &amp; <italic>Mucosal Immunol</italic> 2019 are demonstrative work on acute-phase destruction. We have cited non-neonatal/vaccine-related ones suggested, including these two, in the revised manuscript. The biphasic dysregulation of Th (acute-phase destruction and chronic-phase adverse hyper-expansion) may indeed have a unique role with the current phenotype, which is beyond aim of the current analysis. We have concisely mentioned on this in the Discussion.</p>
<disp-quote content-type="editor-comment">
<p>Then, the authors assess the potential B-cell-intrinsic influence of the G63E-Nef phenotype. The rational here is clearly indicated, making sense with figure 1. Furthermore, this part is clearer. The dot-plots merit to be revised and the markers used better stated. The authors indicate that Nef invasion upregulates pAkt Ser473 assuming aberrant PI3K/mTORC2 signaling. What is the impact of Nef-G63E mutant on pAkt Ser473 using in vitro model of transfer. This is not addressed for comparison.</p>
</disp-quote>
<p>We appreciate the remarks/suggestions, also pointed out by Reviewers 1 and 2. We have performed three sets of <italic>in vitro</italic> reconstitution experiments visually and functionally addressing how Nef transfer to B cells can be modulated (new Fig 6), and edited text accordingly.</p>
<disp-quote content-type="editor-comment">
<p>Minor points are:</p>
<p>- the presence of references in the legend.</p>
<p>-some Ab clones are in the table, however they are not used such CD38 and CD138, which are well known to be non-valid B cell markers for monkeys.&quot;</p>
</disp-quote>
<p>We appreciate the suggestions.</p>
<p>Mentioning on reference have been removed from the legend (Fig.1, Fig. 3) and moved to the corresponding Methods section (Fig. 1).</p>
<p>We also understood this well in advance (CD38/CD138), and incorporated them in the memory B-cell panel just to check whether they ever behave in a specific pattern. As expected, no notable behavior was observed in these NAb inducers.</p>
</body>
</sub-article>
</article>